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Abstract 
As the supply of natural gas becomes more scarce, it is becoming increasingly more attractive 
and financially viable to start using reserves that were previously determined to be to impure 
to use. H2S and CO2 are a couple of the major impurities found in natural gas. Natural gas 
high in these chemicals is referred to as sour gas. Presence of these impurities increases the 
chances of clathrate hydrate formation in pipelines, which can lead to pipe blockages or 
ruptures. To prevent clathrate hydrate formation, low dosage, polymeric, kinetic hydrate 
inhibitors (KHIs) are used. KHIs are water soluble polymers, most commonly 
polyvinylcaprolactam (PVCap) and polyvinylpyrrolidone (PVP). There is to date no definitive 
answer to the method of hydrate inhibition by KHIs and knowing how they work could lead 
to the design and manufacture of more effective inhibitors.  
This thesis begins with the synthesis of model compounds. Low molecular weight 
compounds containing pyrrolidone and/or caprolactam rings were created to mimic PVP and 
PVCap. To look at the crystallisation behaviour of the model compounds, a wide range of 
different multicomponent crystallisations were attempted with pharmaceutical coformers, 
hydrogen bond donors, halogen bond donors and metal salts. Successfully formed cocrystals 
were analysed by single crystal x-ray crystallography. Cocrystals formed with boronic acids 
were tested for their ability to gel guar and compared with the commercially used boric acid. 
The effect of sour gas on the interactions of the KHIs and model compounds with water was 
investigated using IR and NMR techniques. Small angle neutron diffraction was used to 
explore the synergistic effect between butoxyethanol and PVCap which leads to a significant 
improvement in hydrate inhibition. 
Finally the ability of the model compounds to prevent crystallisation was applied to 
pharmaceuticals. Attempts to stabilise the amorphous forms of a range of drugs by creating 
coamorphous mixtures with the model compounds were investigated by hot-stage 
microscopy, DSC and PXRD.  
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1 Introduction 
1.1 Clathrate hydrates 
Natural gas reserves can be generalised into two categories: sweet and sour. Sour gases 
contain a significant amount of acid gas components. The acid gases are most commonly CO2 
and H2S, although other sulfur-containing compounds (mercaptans) can also be present. Due 
to an increase in gas consumption and the depletion of many sweet gas reserves, sour gas is 
becoming more frequently exploited.1 There are a plethora of danger associated with sour 
gas, including its toxicity, its ability to corrode pipes and that it is more likely to form clathrate 
hydrates than sweet gas.2 Clathrate hydrates are cages of hydrogen-bonded water molecules 
which form around small molecules, for example methane found in natural gas, in favourable 
conditions of low temperatures and high pressures, such as those in undersea pipelines. 
When grown to a large enough size, these clathrates can form plugs that block pipes causing 
large delays that are costly and hazardous. Pipe rupturing and the flammable nature of the 
clathrates are a significant concern.3  
The size of the guest molecule determines the structure of clathrate that is formed.4,5 The 
structures shown below in Figure 1.1 are the most commonly formed clathrates, the cubic 
structure I and structure II and the hexagonal structure H.6 It is possible to form more exotic 
structures with certain guests, for example dimethyl ether promotes the formation of a 
trigonal structure T. In pipelines it is usually structure I and structure II that occur. The smaller 
components such as methane, CO2 and H2S form structure I clathrates whilst larger 
components like ethane form structure II clathrates.7 
  
Figure 1.1 - The structures of the most common types of clathrate hydrate.  
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It was originally thought that clathrate hydrates are metastable crystal structures and that 
favourable interactions with a guest increased the stability. Rodger8 simulated the formation 
of clathrates to test the validity of the assumptions made in the cell theory by van der Waals 
and Platteeuw.9 Van der Waals and Platteeuw created a statistical thermodynamic model 
based on the assumptions that the free energy of the clathrate lattice is unaffected by the 
guest molecule, cavities only have one guest, guest-guest interactions do not occur and 
quantum effects can be ignored. Rodger used these assumptions to run a molecular 
dynamics simulation of clathrate formation and found that the free energy of the water 
crystal is significantly affected by the guest, thus the assumption that the free energy is not 
affected is not appropriate. He further concluded that clathrate hydrates are not in fact 
metastable, but will collapse to an ice phase, Ih, or liquid water upon removal of the guest, 
depending which is the more thermodynamically stable state under the conditions used. His 
calculations suggest that it is not the favourable interaction between cage and guest that 
give the hydrates their stability, but the hydrophobic interaction between an aliphatic guest 
and the water, that keeps the cage open, agreeing with the observation of Jeffrey in 198410 
that molecules with either many or strong hydrogen bonding groups do not readily form 
clathrates. Looking at the temperature of decomposition for hydrates of propane, ethane 
thiol and ethanol, ethanol shows by far the least stable structure. The ethanol hydrate 
decomposes at -73 °C compared to ethane thiol at 3 °C and propane at 6 °C.11 The OH of the 
ethanol hydrogen bonds with the water, introducing defects into crystal structure, 
decreasing the stability. This further evidences the theory that repulsive interactions stabilise 
the clathrates. Adding polar species, such as ethanol and methanol, destabilise the clathrate 
enough to act as inhibitors. 
Hydrogen sulfide forms hydrates at the lowest partial pressure of all the components in sour 
gas. This seemingly contradicts the theory that more polar molecules make less stable 
clathrate hydrates as H2S is more polar than methane.11 One theory of the unexpected low 
clathrate formation pressure of H2S is that the presence of H2S changes the polarity of the 
system and increases the level of moisture in the gas.12 The more water there is in the 
system, the higher the likelihood of it crystallising and hydrates forming. It has also been 
proposed that favourable size could more readily form clathrates.13 Addition of H2S to a 
mixture of cyclohexane and water actually promotes formation of a cyclohexane clathrate 
hydrate.14 Normally cyclohexane is too big to be a suitable guest in a structure II type cage, 
but H2S fills the smaller cavities in the structure stabilising the clathrate, smaller molecules 
stabilising clathrates that wouldn’t normally form are referred to as help gases.15 In 
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methane/H2S clathrates H2S fills the smaller cavities of the structure I clathrate whilst 
methane fills the larger cavities.16 
The favourability of H2S clathrate formation brings added danger to the system as hydrates 
formed in a sour system are rich in H2S.13,17  In a mixture of methane and H2S with 1 % H2S, 
the resulting clathrate will on average contain 12 % H2S as a guest.16 As well as the health 
hazard associated with the formation of clathrate hydrates, such as flammability and pipe 
blockage, these H2S rich clathrates also bring all the troubles associated with H2S toxicity.  
1.1.1 Hydrate inhibition 
Thermodynamic inhibitors, like methanol, are commonly used to prevent pipe blockages by 
clathrate hydrates. The requirement for very high loading, between 20 and 50 %,18 makes 
them a very costly method of inhibition, though less costly than cleaning up after and 
repairing a ruptured pipe. A desire for a less high loading, and thus, less expensive, inhibitors 
started research into low dosage hydrate inhibitors (LDHIs).  Water soluble synthetic 
polymers were tested as a method of inhibiting hydrate formation, as many such polymers 
were already in use for other applications so are readily and cheaply available for testing. It 
was found by Colorado School of Mines that polyvinylpyrrolidone (PVP) (1), a polymer 
already used for a wide range of applications from blood plasma expanders19 to hair curling,20 
showed potential as a hydrate inhibitor.18 Though PVP is not as effective as anti-freeze 
proteins at hydrate inhibition,21 it is effective enough to prevent blockages during the 
timeframe and conditions required and the relative cost of production makes it much more 
desirable in an industrial setting. The low toxicity of PVP is an added bonus, as this would 
minimise the environmental impact of a pipe rupture, if one should occur. Replacement of 
methanol with PVP has been successfully implemented at many sites, including a Texaco site 
in southwest Wyoming for example.22 These inhibitors are referred to as kinetic hydrate 
inhibitors (KHIs) as they do not make it thermodynamically unfavourable to form clathrates, 
just delay their formation until it is no longer a concern. 
 
To further improve the efficiency of the inhibitor other similar compounds were tested Such 
as polyvinylpipiridone (PVPip) (2) and polyvonylcaprolactam (PVCap) (3). PVCap shows a 
greater ability than PVP to inhibit hydrate formation, though the reason for this is not fully 
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understood.23 A range24 of copolymers have also proven effective, an example of which being 
a vinylcaprolactam (VCap)/vinylpyrollidone (VP)/dimethylaminoethyl methacrylate 
terpolmer.18 Copolymers show greater hydrate inhibition than PVP alone, whilst bringing 
down the costs of using solely the more expensive PVCap. Addition of a third type of 
monomer can impart other desirable properties, such as increasing the cloud point, 
corrosion resistance or helping improve compatibility with existing pipeline corrosion 
inhibitors. A VCap/phosphoric acid copolymer (4) is an example of adjusting the properties 
of PVCap by copolymerisations.25 The phosphoric acid groups make the polymer an effective 
corrosion inhibitor and anti-agglomerant as well as a KHI, forgoing the need of multiple 
additives to control the corrosion and hydrate formation that occur in sour pipelines.  
Another example of copolymer modification is VCap/vinyl alcohol copolymer (5) which is 
been produced to supply the hydrate inhibition associated with pure PVCap with a superior 
biodegradability.26 
 
With PVP and PVCap being effective hydrate inhibitors, it would be expected that the 6-
membered lactam analogue, PVPip, also referred to as polyvinylvalerolactam (2), would be 
so as well. Chua et al.23 tested the hydrate inhibiting ability of PVPip compared to PVP and 
PVCap. They did find PVPip to be an effective inhibitor, better in fact than PVP. Though still 
less effective than PVCap, PVPip is not as effective as the current inhibitors, and the 
monomer is not commercially available, raising the cost. Though there are no examples of 
PVPip based polymers being used in an operating system, they have been patented for use 
as hydrate inhibitors,27,28 so may come into use if economic considerations allow.  
Inspiration for designing LDHIs can also be taken from nature, as a number of biological 
systems have developed natural antifreezes.21,29 Cold water fish, such as winter flounder, live 
in polar regions, yet their blood does not freeze in the sub-zero temperatures they 
encounter. Antifreeze proteins, high in hydrophilic amino acids, prevent ice from forming in 
the blood.29  Synthesis of these proteins has been successful and their ability of hydrate 
inhibition is as good as expected.18 Unfortunately, it is not an economically viable option, 
with protein synthesis being costly and time consuming.  
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Most inhibitors are not sold as pure polymer. The polymer powder is messy to handle and 
does not easily disperse in the pipeline, so is often sold in a solution. The solvent chosen can 
have a big effect on the efficiency of the inhibitor. Whilst some solvents may retard the 
inhibitor, others actually improve it. One such solvent is butoxyethanol. 
1.1.2 Butoxyethanol 
PVCap is commercially available in a 50 wt% mix with 2-butoxyethanol. The 2-butoxyethanol 
acts as a solvent, creating a syrup that aids in the dispersion of the inhibitor throughout the 
pipeline. Butoxyethanol also works as a synergist, improving the inhibition of the product. 
Butoxyethanol functions as a hydrate inhibitor in its own right, though unlike PVCap that is a 
kinetic hydrate inhibitor (KHI), butoxyethanol is an anti-agglomerant (AA). 
KHIs prevent the formation of hydrate crystals, AAs on the other hand, do not prevent the 
formation of hydrate crystals, but prevent the formation of pipeline blockages. AAs are 
surfactant like molecules that surround a forming hydrate, hydrophilic head groups interact 
with the water of the hydrate, and hydrophobic tails interact with the surrounding 
hydrocarbon environment in the pipeline. This stabilises small hydrate crystals, preventing 
agglomeration. This stops plugs forming and keeps the pipeline flowing as a slurry of small 
hydrate particles.  
Butoxyethanol’s properties as a surfactant are well documented, with studies using small 
angle x-ray scattering,30 small angle neutron scattering31–34 and dynamic and Rayleigh light 
scattering35 techniques. Butoxyethanol is only a weak anti-agglomerant, with most 
commercial AAs consisting of long chain, quaternary ammonium salts.36 Addition of 
butoxyethanol to a KHI, greatly increases the amount of time before a macroscopic hydrate 
is formed. For the example of a VP/VCap/(dimethylamino)ethylmethacylate terpolymer, the 
onset time is increased from 40 min to 1200 min.28 This is a very large improvement, much 
larger than would be expected just from the addition of weak anti-agglomeration effect of 
butoxyethanol. This suggests that there is a truly synergistic effect, that the butoxyethanol 
is interacting with the KHI to enhance its inhibiting ability. Though to date, there has been 
no research into how the synergistic effect works.  
1.1.3 Mechanism of hydrate inhibition 
To further the understanding of the mechanisms in systems using polymers, it is often 
advantageous to use model compounds. Polymers are large and have a range of chain 
lengths making them difficult to study by common techniques such as NMR. Suitable models 
can be as small as a monomer up to moderate sized oligomers, with the longer chain lengths 
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being more true to polymer, but harder to analyse. Davenport et al.37 synthesised two 
vinylcaprolactam dimers (6 and 7), which infrared spectroscopic analysis shows to interact 
with water in a very similar fashion to the polymer, making it a suitable model for the 
inhibitor.   
 
Simulating polymers can also be very computationally expensive so similar model 
compounds are used in simulations. Kuznetsova et al.38 used up to a PVP octamer in their 
simulations with methane and water. Oligomers around this length have also been shown to 
be more effective as inhibitors than the larger polymers,39 making an octamer a good model 
to choose when wishing to observe how hydrate inhibition occurs. They established that PVP 
does not interact with the surface of a forming hydrate, but may create a barrier between 
the aqueous and hydrocarbon phase. The barrier slows down diffusion of the natural gas into 
the water, slowing the onset of clathrate formation. Contrastingly, a small angle neutron 
study of PVP in water by Hutter et al.40 concluded that PVP does adsorb onto the surface of 
the forming ice. Anderson et al.41 proposed a two-step mechanism based on molecular 
dynamics simulations. The first step is that KHIs disrupt the local organization of the water 
molecules making nucleation much more difficult. The second step occurs after nucleation, 
the KHI adsorbs onto the hydrate blocking further growth. A number of different KHIs were 
modelled and they hypothesised that the more effective inhibitors would bind more strongly 
to the forming hydrate with the simulations agreeing. Molecular dynamic simulations by 
Moon et al.42 however, do not come to the same conclusion. In their simulation the KHI, PVP 
in this case, does not bind to the forming hydrate. They state that the PVP resides in an 
environment independent of the hydrate and remains typically two solvation shells away 
from the hydrate. Instead it is concluded that PVP forms halos of ordered water around the 
lactam functionalities, which whilst being more ordered than bulk water, actually disrupt the 
ordering required for nucleation. These contrasting conclusions suggest that more research 
into the mechanism of hydrate inhibition is needed before the mode of action can be fully 
understood. 
To study how KHIs prevent crystallisation it is of interest to see if it is possible to crystallise 
low molecular weight models of the polymers in a range of different conditions. Knowing 
under what conditions crystallisation occurs may help elucidate how KHIs prevent 
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crystallisation. If the goal is to create crystals or prevent them occurring, an understanding 
of what crystallisation is and how the crystallisation process proceeds is a useful tool to have.  
1.2 Crystallisation 
Crystallisation is a commonly used technique for purifying products in synthesis and is 
generally taken as standard lab practice. Whilst purification is a useful application of 
crystallisation, it is far from the full potential which can be achieved. Large enough single 
crystals can be analysed by single crystal x-ray diffraction to give crystal structures, showing, 
within an often small amount of error, the relative positions of the atoms in the crystal 
structure and revealing the molecular structure. Comparing and analysing crystal structures 
can give information of the stability of solids forms, interactions between molecules and 
favourable conformations of compounds. Single crystals can even be used as models to study 
the mechanism of solid state catalysts.43,44 
Crystallisations can be performed by a range of different methods: evaporation of solvent, 
cooling of a heated, solvent containing system, antisolvent diffusion, melting and freezing 
and conversion of an amorphous solid. The best method to crystallise a particular compound 
cannot be predicted, so it is advisable to try a wide range of different solvents and methods.45 
In solvent based crystallisations the compound of interest is required to completely dissolve 
in the chosen solvent. From an undersaturated solution, crystals will never form. For the 
formation of crystals the solution must become supersaturated.46,47 A supersaturated 
solution is usually formed in one of three ways. The first is to dissolve as much of the desired 
solid as possible in a heated solvent then slowly cool the solution down. Solubility increases 
with temperature, so as a hot saturated solution cools down the saturation level increases 
until a supersaturated solution is formed. The second method is to dissolve the desired solid 
in a solvent then allow this solvent to evaporate, reducing the amount of solvent until 
supersaturation occurs. The final method is to add an antisolvent, either by vapour or liquid 
diffusion. This involves adding a second solvent, called an antisolvent, in which the solute is 
not soluble. As the antisovent:solvent ratio of the solution increases, the solute becomes less 
soluble, finally forming a supersaturated solution.48 Supersaturated solutions are metastable 
and convert over time to a solid, the desired crystals or a precipitate, and a saturated 
solution. For crystals to form nucleation must occur.47 To prevent too many nucleation points 
from forming, which would result in many small crystals which may agglomerate, the level 
of supersaturation must be increased slowly. This is achieved by slowing down the rate of 
cooling,49 solvent evaporation or antisolvent addition.50 There are two types of nucleation: 
heterogeneous and homogeneous.  
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Homogeneous nucleation is where the solution nucleates itself without external influence. 
Classical nucleation theory states that nucleation occurs due to fluctuations in concentration 
which occur when multiple molecules of the solute come together, this is a statistical event 
in a fluid system which must overcome a kinetic barrier.51 The more concentrated the 
solution, the higher the probability of molecules of solute being near each other, so the more 
supersaturated a solution, the more likely nucleation is to occur. For a nucleus to form the 
surface energy of the forming nucleus must be less than that of the bulk solution, which 
requires a critical minimum size for the surface energy to reduced adequately,52 as illustrated 
in Figure 1.2. This critical radius is system dependant and not predictable. As crystals form, 
the smaller crystals, which have higher surface energy so are less stable than larger particles. 
The smaller crystals dissolve and the dissolved material adds to the larger crystals, promoting 
their growth. This mechanism of crystal dissolution and growth, where the small crystals 
dissolve and the large particles grow, is called Ostwald ripening.53,54 To calculate the rate of 
nucleation, classical nucleation theory assumes that the nuclei which form have the same 
structure and properties as the final crystal.51 Ostwald’s rule of stages states that in 
polymorphic systems the less stable polymorph will form first then convert to the more 
stable polymorph over time,55 so in polymorphic systems calculation of rate using classical 
nucleation theory is not accurate.56 An example of this if the crystallisation of calcium 
carbonate which is reported to first precipitate as an amorphous form and converting to a 
more stable crystal after.57 
 
Figure 1.2 – Graph of free energy against radius showing how size dictates the energetics of nuclei in solution 
in classical nucleation theory.56 
To further classical nucleation theory, pre-nucleation clusters have been proposed. Pre-
nucleation clusters are defined be Gebauer et al.56 as small, thermodynamically stable 
species with no official phase boundary between them and the bulk solution, which are 
highly dynamic and have structural similarities to the polymorph which will form first, which 
allows for more accurate analysis of polymorphic systems than is possible with classical 
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nucleation theory. Pre-nucleation clusters can involve more than one species, for example 
solvent molecules could have a role in pre-nuclei whilst not appearing in the final crystal 
structure. As pre-nucleation theory does not treat nuclei the same as the bulk material, much 
more accurate models of nucleation can be achieved than in classical nucleation theory.  
Melt crystallisation often proceeds by homogeneous nucleation. Upon cooling a metastable 
state is reached, similar to supersaturation in solutions, where it begins to be more stable to 
have two phases: the molten product and crystals. Forming crystals from a melt is highly 
dependent on the rate of cooling.45,51 Crystals are more thermodynamically stable than 
amorphous forms so slow cooling allows for the more stable, crystalline phase to form.  
Heterogeneous nucleation is where an entity which is not the desired crystal, nucleates 
crystal formation. Heterogeneous nucleation can occur at interfaces between solutions, at 
defects or scratches in the crystallisation vessel, by pieces of dust or other contaminants. 
Heterogeneous nucleation lowers the energetic barrier for crystal formation as the 
interfacial energy between the heterogeneous nucleus and the forming crystal is less than 
the interfacial energy between the crystal and bulk solution.52 As well as lowering the barrier 
to crystallisation, heterogeneous nucleation can lead to particular crystal shapes or 
polymorphs forming. In nature, heterogeneous nucleation is used to uniformly form crystals, 
one example of which is the growth of hydroxyapatite crystals,52 which make bones hard and 
stiff. It is believed that the periodic fashion in which the collagen fibres in bones pack, results 
in the uniform size and orientation of the apatite crystals. Microemulsions58,59 and  gels60 
heterogeneously nucleate supersaturated solutions. This can aid polymorph selectivity by 
supplying nucleation points which lower the thermodynamic energy barrier to crystallisation 
as well as offering a unique enclosed environment which may favour certain polymorphs. 
Secondary nucleation occurs when an already formed crystal nucleates crystal growth.61 
Seeding is a form of secondary nucleation which is used to promote and control 
crystallisation.47 A small amount of crystalline material is added to a supersaturated solution, 
this solid material nucleates the solution, allowing crystal growth on its surface. One use of 
seeding is used to promote protein crystal growth.62  There has been extensive work into 
looking for a ‘universal nucleant’ which would cause any protein to crystallise, making 
protein crystallisation a much more reproducible and simple endeavour.63 Whilst no perfect 
solution has been found, limited success has been achieved with charged surfaces, epitaxy64 
and porous materials.65 Another commonly employed use for seeding is selectively forming 
a particular polymorph. Polymorphs of the same chemical can have varying physical 
properties, such as solubility and melting point.45 Controlling which polymorph forms is 
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important in a variety of applications. The exact polymorph can change the colour of a 
pigment,66 decrease or increase the efficiency of explosives67 and vary the bioavailability of 
drugs.68,69 A small crystal of the desired polymorph is added to the supersaturated solution. 
This acts as a nucleation point and promotes formation of the same polymorph which was 
used to seed.  
So far, the focus has been on crystallising single components. Sometimes in solvent 
crystallisations the solvent becomes part of the crystal structure, creating solvates. Not only 
solvent, but a whole host of other materials can be incorporated into crystal, creating 
multicomponent crystals. 
1.3 Multicomponent crystals 
1.3.1 Cocrystals 
By the classification system by Grothe et al.70 a cocrystal is a crystal containing two or more 
coformers which are defined as neutral components which are solid at room temperature 
which is defined as 293.15 K. The cocrystal classification can be broken down into four sub 
classifications: true cocrystals containing only coformers; solvate cocrystals containing two 
or more coformers and a one or more solvent molecules; salt cocrystals contain two or more 
ions and at least one coformer and finally cocrystal salt solvates which contain at least two 
ions, one or more solvent molecule and one or more coformer. A cocrystal can show different 
physical properties to the pure sample, such as variations in melting point and often a change 
in the solubility. Similar to polymorph selection, the variation in cocrystal solubility is of 
particular interest in pharmaceutics to aid the bioavailability of poorly water soluble drugs 
and possibly give an easy route to patenting a product without going through the full clinical 
trials required by analogues.71  
There exists a list of potential cocrystallising compounds (coformers) which are generally 
recognised as safe (GRAS) which forms the foundation of cocrystal screening in the 
pharmaceutical industry. A few programs, such as COSMOfrag,72 exist to calculate the 
expected interaction between a compound and this list of additives. The top 10% of additives 
which are shown to be eligible are usually chosen for further screening. This at the time of 
writing results in 37 potential additives, which is not an insignificant number to work with. 
After this selection is made, there are two main ways of screening for cocrystals.  
The first is to dissolve the two components together and allow the solution to crystallise, 
often by slow evaporation, but cooling can be also used. This method can run afoul of the 
difference in solubility between the two components.73,74 For example, in a 1:1 mixture of A 
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and B, where B is more soluble, when evaporating crystals of A will form, whilst B will stay in 
solution, line L in Figure 1.3. There are two options to avoid this.  First, mix the components 
in the ratio of their solubility then evaporate, line P in Figure 1.3.  Second, create a saturated 
(or almost saturated) solution of one component, in this case B, then add small amounts of 
A, following line R (or Q if almost saturated) on the diagram. 
 
Figure 1.3 - Ternary diagram with coformers A and B, where B is more soluble than A and solvent S. Path L 
shows the evaporation of a 1:1 mixture of A and B. Path P shows the evaporation of the conformers mixed in 
the ratio of their solubility. R and Q are A being added to a saturated and nearly saturated solution of B 
respectively.73 
The second method of screening is mechanochemistry, such as grinding.75–78 A mix of 
components are ground together and then analysed by a technique not requiring single 
crystals, such as powder x-ray diffraction, IR and Raman spectroscopy. If the interactions are 
not sufficient for cocrystal formation, the powder pattern will just show a mixture of the two 
components. In a successful cocrystal formation, a new species, that of the ground cocrystal, 
should appear. Grinding can be done by hand, in a mortar and pestle, or mechanically in a 
mill. It can be advantageous to add a small amount of solvent. This increases the surface area 
by dissolving a small amount of material, so facilitates the interactions between the two 
components. This is referred to as solvent drop grinding.79,80 Another method is sonic slurry. 
1: Introduction 
23 
 
The coformers are added to a solvent in which they are not soluble to make a slurry. This 
slurry is then sonicated. This mixes the coformers in a similar way to the grinding process, 
potentially creating a cocrystal powder.73,78    
1.3.2 Hydrates 
Solvates are classified by Grothe et al.70 as crystals contain one or more solvent molecules, 
with a solvent being defined as a compound which is liquid at 293.15 K and another 
component. In true solvates this second component is a single coformer; in salt solvates it is 
two or more ions; in cocrystal solvates it is two or more coformers and in a cocrystal salt 
solvate it is at least two ions and at least two coformers. Hydrates are the most commonly 
formed type of solvate. Searching for ‘hydrate’ in the Cambridge Structure Database (CSD)81 
returns over 83,000 results. The large number of hydrate structures is at least partially due 
to the ubiquity of water. Water can get into a crystallisation from a damp solvent, absorption 
from the air, or left over from a previous reaction step.  
There is not yet a completely reliable method for reliably predicting the formation of 
hydrates, or the stoichiometry. Predicting if a hydrate will form is more complicated than 
simply looking for potential interactions between the molecule and water. Inclusion of 
hydrogen bonding groups, such as OH, NH or SH, will not necessarily result in a hydrate 
crystal. For example, 2,4-dihydroxybenzoic acid forms two different hydrates, with different 
stoichiometry, whilst 2,5-hydroxybenzoic acid forms none, even though they are isomers.82 
Braun et al.82 successfully predicted which hydroxybenzoic acid hydrates would form by 
comparing calculated lattice energy of the hydrate structures to the lattice energies of a 
selection of ice polymorphs. Those with a more negative lattice energy than ice, or that fall 
within the range of the ice polymorphs, are capable of forming hydrated crystals. The 
predictions held true for which hydrates of 2,4-dihydroxybenzoic acid will form and that 2,5-
hydroxybenzoic acid forms none, though the relative stability of the structures was not 
successfully predicted. Whilst a promising start into hydrate prediction, there are 
improvements to be made before this method can be applied reliably to other systems.  
Even though there are not steadfast rules, analyses of the CSD has given rise to a number of 
general trends.83 The more hydrogen bonding groups that there are and the greater polarity 
a molecule has, the more likely for a hydrate to form. Also, a molecule which has more 
hydrogen bond accepting groups than donating groups, will mainly accept hydrogen bonds 
from water. Similarly if a molecule had more hydrogen bond donating groups than accepting 
groups, it will mostly donate hydrogen bonds to water. Water’s ability to donate and accept 
multiple hydrogen bonds allows molecules with inequality in the number of donor and 
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acceptor groups to maximise the number of hydrogen bonds formed by hydrogen bonding 
with water molecules. This makes a more thermodynamically stable crystal structure and is 
suggested to be a possible driving force for hydrate formation.83 This has not been proven 
though, as there is no correlation between the inequality in donor and acceptor groups and 
the formation of hydrates.83  
In a system where there are multiple water molecules for every molecule of the crystal 
forming species, these water molecules hydrogen bond together. There is a range of 
commonly formed motifs, that almost all hydrate structures fall into.84 There are five 
classifications of hydrogen bonded water motifs in hydrates and a sixth that is for the 
unclassified:  
Discrete chains – a single water molecule or a small number of water molecules bonded 
acyclicly 
Discrete rings – isolated rings of water atoms 
Infinite chains – one dimensional lines of water with no rings 
Infinite tapes – one dimensional, involves rings 
Infinite layers – two dimensional layer, involves rings 
Unclassified – complexes networks, possibly contains a mixture of the other classifications.  
As most arrangements of water have been seen in a crystal structure before, there is debate 
on the novelty and use of trying to identify more hydrates. In a critical review on the matter, 
Mascal et al.85 conclude that a new hydrate structure is probably in itself not novel, 
interesting or giving any specific information about the system studied. But as part of a 
whole, included with every other hydrate structure known, it adds to the collective 
information of the interaction of water with an immense range of different compounds, 
adding to the overall story of how water freezes in different environments. 
1.4 Coamorphous materials 
There are occasions where crystalline products are not desirable and instead an amorphous 
solid is required. One example of this is the prevention of ice crystals forming in ice cream. 
To help prevent ice formation and keep the texture smooth polymeric additives, such as guar 
gum, are added.86,87 In the pharmaceutical industry coamorphous materials are of particular 
importance. As previously described in section 1.1, many drug molecules are highly 
polymorphic and making sure that only one polymorph is formed reliably on an industrial 
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scale can be challenging and variations in polymorph can result in variations in dosage and 
efficiency. Stabilising the amorphous form of a drug is a desirable alternative, as it is can be 
easier than harvesting a single polymorph, especially if the polymorph required readily 
converts to a different crystal form, or multiple forms crystallise from similar conditions. 
Amorphous materials are less thermodynamically stable than crystalline forms of the same 
chemical, this results in a higher solubility of the amorphous forms. With respect to drug 
formulation, this can lead to better bioavailability as more of the drug can dissolve. The exact 
degree of solubility improvement can be difficult to quantify as the metastable nature of 
amorphous forms may result in conversion to a crystal form before an accurate value has 
been recorded. Calculations based on the thermodynamic stability of the amorphous and 
crystalline forms of drugs predict increases in solubility between 10 and 1600 times greater 
for the amorphous form than the most stable crystal form.88 In reality, values between 1.4 
and 10 have been recorded,89–93 though it has been suggested that only low levels of 
amorphous material, 10 % or less, can increase the solubility two fold or more.88 
Amorphous drug formulations are often stabilised by dispersing the drug in a glassy polymer, 
such as PVP.94–97 This stabilisation arises from decreasing the molecular mobility of the drug 
molecules.98 Polymers can often have a relatively high glass transition temperature, Tg, when 
compared to drug molecules and dispersion in the glassy polymer inhibits molecular mobility 
enough to prevent the rearrangement necessary for crystallisation. Chemical bonding, such 
as hydrogen bonding to the carbonyl groups in PVP, further lowers the molecular mobility of 
the drug molecules, increasing the amorphous stability. The down side of using polymers 
such as PVP, is that many which have enough interaction with the drug molecules to be 
effective stabilisers, also interact with water.99 This leads to moisture uptake from the air. 
The water acts as a plasticiser, increasing molecular mobility and promoting crystallisation.100 
Another potential issue with hydrophilic polymers as amorphous stabilisers is the miscibility 
of the polymer and drug.101 Poor miscibility requires a high loading of polymer which results 
in either large pills, or multiple pills, to achieve the necessary therapeutic dose. 
To avoid complication due to moisture uptake and poor polymer miscibility, small molecule 
stabilisers have been investigated. In some cases, a second drug molecule can stabilise the 
amorphous form as well as administer two drugs at once.102 Amino acids have also been 
tested, as many drugs interact with proteins in the body, it stands to reason that amino acids 
may interact with drug molecules outside of the body.103,104 ROY (5-methyl-2-[(2-nitro- 
phenyl)amino]-3-thiophenecarbonitrile), standing for red, orange, yellow which are the 
colours of its many polymorphs, is a precursor to the antipsychotic drug olanzapine. ROY has 
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been extensively studied as it is highly polymorphic with 10 forms found so far.105,106 Corner 
et al.107 found it is possible to stabilise the amorphous form of ROY using pyrogallol which 
showed comparable efficiency to amorphous ROY stabilised with PVP. 
1.5 Project aims and overview 
The aim of this project is to get closer towards fully understanding how PVCap and PVP 
prevent clathrate hydrate formation by exploring the interactions of low molecular weight 
model compounds in a variety of different situations. In chapter 2, the synthesis of model 
compounds to mimic the KHIs is covered.  
Chapter 3 covers attempts to cocrystallise the model compounds. The ideal conclusion would 
be to achieve a hydrated crystal which would allow observation of how the model 
compounds interact with water, though interactions with coformer without water would 
also give information on the behaviour of the model compounds. 
Chapter 4 covers the crosslinking of guar using cocrystals of the model compounds. It is 
explored whether the interactions which hold the cocrystal together are persistent enough 
in solution to modify the reaction of boronic acids with guar. 
The effects of the acid gases H2S and CO2 on the interactions of KHIs with water is explored 
in chapter 5. Clathrate hydrates are especially troublesome and dangerous in sour gas 
pipelines and it has been observed that more inhibitor must be added to control their 
formation.13 Section 5 investigates if the acid gases interfere with the KHIs interactions with 
water. 
Neutron scattering is used in chapter 6 to study butoxyethanol and PVCap in water. 
Butoxyethanol is a known synergist for PVCap.24 Small angle neutron scattering (SANS) was 
used to try and visualise any interactions between PVCap and butoxyethanol. 
Finally chapter 7 tests the model compounds’ efficiency at stabilising amorphous forms of 
drugs. PVP is a used amorphous stabiliser,94–97 so low molecular weight compounds designed 
to mimic PVP may also be capable at stabilising amorphous forms. 
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2 Model compounds 
2.1 Introduction 
The KHIs used in the oilfield industry are all water soluble polymers.1 Unfortunately polymers 
are notoriously difficult to study and characterise, as the large molecular weights and 
polydispersity of the samples makes commonly used analytical techniques, such as NMR 
spectroscopy, complicated. Well-defined, low molecular weight models of polymers are a 
useful tool to avoid the difficulties in analysis which arise from high molecular weights. Whilst 
low molecular weight models are easier to analyse, they may not exhibit the same 
characteristics or behaviour as the polymer. The nearer to the polymer a model is, the more 
relevant the data becomes. For example, a dimer is a better model than a monomer and an 
oligomer is a better model than a dimer, but increasing the chain length of the model soon 
leads to the same difficulties of analysis as the polymer.  Davenport et al.2 previously 
synthesised a vinylcaprolactam dimer, bisVCap and the hydrogenated version, H2bisVCap to 
serve as models for PVCap. They went on to show by way of IR and NMR titrations, in which 
water was added to the model compounds and the polymer, PVCap, that the model 
compounds interact with water in a way comparable to PVCap, suggesting that the dimers 
are reasonable compounds to model the polymer. 
The aim of this chapter is to synthesise low molecular weight model compounds of common 
KHIs. The most straightforward models are dimers of vinylpyrrolidone (VP) and 
vinylcaprolactam (VCap), the monomers used to produce PVP and PVCap respectively. 
Dimers of VP and VCap, bisVP and bisVCap, and their hydrogenated forms, H2bisVP and 
H2bisVCap are already known.2,3 Model compounds containing a pyrrolidone and 
caprolactam ring are of interest as copolymers of VP and VCap are commercially used as 
hydrate inhibitors in pipelines.1 Similarly alcohol and ether functionalities are common in KHI 
copolymers,1 leading to new possibilities for low molecular weight model compounds of 
commercial KHIs. 
2.2 Results and discussion 
To mimic PVP and PVCap a range of low molecular weight compounds containing pyrrolidone 
and caprolactam rings have been synthesised as shown in Scheme 2.1. Compounds 6-9 have 
been previously synthesised in the group and 11 was supplied by Ashland Inc. all of which 
have previously been used by the group.2,3 Perrin found 11 much more effective than 6-9 in 
2: Model compounds 
34 
 
complexing metals,3,4 so more model compounds containing ether links similar to 11, 
compounds 11-16,  were designed and synthesised to attempt complexation with metals.  
 
Scheme 2.1 – Structure of the models compounds based on industrially used KHI polymers. 
2.2.1 BisVCap and H2bisVCap 
BisVCap was prepared by the method outlined by Davenport et al.2 and resulted in a white 
powder. The hydrogenation to H2bisVCap was performed using a balloon of hydrogen and a 
Pd/C catalyst, resulting in a viscous, pale yellow liquid.  
Previously Davenport et al. synthesised bisVCap and bisVCap to model PVCap. To prove the 
validity of the model IR and NMR titrations, where water was added to acetonitrile solution 
of PVCap, bisVCap and H2bisVCap and changes in the spectra monitored, were performed. 
The titrations showed the hydration behaviour of the model compounds, 6 and 7, to be 
similar to that of PVCap and thus be appropriate models with which to study the hydrate 
inhibition effects of PVCap. To further assess the validity of the model compounds, the 
moisture absorption of PVCap, 5 and 6 was studied using dynamic vapour sorption (DVS). 
DVS is used to study the uptake of water by a compounds against humidity. The sample is 
loaded onto an accurate microbalance and the relative humidity (RH) is increased and 
decreased. The changes in mass of the sample are measured and plot against RH. This gives 
information on hydroscopicity and hydrate formation. Samples begin at room humidity, 
often 40 %RH, the humidity is then increased to 90 %RH, decreased to 0 %RH, increased 
again to 90 %RH and finally decreased once more to 0 %RH. Percentage mass changes are 
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calculated using the smallest recorded mass, so if a sample began with some absorbed or 
adsorbed water which is lost on decreasing the RH, the lowest value, which is the mass 
closest to the mass of the completely dehydrated sample, is used as the mass of the sample.    
In Figure 2.1 the DVS plots for PVP and PVCap can be found. Both show the hysteresis 
associated with hydroscopic materials which readily hydrate but require a significant 
decrease in humidity before it starts to lose water again because of the strong interactions 
between the water and the material. PVP shows a large increase in mass, 39.8 %, which is in 
agreement with the literature.5 This mass increase corresponds to 2.5 water molecules per 
carbonyl group. PVCap on the other hand is less hydroscopic, showing a mass increase of 
16.6 % which corresponds to 1.3 water molecules per carbonyl group. 
   
Figure 2.1 - DVS plot of a) PVP and b) PVCap. 
The DVS plot for bisVCap, Figure 2.2, does not suggest the formation of any hydrates. The 
lack of hysteresis and small mass increase, 0.35 %, is indicative of moisture adsorption onto 
a surface with no strong interactions. As a mass increase of 0.35 % gives 0.05 water molecules 
per molecule of bisVCap, it is apparent that no hydrate structure is formed.  
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Figure 2.2 - DVS plot of bisVCap.  
H2bisVCap is normally a liquid at room temperature. As a crystal structure has been 
previously reported on a sample which had undergone very vigorous drying,2 it is probable 
that H2bisVCap is only liquid due to adsorbed water. During the DVS experiment the humidity 
was first set to 0 %RH and the sample was left until a mass change smaller than 0.001 % was 
detected to dehydrate the sample as much as is possible in the experimental setup. The 
humidity was then increased to 90 %RH, decreased to 0 %RH, increased again to 90 %RH. On 
the final decrease the humidity was only decreased to 40 %RH and a final increase to 96 %RH 
was performed as can be seen in Figure 2.3. The DVS plot for H2bisVCap shows a significant 
hysteresis which is indicative of a hydroscopic material. From the smallest mass to the mass 
at 90 %RH there is a mass increase of 17.8 %, which corresponds to 2.8 water molecules per 
molecule of H2bisVCap. As H2bisVCap has two carbonyl moieties this results in 1.4 water 
molecules per carbonyl moiety. This is comparable to the 1.3 water molecules per moiety 
seen at 90 %RH with PVCap. DVS shows the hydrogenated dimer to be a much better model 
for H2bisVCap, as it shows similar hydroscopic nature and the same degree of water 
adsorption by 90 %RH.  
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Figure 2.3 - DVS plot of H2bisVCap. 
Upon increasing the humidity to 96 %RH there is a further increase to 26.7 % mass increase. 
This corresponds to 4.2 water molecules per molecule of H2bisVCap or 2.1 water molecules 
per carbonyl moiety. In a hydration study on PVP by Kobyakov et al.6 it was proposed that at 
low water:PVP ratio, 1.7:1 or less, there was a single water molecule hydrogen bonding to 
the carbonyl groups, Scheme 2.2a, but at higher water:PVP ratio there was two water 
molecules, one hydrogen bonding to each lone pair of the oxygen, Scheme 2.2b. The 
absorption of two water molecules per carbonyl group in H2bisVCap at 96 %RH probably 
follows a similar bonding scheme to that suggested for PVP, with both lone pairs of the 
carbonyl oxygen atoms hydrogen bonding with water. 
 
Scheme 2.2 – Schematic of PVP binding a) one water molecule and b) two water molecules as proposed by 
Kobyakow et al.6 
For comparison a DVS plot of the monomer, VP, was also made. VP is usually not used as a 
model for PVCap as dimeric molecules are closer in structure to the polymer, so often better 
models to mimic the polymer. As can be seen in Figure 2.4, VP shows a small amount of 
hysteresis suggesting some hydroscopic behaviour. The mass increase is 5.4 % which 
corresponds to 0.4 water molecules per molecule of VP. Whilst the mass increase is greater 
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than that for bisVCap it is still lower than PVCap or H2bisVCap, suggesting that whilst VP may 
show some hydroscopic characteristics, it does not interact as strongly with water as 
H2bisVCap or PVCap so is a less suitable model to study PVCap than H2bisVCap. 
 
Figure 2.4 - DVS plot of VP. 
In conclusion, the hydrogenated dimer, H2bisVCap, is a good model for PVCap, better than 
either bisVCap or VCap, which is expected as it is the nearest in structure to PVCap. VCap is 
a monomer and both VCap and bisVCap have alkene functionalities which are not present in 
the polymer. The water uptake of H2bisVCap is very similar to that of PVCap, including a 
hysteresis from being hydroscopic and adsorbing the same amount of water within error. 
2.2.2 BisVP 
BisVP was prepared using a modified version of the bisVCap preparation. The synthesis of 
bisVCap requires the use of trifluoroacetic acid (TFA).2 In the case of bisVP, trifluoroacetic 
acid resulted in a very poor yield. Changing the acid catalyst to sulfuric acid proved to be a 
much more effective, resulting in a 96 % yield. BisVP was isolated from the reaction mixture 
as a viscous, orange oil and no crystal structure has previously been recorded for this 
compound. A small amount of impurity, less than 1 % as specified by Sigma Aldrich, present 
from the starting material, VP, may be part of the cause for this lack of crystallisation, as the 
weak NMR signals from the impurity visible in the starting material are still present in the 
product. Attempts to crystallise bisVP by solvent evaporation resulted in thick oils and 
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crystallisation attempts by freezing gave glassy, non-crystalline materials. As part of the 
experiments into the effects of sour gases on the interactions of KHIs with water, which are 
detailed in chapter 5, attempts to form clathrate structures of the model compounds with 
CO2 and H2S were performed. One such experiment involved preparing a solution of bisVP in 
acetone, bubbling CO2 through this solution then leaving in the freezer at -20 °C under an 
atmosphere of CO2. After 8 months at -20 °C, large yellow needles of diffraction quality were 
formed and analysed by single crystal x-ray analysis. Even though the crystal structure did 
not contain CO2, this is the first crystal structure of bisVP to be recorded. The crystal packing 
of bisVP can be seen in Figure 2.5. 
 
Figure 2.5 – Crystal packing in the structure of bisVP with the C-H···O hydrogen bonds shown by red dashed 
lines. 
The Hirshfeld surface fingerprint plots of bisVP and bisVCap are shown in Figure 2.6. Both 
fingerprints plots are similarly shaped. The main feature of both fingerprint plots are the 
peaks symmetrically either side of the diagonal, indicated by arrows. The peak in the upper 
left of the plot arises hydrogen bond donation of a C-H···O bond, the bottom right from the 
acceptance of this bond.  In both crystal structures this hydrogen bond is between the 
carbonyl of one lactam ring and a methylene C-H group of a lactam ring in a neighbouring 
molecule, as is illustrated by red dashed lines in Figure 2.5. The hydrogen bonds in bisVP have 
a C···O distance of 3.343(3) Å which is very similar to the length of the C-H···O hydrogen bond 
in the bisVCap crystal structure which has a C···O distance 3.346(2) Å. The fingerprint plot of 
bisVCap has more diffuse blue area than that seen in the fingerprint plot of bisVP. This diffuse 
blue area arises from more space in the crystal packing. This is reflected in the density of the 
two crystal structures, with bisVP being denser, 1.250 g cm-3, than the crystal of bisVCap, 
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1.231 g cm-3.  The pyrrolidone rings of bisVP are smaller and less bulky than the caprolactam 
rings of bisVCap, allowing for closer packing and thus a denser crystal structure. 
            
Figure 2.6 – Hirshfeld surface fingerprint plots of a) bisVP and b) bisVCap with the hydrogen bonding 
interactions shown by black arrows. 
2.2.3 H2bisVCap 
Hydrogenation of bisVP was attempted using a hydrogen balloon and 5 % Pd/C in methanol 
heated to 55 °C for 6 hours. Whilst this method was adequate for hydrogenating bisVCap, it 
did not give satisfactory results with bisVP. Only around 85 % conversion, measured by 1H 
NMR, was achieved and attempts to separate the hydrogenated dimer from the starting 
material using a column were challenging, resulting in broad peaks and many small 
unidentified peaks in the 1H NMR spectrum suggesting the product decomposes and possibly 
polymerises on silica.  
Compared to the hydrogen balloon reaction setup, a much higher pressure of hydrogen can 
be achieved using continuous flow hydrogenation equipment such the ThalesNano H-cube.7 
This often leads to greater selectivity and much higher yields. The ThalesNano H-cube can be 
used with a range of different catalysts, supplied in sealed cartridges.2 The hydrogenation of 
bisVP was attempted with three different catalyst cartridges: 10 % Pd/C, 5 % Ru/C and Raney 
Nickel. All experiments were carried out at 60 °C in methanol.  
None of the catalysts tested gave the desired 100 % conversion. In the experiment using the 
10 % Pd/C catalyst 92 % conversion was achieved. The reaction mixture was reacted a second 
time using the 10 % Pd/C catalyst to see if a better yield could be achieved. After the second 
reaction a slight improvement in conversion was seen. Whilst 93 % conversion is greater than 
92 % conversion, the improvement is small and the diminishing returns of continually 
reacting the same sample are not worth the long reaction times if a large enough sample for 
a) b) 
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crystal screening is to be achieved. Raney nickel gave 89 % conversion and 5 % Ru/C gave 93 
%.  
The NMR spectra of the crude H2bisVCap products produced with the hydrogen balloon and 
5 % Pd/C and those produced using the H-cube with either 10 % Pd/C, 5 % Ru/C or Raney 
Nickel all exhibited extra peaks in their NMR spectra which do not correspond to either bisVP 
of H2bisVP. It is possible that these peaks arise from reduction of the lactam functionality 
instead of, or in addition to, the alkene. Usually amides are relatively unreactive due to the 
high degree of enol character,8 but the ring strain in the pyrrolidone ring reduces the enol 
character,2 making the carbonyl more reactive than would normally be expected and more 
susceptible to reduction.9 Regardless of the nature of the side product, none of the 
hydrogenation methods attempted gave a pure product. 
Attempts to purify the sample of H2bisVP synthesised by the hydrogen balloon method were 
performed by HPLC-MS. A semi-prep scale HPLC was performed three times to recover 
enough of the fraction with a molecular mass of 225 to be able to obtain 1H and 13C NMR 
spectra. After evaporation of the solvent, a clear oil remained, 1H and 13C NMR spectra were 
consistent with the structure of pure H2bisVP.  Unfortunately even on the semi-prep scale 
only around 5-10 mg can be recovered from a 40 min experiment and the high volume of 
solvent required also increases the sample preparation time. As a minimum of 4 – 5 g of 
sample is required for cocrystal screening, HPLC is not a viable method for sample 
production. 
Due to the difficulties in making H2bisVP in reasonable purity, the crystallization experiments, 
detailed in section 3, proceeded with the crude product from the hydrogen balloon and 5 % 
Pd/C experiment. As crystallisation is itself a purification technique, it is possible that crystals 
or cocrystals of H2bisVP can be achieved even from an impure starting material. 
2.2.4 HEPVCap 
The synthesis of HEPVCap (10) was a variation on the synthesises of bisVCap and bisVP. An 
acid catalyst, TFA, was added to VCap and HEP. No bisHEP or bisVCap were formed in the 
reaction. Some residual HEP and VCap remained in the reaction mixture and a small amount 
of ε-caprolactam was formed as a minor side product. Decreasing the reaction temperature 
and increasing the reaction time greatly reduced the amount of starting material and side 
product in the final product and the residual VCap can be removed using an alumina column 
with 75:25 volume ratio of ether:methanol. A six hour reaction at 40 °C results in a product 
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of acceptable purity and the analytical and characterisation data is given in the experimental 
section, section 2.3.5 .  
2.2.5 Methoxyethylpyrrolidone (MEP) 
PVP and PVCap are both hydrogen bond accepting but not strongly hydrogen bond donating. 
Model compounds to mimic them should also reflect this. To remove the hydrogen bond 
donating group from hydroxyethylpyrrolidone (HEP), the hydroxyl group was converted to a 
methyl ether using NaH followed by iodomethane. A white solid was collected in a 95 % yield. 
2.2.6 Vinyl lactam diol reactions 
The synthesis of new ether containing model compounds was attempted to bind metals in a 
fashion similar to bisHEP (10).3,4 VP and VCap were reacted in acidic conditions with a range 
of diols: 1,2-ethandiol, 1,3-propanediol and 1,4-butanediol. The target products were two 
lactam rings, either two pyrrolidone or two caprolactam rings, attached by ether linkages to 
a carbon chain, compounds 13-16 in Scheme 2.1.  
Reaction of VP and VCap with butanediol and a sulfuric acid or TFA catalyst respectively 
resulted in addition of only one vinyl lactam to the butanediol. Increasing the lactam:diol 
ratio and lengthening the reaction time did not result in the addition of a second vinyl lactam. 
As butanediol does not readily react with two equivalents of vinyl lactam, no further work 
on the butanediol with VP and VCap was undertaken. 
Propanediol does not give a pure product with either VP or VCap. LCMS analysis suggests 
that bisVP and bisVCap are formed as major side products. As discussed in section 2.2.2, the 
lactam rings are not silica stable. For both the VP and VCap propanediol reaction mixtures, 
no solvent was found to give good separation on alumina. The crude products, 1,1'-[propane-
1,3-diylbis(oxyethane-1,1-diyl)]di(azepan-2-one) (Pr(OVCap)2) and 1,1'-[propane-1,3-
diylbis(oxyethane-1,1-diyl)]dipyrrolidin-2-one (Pr(OVP)2) were used in crystallisation 
attempts with metals (see section 3.2.3) as bisVCap and bisVP have shown only a very limited 
capacity for binding to metals4 it is possible that complexed structure of these two new ether 
compounds will preferentially bind to metals over bisVCap and bisVP. 
Reactions with VCap and VP with 1,2-ethanediol gave fewer side products than the reactions 
with propanediol. The VP derivative, 1,1'-[ethane-1,2-diylbis(oxyethane-1,1-
diyl)]dipyrrolidin-2-one (Et(OVP)2), contained a significant amount of bisVP, but the 
caprolactam/ethanediol product, 1,1'-[ethane-1,2-diylbis(oxyethane-1,1-diyl)]di(azepan-2-
one) (Et(OVCap)2), precipitated out as an off white solid with a 70 % yield. The full range of 
crystallisations attempted are detailed in section 3.2.3. Crystals of Et(OVCap)2 were isolated 
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by slow evaporation from water as part of attempts to form cadmium(II) chloride and acetate 
complexes of the ligand. The compound was characterised by x-ray crystallography and the 
crystal packing can be seen in Figure 2.7 
          
Figure 2.7 – Crystal packing of Et(OVCap)2 with hydrogen bonds are shown by red dashed lines view down a) 
the crystallographic axis and b) the crystallographic b axis. 
The asymmetric unit contains half of the molecule with a rotation relating the other half of 
the molecule. The crystal structure contains only a single diastereomer even though there 
are two chiral carbon atoms present so potentially three isomers possible. The crystals 
formed in the presence of CdCl2 and the crystals formed in the presence of Cd(O2C2H3)2 both 
contain the same isomer. The NMR spectra of Et(OVCap)2 also do not show two 
diasteroemers, suggesting that the reaction diastereomerically selective. The crystal 
structure is held together primarily by C-H···O hydrogen bonds. Each carbonyl group accepts 
two hydrogen bonds, one from the C-H next to the carbonyl group of one neighbouring 
molecule and the other from the C-H adjacent to the nitrogen of the lactam ring of a different 
molecule. These hydrogen bonds have C···O distances of 3.295(2) Å and 3.243(2) Å 
respectively. The hydrogen bonds can be seen in the Hirshfeld surface fingerprint plot in 
a) b) 
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Figure 2.8 as two peaks equidistant from the diagonal which are highlighted by black arrows. 
The symmetry of these peaks reflects that both the hydrogen bond accepting and donating 
character are identical, which is to be expected from the symmetry of the structure. The 
other feature of note in the Hirshfeld surface fingerprint plot is the green area of very high 
occurrence frequency in the centre of the plot, this arises from H-H proximity from the close 
packing of the crystal structure.  
 
Figure 2.8 - Hirshfeld surface fingerprint plot of Et(OVCap)2. Hydrogen bonding interactions are indicated by 
black arrows. 
2.3 Experimental 
2.3.1 Synthesis of BisVCap 
Adapted from the procedure by Davenport et al.2 
 
 
N-vinyl(caprolactam) (5.00 g, 6.0 mmol) was added to hexane (45 cm3) in a 100 cm3 two neck 
flask with a reflux condenser. Dissolution of the VCap occurred upon heating to 50 °C. TFA 
(0.2 cm3) was added and the reaction mixture was then heated at 60 °C for 3 hours, during 
which a white precipitate formed. The solid was isolated by vacuum filtration using a Buchner 
funnel and subsequently washed with 3x20 mL of n-hexane to give the product as a while 
solid.  
Yield 4.20 g, 15.0 mmol, 84 % 
1H NMR (400 MHz, CDCl3) δ 7.27 (dd, J = 14.9, 1.8 Hz, 1H, vinyl NCH), 5.48-5.41 (m, 1H, NCH 
), 5.02 (dd, J = 14.9, 5.0 Hz, 1H, vinyl CH), 3.59-3.57 (m, 2H, CH2), 3.21-3.18 (m, 2H, CH2), 2.67-
2.64 (m, 2H, CH2), 2.58-2.55 (m, 2H, CH2), 1.76-1.65 (m, 12H), 1.27 (d, J = 6.9 Hz, 3H, CH3). 
2: Model compounds 
45 
 
13C{1H} NMR (101 MHz, CDCl3) δ 200.61, 175.92, 76.69, 48.67, 44.74, 43.32, 43.04, 37.59, 
36.49, 30.56, 29.93, 29.67, 29.33, 23.35, 23.16, 18.60. 
IR ν = 1667 (C=C), 1640 (C=O), 1621 cm-1 (C=O)  
2.3.2 Hydrogenation of BisVCap 
 
 
 
BisVCap (1.00 g, 3.60 mmol) was dissolved in 25 mL of methanol. 0.05 g of 5 % palladium on 
activated carbon was added. A hydrogen balloon and exit needle were used to purge the 
reaction for one minute before the exit needle was removed. The mixture was stirred at 55 
°C for 6 hours. Every hour the exit needle was introduced to relieve pressure, once the exit 
needle was removed the reaction vessel was shaken to assure good accessibility of the 
hydrogen. After the 4 hours, the reaction was allowed to cool to room temperature. The 
solution was then filtered through Celite. The methanol was removed under vacuum leaving 
a yellow oil. This oil was then thoroughly mixed with 40 cm3 of diethyl ether which was the 
evaporated under vacuum. The addition of ether and evaporation was repeated 3 times. The 
resulting yellow oil was left in a vacuum desiccator under vacuum overnight. 
1H NMR (400 MHz, CDCl3) δ 4.77-4.68 (m, 1H), 3.59-3.52 (m, 1H), 3.36-3.33 (m, 2H), 3.29-
3.24 (m, 2H), 3.09-3.01 (m, 1H), 2.61-2.45 (m, 4H), 1.82-1.53 (m, 14H), 1.12 (d, J = 6.9 Hz, 3H) 
13C {1H} NMR (101 MHz, CDCl3) δ 176.06, 175.71, 50.12, 46.77, 46.46, 42.50, 37.65, 37.26, 
32.46, 30.05, 29.99, 29.38, 28.68, 23.49, 23.37, 18.62 
IR ν = 1631 cm-1 (C=O)  
2.3.3 Synthesis of BisVP 
Adapted from the procedure by Zhuo.10 
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N-vinyl(pyrollidone) (29.0 cm3, 272 mmol) was added to cyclohexane (13 cm3) in a two neck 
round bottom flask with a reflux condenser. The mixture was heated to 50 °C and 3 drops of 
H2SO4 added. The mixture was then heated at 70 °C for 6 hours. A majority of the solvent 
was removed under vacuum to leave a thick yellow-orange oil. This oil was then thoroughly 
mixed with 40 cm3 of ether which was the evaporated under vacuum. The addition of ether 
and evaporation was repeated 3 times. The resulting yellow-orange oil was left in a vacuum 
desiccator under vacuum overnight. 
Yield 28.0 g, 126 mmol,  96 % 
1H NMR (400 MHz, CDCl3) δ 6.95 (d, J = 13.9 Hz, 1H, vinyl NCH), 4.92-4.81 (m, 2H, vinyl CH 
and NCH ), 3.45 (t, J = 7.2 Hz, 2H, CH2), 3.33-3.20 (m, 2H, CH2), 2.45 (m, 2H, CH2), 2.35 (m, 2H, 
CH2), 2.11-2.04 (m, 2H, CH2), 1.99-1.92 (m, 2H, CH2), 1.25 (d, J = 6.8 Hz, 3H, CH3) 
13C {1H} NMR (101 MHz, CDCl3) δ 174.13, 173.22, 125.09, 110.66, 45.99, 45.16, 42.34, 31.46, 
31.15, 26.85  
IR ν = 1673 (C=O), 1659 cm-1 (C=O) 
2.3.4 Hydrogenation of BisVP 
 
 
 
BisVP (7.00 g, 31.5 mmol) was dissolved in ca. 25 mL of methanol. 0.2 g of 5 % palladium on 
activated carbon was added. A hydrogen balloon and exit needle were used to purge the 
reaction for one minute before the exit needle was removed leaving the balloon attached to 
the apparatus. The mixture was stirred at 55 °C for 6 hours. Every hour the exit needle was 
introduced to relieve pressure, once the exit needle was removed the reaction vessel was 
shaken to assure dissolution of the hydrogen. The solution was filtered through Celite and 
the methanol evaporated under vacuum, leaving a yellow oil. This oil was then thoroughly 
mixed with 40 cm3 of ether which was the evaporated under vacuum. The addition of ether 
and evaporation was repeated 3 times. The resulting yellow oil was left in a vacuum 
desiccator under vacuum overnight. 
Conversion 85 % by NMR.  
2: Model compounds 
47 
 
Four solutions of bisVP (0.5 g, 2.24 mmol) in methanol (20 mL) were hydrogenated using a 
ThalesNano H-Cube® Continuous-flow Hydrogenation Reactor at 60 °C, 5 bar of hydrogen 
and a flow rate of 1 mL min-1. For three of the reactions different catalysts were used: 10 % 
Pd/C, 5 % Ru/C and Raney nickel. For fourth solution the 10 % Pd/C catalyst was used and 
the reaction mixture was run through the machine twice to try and convert and remaining 
unconverted material. 
Conversion from 10 % Pd/C 92 % by NMR.  
Conversion from 5 % Ru/C  93 % by NMR.  
Conversion from Raney nickel 89 % by NMR.  
Conversion from two runs of 10 % Pd/C 93 % by NMR.  
Chromatography was performed with a semi-prep Varian LC with a UV-vis detector using a 
Sunfire C18 OBD 19x 100 mm i.d. 5 µm column. The solvent gradient used was 20 % methanol 
80 % water changing to 40 % methanol 60 % water over the course of 10 minutes. Fractions 
were analysed by electrospray mass spectrometry.  
The fraction relating to the peak at 5.91 minutes with a mass of 225 was collected. A majority 
of the solvent was removed under vacuum to leave a clear, colourless oil. This oil was then 
thoroughly mixed with 40 cm3 of ether which was the evaporated under vacuum. The 
addition of ether and evaporation was repeated 3 times. The resulting clear oil was left in a 
vacuum desiccator under vacuum overnight. 
1H NMR (400 MHz, CDCl3) δ 4.23-4.16 (m, 1H), 3.52-3.48 (m, 1H), 3.45 – 3.30 (m, 4H), 3.16-
3.09 (m, 1H), 2.55 – 2.36 (m, 4H), 2.13-2.02 (m, 4H), 1.80 – 1.67 (m, 2H), 1.18 (d, J = 6.8 Hz, 
3H) 
13C {1H} NMR (101 MHz, CDCl3) δ 175.40, 175.28, 47.65, 44.81, 42.31, 39.95, 31.45, 31.31, 
30.92, 18.12, 17.99 
2.3.5 Synthesis of HEPVCap 
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N-vinyl(caprolactam) (2.0 g, 14.4 mmol) and hydroxyethylpyrrolidone (1.9 g, 14.4 mmol) 
were added to cyclohexane (10 cm3) in a two neck round bottom flask with a reflux 
condenser. 0.5 cm3 of TFA was added and the mixture was heated at 40 °C for 6 hours. The 
solvent was removed under vacuum to leave an orange oil. Unreacted VCap was removed 
using an alumina column with 75:25 diethylether:methanol mobile phase. The solvent was 
removed under vacuum and the resulting yellow oil was left in a vacuum desiccator under 
vacuum overnight to remove any remaining solvent residues. The elemental composition 
was confirmed by accurate mass mass spectrometry.  
1H NMR (400 MHz, D2O) δ 5.58 (q, J = 6.0 Hz, 1H), 3.54 – 3.37 (m, 6H), 3.37 – 3.28 (m, 1H), 
3.23-3.15 (m, 1H) 2.63 – 2.42 (m, 2H), 2.35 (t, J = 8.1 Hz, 2H), 2.00 (q, J = 7.5 Hz, 2 H) 1.79 – 
1.46 (m, 6H), 1.23 (d, J = 6.0 Hz, 3H). 
13C {1H} NMR (101 MHz, CDCl3) δ 176.70, 175.18, 79.33, 65.37, 48.34, 42.36, 40.96, 37.61, 
30.82, 29.98, 29.26, 23.48, 19.19, 18.05. 
m/z 559 (2M+H+, 100%), 269 (M+H+, 58), 140 (45), 130 (36), 65 (14) 
2.3.6 Synthesis of methoxyethylpyrrolidone  
 
Hydroxyethylpyrollidone (5.00 g, 38.5 mmol) was dissolved in dry THF (50 cm3). The mixture 
was cooled to 0 °C using an ice bath then NaH (1.38 g, 57.7 mmol) was added. The resulting 
suspension was stirred and allowed to slowly warm to room temperature for 1.5 hours. 
Iodomethane (2.24 cm3, 38.5 mmol) was added and the reaction mixture was stirred at room 
temperature for 1.5 hours before a second addition of iodomethane (2.24 cm3, 38.5 mmol) 
which was stirred at room temperature for a further 1.5 hours. The white precipitate was 
removed by filtration through a sintered glass funnel. This white solid was then dissolved in 
acetone, filtered through a sintered glass funnel and the solvent was removed under vacuum 
giving 2.5 g of a white solid. The filtrate from the reaction mixture had the solvent removed 
under vacuum, diethylether (20 cm3) was added to the resulting yellow oil and the sample 
was sonicated for one minute. The sample was left for 2 minutes until two distinct layers had 
formed. The cloudy top layer was decanter away. The washing with diethylether (20 cm3) 
was performed a total of 4 times, resulting in an off-white damp looking solid. The solid was 
left in a vacuum desiccator under vacuum overnight to remove any residual diethylether. 
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The resulting damp yellow solid was repeatedly pressed between two clean filter papers until 
a dry white powder, 3.2 g remained.     
Yield 5.2 g, 36.4 mmol, 95 % 
1H NMR (400 MHz, D2O) 3.56 (t, J = 5.3 Hz, 2H), 3.7 (t, 8.2 Hz, 2H), 3.39 (t, J = 5.3 Hz, 2H), 3.29 
(s, 3H), 2.37 (t, J = 8.2 Hz, 2H), 1.98 (d, J = 8.2 Hz, 2H) 
13C NMR (101 MHz, D2O) δ 178.65, 68.69, 57.87, 48.26, 41.91, 30.95, 17.26 
m/z 144 (M+H+, 58 %), 112 (100) 
2.3.7 Synthesis of Et(OVCap)2 
 
Ethylene glycol (1 cm3, 17.9 mmol) and VCap (4.97 g, 35.8 mmol) were added to dry hexane 
(20 cm3) in a 100 cm3 two neck flask with a reflux condenser. TFA (0.2 cm3) was added to the 
reaction was heated at 70 °C for 6 hours. The reaction was then allowed to cool to room 
temperature and left to stand overnight for 17 hours. Overnight an off white solid formed. 
This solid was filtered under vacuum and washed with hexane (2 x 10 cm3).  
Yield 4.2 g, 12.6 mmol, 70 %  
1H NMR (400 MHz, CDCl3) δ 5.89 (q, J = 6.1 Hz, 2H), 3.57 – 3.42 (m, 4H), 3.42-3.32 (m, 7.1, 
2H), 3.31-3.18 (m, 2H), 2.66-2.45 (m, 4H), 1.89 – 1.57 (m, 10H), 1.6-1.47 (m, 2H), 1.28 (d, J = 
6.1 Hz, 6H) 
13C NMR (101 MHz, CDCl3) δ 176.57, 79.62, 66.69, 41.02, 37.80, 30.14, 29.37, 23.63, 19.26 
m/z 364 (M+Na+H+, 100 %), 158 (72), 141 (85)  
IR ν = 1636 cm-1 (C=O) 
2.3.8 Synthesis of Et(OVP)2 
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Ethylene glycol (1 cm3, 17.9 mmol) and VP (3.97 g, 35.8 mmol) were added to dry hexane (20 
cm3) in a 100 cm3 two neck flask with a reflux condenser. Sulfuric acid (0.2 cm3 ) was added 
to the reaction was heated at 70 °C for 6 hours. The reaction was then allowed to cool to 
room temperature and left to stand overnight for 17 hours. A viscous orange oil formed and 
settled to the bottom of the reaction vessel. The solvent was decanter off and the product 
dried under vacuum in a desiccator overnight.  
m/z 308 (M+Na+H+, 100 %), 223 (90), 83 (50)  
Due to impurity of the sample and long term HPLC issues, no clean NMR spectra were taken. 
2.3.9 Synthesis of Pr(OVCap)2 
 
Propane-1,3-diol (1 cm3, 14.1 mmol) and VP (3.94 g, 28.2 mmol) were added to dry hexane 
(20 cm3) in a 100 cm3 two neck flask with a reflux condenser. TFA (0.2 cm3) was added to the 
reaction was heated at 70 °C for 6 hours. The reaction was then allowed to cool to room 
temperature and left to stand overnight for 17 hours. A viscous orange oil formed and settled 
to the bottom of the reaction vessel. The solvent was decanter off and the product dried 
under vacuum in a desiccator overnight.  
m/z 378 (M+Na+H+, 35 %), 140 (100), 83 (35)  
Due to impurity of the sample and long term HPLC issues, no clean NMR spectra were taken. 
2.3.10 Synthesis of Pr(OVP)2 
 
Propane-1,3-diol (1 cm3, 14.1 mmol) and VP (3.12 g, 28.2 mmol) were added to dry hexane 
(20 cm3) in a 100 cm3 two neck flask with a reflux condenser. Sulfuric acid (0.2 cm3 ) was 
added to the reaction was heated at 70 °C for 6 hours. The reaction was then allowed to cool 
to room temperature and left to stand overnight for 17 hours. A viscous orange oil formed 
and settled to the bottom of the reaction vessel. The solvent was decanter off and the 
product dried under vacuum in a desiccator overnight.  
m/z 322 (M+Na+H+, 10 %), 197 (57), 111 (100)  
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Due to impurity of the sample and long term HPLC issues, no clean NMR spectra were taken. 
2.3.11 IR and NMR 
NMR spectra were recorded on a Bruker-Advance spectrometer, operating at 400 MHz, 
chemical shifts reported in ppm (δ) relative to residual solvent. 
IR experiments were performed on a Perkin Elmer FTIR spectrum 100 with an attenuated 
total reflectance (ATR) attachment. Data were recorded at a resolution of 1 cm-1 for 16 runs 
over the range 4000 – 600 cm-1. Spectral analysis was performed using SpekWin32.11 
2.3.12 Dynamic vapour sorption 
DVS was performed using an SMS DVS-1 with a 10 %RH step between humidity values with 
equilibrium achieved at 0.01% weight change before moving to the next step. Methods 
began at the humidity of the room at ambient which was measured by a Rotronic A/H 
hygrometer. The humidity was then increased to 90%RH before cycling to 0%RH, to 90%RH, 
to 0%RH. Samples weighing between 5-20mg were used. 
For the sample of H2bisVCap the humidity was first set to 0 %RH and the sample was left until 
a mass change smaller than 0.001 %. The humidity was then increased to 90 %RH, decreased 
to 0 %RH, increased to 90 %RH decreased to 40 %RH and finally increased to 96 %RH 
2.3.13 X-ray crystallography 
Single crystal crystallographic analysis of bisVP was performed on a Bruker Photon D8 
Venture diffractometer (ImuS microsource, λCuKα, λ = 1.54178 Å) equipped with a 
Cryostream (Oxford Cryosystems) open-flow nitrogen cryostat, at 120 K. The data collection 
and refinement was kindly carried out by Dr Dmitry S. Yufit.  
BisVP crystal data: Empirical formula C12H18N2O2, space group Pca21, a = 12.4684(9) Å, b = 
10.6073(8) Å, c = 8.9326(6) Å, α = 90.00°, β = 90.00°, γ = 90.00°, volume = 1181.39(15) Å3, Z 
= 4, F(000) = 480.0, CuKα (λ = 1.54178) 2θ range for data collection = 8.34 – 139.88°, data = 
2074, parameters = 146, goodness-of-fit on F2 = 1.084, R1 = 0.0583, wR2 = 0.1860  
Single crystal crystallographic analysis of bisVP was performed on a Bruker Photon D8 
Venture diffractometer (ImuS microsource, λMoKα, λ = 0.71073 Å) equipped with a 
Cryostream (Oxford Cryosystems) open-flow nitrogen cryostat, at 120 K. The data collection 
and refinement was kindly carried out by Dr Dmitry S. Yufit.  
Et(OVCap)2 crystal data: Empirical formula C18H32N2O4, space group P21/n, a = 11.6915(3) Å, 
b = 6.1181(2) Å, c = 13.8658(4) Å, α = 90.00°, β = 109.617(3)°, γ = 90.00°, volume = 934.25(5) 
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Å3, Z = 2, F(000) = 372.0, MoKα (λ = 0.71073) 2θ range for data collection = 5.582 – 59.996°, 
data = 2728, parameters = 110, goodness-of-fit on F2 = 1.046, R1 = 0.0799, wR2 = 0.1210 
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3 Cocrystallisation of hydrate inhibitor models 
3.1 Introduction 
One method to study the behaviour of KHIs with water is to crystallise hydrated structures 
of the model compounds in Scheme 2.1. Single crystal x-ray diffraction studies of a hydrated 
structure would give information into the bonding behaviour between the model 
compounds and water, including bond length and bond angle which could be used to help 
explain how the polymers behave with water. 
Previous attempts to create hydrate crystals of model compounds 6-10 have not successfully 
created model compound hydrates.1 As the model compounds are based on polymers which 
are used for their ability for preventing water crystallising it is not unexpected that low 
molecular weight molecules designed to emulate hydrate inhibitors do not easily form 
hydrates. As simply forming hydrates from the pure model compounds from wet solutions is 
not effective, other methods must be explored. One such method is the formation of 
cocrystals. 
Cocrystals are crystals with more than one distinct molecule in the structure.2 Addition of 
the second component can be used as a method to crystallise difficult to crystallise products 
by supplying interactions between the molecules which the single component on its own is 
lacking. The model compounds all have the ability to accept hydrogen bonds, but have no 
strong hydrogen donating groups.3,4 Adding a molecule capable of hydrogen bond donation 
to the crystallisation attempts with the model compounds may provide the missing 
supramolecular interactions required for crystal growth. Hydrates can also be formed this 
way, though even cocrystals which are not hydrated will give insight into how the model 
compounds interact with different species. 
3.2 Results and Discussion 
A range of crystallisation series were performed to try and create cocrystals of the model 
compounds with different components. 
3.2.1 Macrocycles 
Macrocycles, such as calixarenes, cyclodextrins and cucurbiturils, are host compounds, 
capable of hosting a guest in their cavities. In most cases when there is no other guest 
present the macrocyclic cavity is filled with water and the entropy gain associated with 
freeing the water molecules is a large driving force for guest incorporation.5 Unless a guest 
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nearly completely fills the macrocycle, water molecules can also remain in the host along 
with the newly introduced guest. As this commonly occurs, finding a macrocycle that will 
hold both one of the model compounds and some water is a possible solution to trying to 
acquire hydrated crystal structures of the model compounds and thus observe the nature of 
the bonding between the lactam rings and water. 
A range of different types and sizes of macrocycles were tested with the model compounds 
in an attempt to find the right combination of interactions and cavity size. Slow evaporation 
crystallisation experiments using 1:2, 1:1 and 2:1 molar ratios of macrocycle:model 
compound were performed.  The macrocycles used were α, β and γ cyclodextrin, p-
sulfonatocalix[n]arene where n = 4, 6 or 8 as a sodium salt and as the free acid, 4-tert-
butylcalix[4]arene, benzyloxycalix[5]arene and mixtures of cucurbiturils 5, 6, 7 and 8. Model 
compounds 6-10 were used. The macrocycle/model compound mixtures were dissolved in 
water, except for the experiments using 4-tert-butylcalix[4]arene and benzyloxycalix[5]arene 
for which a 1:1 volume ratio of toluene:acetone was used. 
Many macrocycles are difficult to crystallise due to their large size and the chance of 
crystallisation is greatly affected by the guest molecule. Smaller macrocycles have less 
conformational freedom so often crystallise more readily than their larger counterparts. 
Unfortunately the smaller macrocycles have much smaller cavities, so struggle to incorporate 
many guests of interest. This has been evident with the p-sulfonatocalix[n]arene salts and 
free acids. The n = 6 and n = 8 derivatives have failed to yield any crystals of diffraction quality 
in any experiment attempted, resulting in solid films which show no birefringence under 
polarised light. On the other hand, a 1:1 molar ratio mix of p-sulfonatocalix[4]arene 
(SC4):bisVCap produced crystals of diffraction quality. Single crystal x-ray analysis of the 
crystals revealed the crystals to be p-sulfonatocalix[4]arene pentasodium dodecahydrate. 
This a known crystal structure most recently reported by Fucke et al.6 and does not 
incorporate the model compound. 
The model compounds are all dimeric lactams, so their failure to crystallise in the SC4 cavity 
may be due to their size being too large to fit in the cavity. Smaller monomeric models, 
ethylpyrrolidone and ethylcaprolactam were tried to see if a smaller compound would bind 
into the SC4 cavity. Both ethylpyrrolidone and ethylcaprolactam used in slow evaporation 
crystallisation experiments using 1:2, 1:1 and 2:1 molar ratios of macrocycle:model 
compound were performed.  The macrocycles used were α, β and γ cyclodextrin, p-
sulfonatocalix[n]arene where n = 4, 6 or 8 as a sodium salt and as the free acid, 4-tert-
butylcalix[4]arene, benzyloxycalix[5]arene and mixtures of cucurbiturils 5, 6, 7 and 8. The 
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macrocycle/model compound mixtures were dissolved in water, except for the experiments 
using 4-tert-butylcalix[4]arene and benzyloxycalix[5]arene for which a 1:1 volume ratio of 
toluene:acetone.   
3.2.1.1 p-sulfonatocalix[4]arene/ethylpyrrolidone 
Crystals of diffraction quality grew from the slow evaporation of a 1:1 mixture of 
ethylpyrrolidone and the free acid of SC4 dissolved in water over the course of 18 months, 
the resulting crystal structure can be seen in Figure 3.1. P-sulfonatocalix[n]arenes are 
sulfonic acids and thus are highly acid. The pH of a solution of the same SC4 concentration 
as the starting solution of the crystallisations was measured to have a pH of 2.1, this will 
experience some variance as the evaporation of the solvent increases the concentration. The 
low pH leads to the ethylpyrrolidone guest being protonated and a new material, crystal 1, 
being formed with the formula C28H20O16S4.3(C6H12NO).H3O.4H2O.  
 
Figure 3.1 – Asymmetric unit of crystal 1 showing the SC4 macrocycle and three protonated ethylpyrrolidone 
molecules, EP 1 in the SC4 ring, EP 2 and EP 3. Hydrogen bonds are shown by red dotted lines.  
Crystal 1 is a hydrated structure, with the unit cell containing four water molecules and a 
hydronium ion. The crystal structure has three distinct ethylpyrrolidone molecules EP 1, EP 
2 and EP 3 as shown in Figure 3.1. EP 1 rests in the SC4 cavity and the other two lie above 
the upper rim of the macrocycle. To compare the different environments of the 
ethylpyrrolidone molecules Hirshfeld surface analyses were performed for each 
ethylpyrrolidone molecule. The Hirshfeld surface fingerprint plots can be found in Figure 3.2 
and show the similarities and differences between the environments and interactions of the 
three ethylpyrrolidone molecules. 
1 
2
 
 1 
 1 
3
 
 1 
 1 
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The Hirshfeld surface fingerprint plots of all three ethylpyrrolidone molecules have ‘wings’ 
in the upper left of the plot, which arise from the C-H part of a C-H…π interaction. For EP 1, 
the ‘wing’ comes from the hydrogen atoms on the carbons of the lactam ring interacting with 
all four of the aromatic rings of the SC4 in which it resides. The ‘wing’ of EP 2 arises from the 
C-H…π interaction between the hydrogen atoms on the carbon adjacent to the carbonyl 
group of the lactam ring interaction with the outside of a neighbouring SC4. Finally the ‘wing’ 
of EP 3 arises from interaction of the hydrogen atoms of the methylene group adjacent to 
the nitrogen in the lactam ring with a different neighbouring SC4. The centre 
ethylpyrrolidone molecule C-H…π bonds in an edge to face fashion, with the lactam ring 
approaching being perpendicular with the aromatic ring. The outer ethylpyrrolidone 
molecule on the other hand, C-H…π bonds in a face-face fashion, with the lactam and 
aromatic rings being almost parallel to one another.  
 
Figure 3.2 – Hirshfeld fingerprint plots for the ethylpyrrolidone molecules in crystal 1, a) EP 1, b) EP 2, c) EP 3. 
Diffuse blue regions found in the top right corners of the Hirshfeld surface plots, arise from 
less efficient packing such as void spaces. Moving from the EP 1 to EP 2 then EP 3 this diffuse 
region becomes larger and more prominent. This shows that the molecule inside the SC4 
cavity has very little space around it and much closer neighbours than the outer molecules.  
The Hirshfeld fingerprint plot for all three ethylpyrrolidinium cations in the crystal structure 
show long, sharp peaks in the upper left part of the plot which are demonstrative of 
a) b) 
c) 
3: Cocrystallisation of hydrate inhibitor models 
57 
 
hydrogen bond donating character. As the carbonyl groups of all three pyrrolidone molecules 
are protonated it is to be expected that they would exhibit hydrogen bond donation 
capability. None of the Hirshfeld surface fingerprint plots show any peaks characteristic of 
hydrogen bond accepting interactions, suggesting that the ethylpyrrolidone molecules are 
only hydrogen bond donating. EP 1 has a hydrogen bond to water with an O···O distance of 
2.459(2) Å, which is classified as a strong, mostly covalent bond according to the definition 
by Jeffery.7 This water molecule donates a hydrogen bond to the sulfonate group of the SC4 
in which the pyrrolidone molecule resides and the sulfonate group of a neighbouring SC4 as 
well as accepting a hydrogen bond the hydroxyl group of another SC4 ring. EP 3 donates a 
hydrogen bond with a O···O of 2.430(2) Å to the nearest water molecule. This water molecule 
also donates hydrogen bonds to two other water molecules, which both donate hydrogen 
bonds to the sulfonate groups of neighbouring SC4 molecules. EP 2 does not hydrogen bond 
to water. Instead it donates a hydrogen bond with an O···O distance of 2.527(2) Å to a 
sulfonate group of a neighbouring SC4 molecule. None of the ethyl pyrrolidone molecules 
accept hydrogen bonds. There are also no short contact interactions between the 
pyrrolidone molecules, any interactions are mediated by water.  
In conclusion a hydrated lactam structure was successfully created and characterised by 
single crystal x-ray crystallography. Instead of the hydrogen bond accepting interactions 
which would be expected from the lactam functionality, the acidic nature of SC4 resulted in 
protonated lactam groups which only donate, and do not accept, hydrogen bonds. This does 
not make for a realistic model of PVP in an oil pipeline where the pH is generally higher than 
2, so it would be expected that the lactams would not be protonated and thus not donate 
hydrogen bonds. So whilst this crystal structure is interesting in its own right, it does not add 
anything to the knowledge of kinetic hydrate inhibition in pipelines.   
3.2.2 Halogen Bonding 
Halogen bonds are highly directional, relatively strong intermolecular interactions which 
have strong analogies to hydrogen bonds. Halogen bonds are possible due to the polarisable 
nature of the electron density around the later halogens, especially iodine. Attaching 
electron withdrawing groups to iodine results in the electron density being pulled away from 
one side of the atom, resulting in a δ+ charge termed a ‘sigma hole’. This charge can interact 
with a range of nucleophiles to from supramolecular systems. One of the most common and 
one of the most effective halogen bond donors is 1,4-diiodotetrafluorobenzene (pDITFB).8–
10  
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The simplest halogen bonding molecules are the diatomic, elemental halogens themselves, 
particularly iodine due to its polarisable electron density. The electron density around I2 can 
be influenced by external molecules, creating the partial charges required for 
supramolecular assembly. Topically, iodine also has a history of interacting with PVP. Iodine 
is administered as an anti-septic often in a form complexed with PVP called povidone-
iodine.11,12 As PVP has already shown affinity for iodine, it was reasoned that the model 
compounds studied herein will show a similar kind of interaction. 
Much stronger halogen bonding compounds can be formed by covalently bonding electron 
withdrawing groups to the halogen instead of relying intermolecular interactions to cause 
the required partial charge. For example pDITFB has been used in creating a plethora of 
cocrystals8–10 and even co-liquid-crystalline materials.13,14 Part of its widespread use can be 
related to its commercial availability, relative stability and strength of the halogen bond it 
forms. The fluorinated aromatic ring is strongly electron withdrawing, resulting in a 
significant δ+ charge at the tips of both of the iodine atoms. Compounds with an alkene 
functionality between the benzene ring and the iodine atoms, such 1-iodoethynyl-4-
iodobenzene, are even stronger halogen bond donors. Unfortunately a multistep, inert 
conditions reaction is required to synthesise 1-iodoethynyl-4-iodobenzene , which is much 
less stable to air, heat and moisture than pDITFB.  1,2-diiodotetrafluorobenzene (oDITFB) is 
also a commercially available compound which is stable to benchtop conditions. The ortho 
derivative, oDITFB, is less commonly used than the para version, pDITFB, with only 30 results 
when searching for cocrystals in the CSD compared with 205 results for pDITFB. This is 
possibly due to steric reasons as both of the halogen bonding groups are adjacent on the 
benzene ring making interaction with multiple molecules challenging. The steric clash of 
having the two iodine atoms adjacent on the ring will also make it more difficult to synthesise 
than the para version, making it a more expensive molecule to buy, this may also contribute 
to the fewer recorded cocrystals of oDITFB. 
Slow evaporation crystallisation experiments were performed with the model compounds 6-
11 and the halogen bond donors: pDITFB, oDITFB, 1,4-diiodobenzene, 1-chloro-(2-
iodoethynyl)benzene and iodine. All halogen bond donors were weighed out in a 1:1 ratio 
with compounds 6-11. For crystallisations containing iodine the components were dissolved 
in water, whilst pDITFB, oDITFB, 1,4-diiodobenzene and 1-chloro-(2-iodoethynyl)benzene 
crystallisations were dissolved in a 1:1 volume ratio of acetone:DCM. The solvent was 
allowed to evaporate at room temperature. After one week, pDITFB with bisVCap gave 
crystals of diffraction quality. 
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3.2.2.1 1,4-diiodotetrafluorobenzene/bisVCap 
Slow evaporation of a 1:1 molar ratio of pDITFB:bisVCap from a DCM/acetone 1:1 mixture 
gives a 1:1 pDITFB:bisVCap cocrystal, crystal 2, with the formula C16H26N2O2.C6F4I2. Crystal 2 
was also successfully formed from a 1:1 molar ratio of pDITFB:bisVCap dissolved in acetone 
and allowing the solvent to evaporate at room temperature, this was verified by PXRD. 
Crystal 2 is the only BisVCap cocrystal isolated so far. Attempts to produce cocrystals of 
bisVCap usually result in crystals of bisVCap as a single component. 
The x-ray crystal structure of crystal 2 can be seen in Figure 3.3. The halogen bonds are shown 
by red dashed lines. The halogen bonds between the oxygen atom of the carbonyl and the 
iodine of pDITFB have I···O distances of 2.897(6) Å and 2.916(6) Å. A search of the Cambridge 
structural database for cocrystals of pDITFB with a molecule containing a carbonyl group 
yields 23 results, 12 of which contain no halogen bond between pDITFB and the carbonyl. Of 
the 11 remaining structures 3 contain halogen bonds with a length shorter than 2.95 Å,15–17 
showing the halogen bond of crystal 2 to a relatively strong bond when compared to similar 
cocrystals. 
 
Figure 3.3 – Crystal structure of crystal 2. a) Both pDITFB and bisVCap with the halogen bonds shown by 
dashed purple lines, b) only bisVCap, highlighting the hydrogen bonds shown by dashed red lines. 
a) b) 
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The Hirshfeld surface fingerprint plots of pDITFB and bisVCap in crystal 2 are shown in Figure 
3.4. In the left hand plot which corresponds to the pDITFB molecule, the halogen bond donor 
interaction is indicated by a black arrow, bottom right of the diagonal. The prominent feature 
along the diagonal is the H···F close packing, the H···F distance range from 2.516(4) – 2.606(5) 
Å.  
 
Figure 3.4 – Hirshfeld surface fingerprint plots of crystal 2, a) pDITFB and b) bisVCap. Halogen bonds are 
indicated by black arrows and CH···O hydrogen bonds are indicated by blue arrows. 
The H···F close packing is also apparent along the diagonal of the Hirshfeld surface fingerprint 
plot of bisVCap, pictured right in Figure 3.3. The plot for bisVCap also has the halogen bond 
interaction indicated by a black arrow. For bisVCap the halogen bonding interaction appears 
to the top left of the diagonal, showing that is the halogen bond accepting interaction. The 
two blue arrows show the C-H···O hydrogen bond interactions between the bisVCap 
molecules. The hydrogen bonds occur between the carbonyl group of a lactam ring and the 
C-H adjacent to the nitrogen of a lactam of a neighbouring bisVCap as shown in Figure 3.3b 
The C···O distance of these hydrogen bonds is 3.493(9) Å. 
It has been suggested that halogen bonds are often too weak to be observed in solution, 
though in some cases NMR titrations have successfully shown halogen bonds in solution.18,19 
To test if this holds true for this system an NMR titration was performed. Acetonitrile was 
chosen as the solvent as it successfully dissolves both bisVCap and pDITFB, but does not have 
any hydrogen bonding interaction with bisVCap which competes with the halogen bonds. 
BisVCap was dissolved in d3-acetonitrile and pDITFB was added in 10 mol equivalent portions 
to the solution until a large excess of pDITFB. As there are no hydrogen atoms in pDITFB, a 
large excess can be added without obscuring the bisVCap signals as no peaks for pDITFB can 
be observed in a 1H NMR spectrum. After 50 equivalents of pDITFB a new product was seen 
to begin forming. Remaking a fresh sample at the same concentration showed no sign of this 
a) b) 
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product however, leaving a sample standing for 2 hours showed the gradual formation of 
the new compound.  
To test if this product was due to a reaction between pDITFB and bisVCap, or with residual 
acid in the sample of pDITFB, a bisVCap/dilute HCl/acetonitrile mixture, a 
pDITFB/bisVCap/acetonitrile mixture and a bisVCap/acetontrile mixture were heated at 60 
°C for three days in acetonitrile. The bisVCap/acetonitrile sample showed no sign of the new 
product. Both the pDITFB/bisVCap/acetonitrile and bisVCap/dilute HCl/acetonitrile samples 
showed the same unknown product. This suggests that the reaction occurs dues to a small 
amount of residual acid present in pDITFB, not because of the pDITFB itself. Electrospray 
time of flight mass spectroscopic analysis of the unknown product gave a peak with mass 
227 which has not successfully been assigned and as it is an acid catalysed decomposition 
product, not a reaction between pDITFB and bisVCap, no further investigation was 
undertaken. 
To prevent this acid decomposition product forming, an NMR titration was performed with 
fresh samples prepared after every three spectra were recorded. There is no change in the 
chemical shift of the bisVCap up to 50 equivalents of pDITFB, at which point the solubility of 
the pDITFB becomes the limiting factor. This suggests that the halogen bonding is not strong 
enough to be observed in solution. 
The cocrystal and individual components were characterised by differential scanning 
calorimetry (DSC) to acquire information on the melt behaviour and screen for any 
polymorph changes. DSC experiments were run at 10 °C/min in a heat/cool/heat cycle. Hot 
stage microscope experiments, emulating the DSC experiments, were performed to clarify 
any unexplained features. 
The DSC thermograph of pDITFB itself, shown in Figure 3.5, shows a variety of features. 
During the first heating cycle, a small endothermic peak at 84 °C is seen. This has previously 
been attributed to a polymorph change, with the high temperature polymorph being 
reported by Chaplot et al.20 A small endothermic peak is also observed at 105 °C before the 
main melt endotherm at 108 °C. When heated above 150 °C pDITFB begins to decompose as 
is characterised by a multitude of ill-defined peaks, so DSC experiments were run past 120 
°C. During the cooling cycle a large loop occurs at 96 °C. This feature often arises from a 
sublimation event, with the compound vaporising and recrystallising on the lid of the pan. 
The second heating cycle shows only the melt peak at 108 °C. 
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Figure 3.5 – DSC heat/cool/heat thermograph of pDITFB. Exotherm up. 
A hot stage microscope experiment was performed to elucidate the cause of the peak at 105 
°C and verify the other features as shown in Figure 3.6. As the glass slide is much thicker than 
the pans used for DSC, the exact temperatures at which events occur are slightly from those 
observed in the DSC experiment. During heating cycles events occur at a higher temperature 
than seen in the DSC thermograph and in cooling cycles the events often occur at a lower 
temperature. This reflects the slower change in temperature of the microscope sample.  
A change in crystal morphology is seen after 85 °C, as would be expected from a polymorph 
change. At 106 °C a there is a sudden and notable change in morphology, quickly followed 
by melting by 108 °C. Judging from the morphology of this new phase, it seems to be liquid 
crystalline in nature. Heating a sample of pDITFB on the hot stage microscope to 100.5 °C 
and holding at this temperature for half an hour results in a slow conversion to this liquid 
crystal phase. The phase has a mosaic texture, with parts which some parts change to black 
when the polarising filter is crossed whilst some parts which remain unchanged. From these 
observations it is possible to say that it is one of the more ordered smectic liquid crystal 
phases such as Sb(cry),21 though any further investigation into the liquid crystal phase is beyond 
the scope of this project. The formation of this liquid crystal phase does explain the peak at 
105 °C in the DSC thermogram. The sample had completely melted by 110 °C. As the cooling 
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cycle began, crystals began forming on the underside of the hot stage window. This is 
deposition of the vaporous pDITFB. This process occurs at a lower temperature in the DSC 
experiment, 93 °C instead of 109 °C. The hot stage window does not significantly heat up 
during the course of an experiment, so the deposition can occur whenever the sample 
evaporates. In the DSC pan, deposition can only occur when the pan has cooled enough to 
not immediately evaporate or sublime the sample.  
   
 
   
Figure 3.6 - Hot stage microscope experiment heating then cooling pDITFB: a) 20 °C, b) 90 °C, held for 30 min 
to allow full conversion of morphology, c) 106 °C, held for 30 min to allow full conversion of morphology, d) 
110 °C, e) 109 °C, sample formed on the inside of the hot stage window from evaporation and deposition of 
pDITFB, f) 103 °C, crystals formed from cooling of the melt.  
The DSC plot for bisVCap can be seen in Figure 3.7. During the first heating cycle the only 
feature is an endothermic peak at 145 °C corresponding to the sample melting. During the 
cooling cycle there is no recrystallisation peak or features of any kind. The second heat cycle 
shows a glass transition at -11 °C and an endothermic, melt peak, which is smaller than the 
melt peak from the first heating cycle, at 139 °C. If there was truly no recrystallisation there 
would be no melt peak on the second heating cycle. This gives two options. The first is that 
there is a recrystallisation on cooling, but it occurs over such a long time scale that no peak 
was observable in the DSC plot. The second is that there is a recrystallisation event on 
heating, which is either over a long time frame or obscured by the melt peak. To visualise 
what is happening, the DSC experiment was reproduced using a hot stage microscope. The 
sample was heated at 10 °C min-1 to 150 °C at which sample had melted completely, then 
cooled at the same rate to -100 °C then heated again to 150 °C also at the same rate. The 
pictures from the experiment can be found in Figure 3.8. 
a) 
d) 
b) 
e) 
c) 
f) 
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Figure 3.7 – DSC heat/cool/heat experiment of bisVCap at a rate of 10 °C/min. Exotherm up. 
The microscope experiment shows all of the sample to have melted when heated to 150 °C. 
No change was observed at temperatures down to the DSC instrument limit of -90 °C. As 
glass transitions are very rate dependant and the hot stage microscope cools slower than the 
DSC below 0 °C, the sample was cooled further to find visual evidence of a glass transition. 
At -100 °C the sample suddenly cracked, which is a common sign that a glass has been 
formed, as the glass becomes brittle when cooled too far and thermal shrinkage caused the 
sample to crack.22,23 On heating all the cracks had disappeared by 10 °C, suggesting the glass 
transition had been passed. Further heating to 100 °C resulted in small crystals beginning to 
form, these crystals continued growing until 150 °C where they began to melt. All of the 
crystals had completely melted by 154 °C. As can be seen by the pictures in Figure 3.8, 
compared to the amount of material at the beginning of the experiment, very little of the 
material has chance to recrystallise at this rate of heating before melting occurs. This would 
account for the reduction in size of the melt peak in the second heating cycle. As the 
recrystallisation occurs over a range of 50 °C and not all of the sample recrystallises, the lack 
of observable recrystallisation peak is due to the heat capacity of the recrystallisation being 
small and the recrystallisation being long, resulting in a peak too broad and too weak to 
observe. 
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Figure 3.8 – Hot stage microscope heat/cool/heat experiment of bisVCap at a rate of 10 °C/min: a) start 
experiment at 18 °C, b) 150 °C, everything has melted, c) -100 °C cracks form, d) 100 °C small crystals begin to 
form, e) 145 °C crystals still continue to grow, f) 150 °C crystals begin to melt whilst crystals are still growing, 
g) 152 °C, melting continues h) 154 °C all crystals have melted. 
The DSC of crystal 2 is similar to the DSC of bisVCap. Upon the first heating cycle the cocrystal 
melts at 109 °C, as shown by an endothermic peak in the DSC thermograph. Heating above 
150 °C quickly leads to decomposition, most probably of the pDITFB as heating the single 
component above 150 °C leads to similar decomposition. In a DSC where decomposition has 
not occurred, such as Figure 3.9, the molten cocrystal can be cooled again, upon which it 
would be expected that a recrystallisation peak would be evident. There is no 
recrystallisation of crystal 2 on cooling. The second heat cycle reveals a glass transition at 9 
°C and another, albeit much smaller, endothermic, melting peak at 109 °C. The second melt 
is at the same temperature as the first within error, suggesting it does not arise from either 
single component or a decomposition product, but from the melting of crystal 2. The smaller 
peak suggests that there is much less material in the second melt than the first melt, similar 
to bisVCap. Again the lack obvious crystallisation peak in the DSC could either be because 
the recrystallisation is too slow to be easily observed or it is obscured by the melt. 
a) b) c) d) 
e) f) g) h) 
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Figure 3.9 – DSC heat/cool/heat experiment of crystal 2 at a rate of 10 °C/min. Exotherm up. 
To test if the slow crystallisation theory holds true, the method of the DSC experiment (10 
°C/min, heat to 150 °C, cool to -90 °C, heat to 150 °C) was reproduced on the hot stage 
microscope, the pictorial results of which can be seen in Figure 3.10. The cocrystal melts at 
110 °C in the hot stage microscope instead of 108 °C in the DSC, as previously mentioned this 
is due to slower temperature changes on the thicker glass slide when compared to the thin, 
metal DSC pans. The next event to occur is upon cooling to -62 °C, when the sample suddenly 
cracks, which is typical of a super cooled glass. More cracks appear as the sample is cooled 
further. During the second heating cycle the cracks start to disappear around 10 °C with all 
having disappeared by 15 °C. Again, this is later than the glass transition in the DSC which is 
at 9 °C and also takes much longer due to the rate of heating on the much thicker glass slide. 
With further heating to 77 °C small crystals appear. These crystal continue to grow as the 
sample is heated. By 106 °C the crystals are still growing but are also starting to melt again. 
Judging by the microscope slide, the crystallisation process occurs over a broad temperature 
range and all not all of the material recrystallises. The smaller amount of crystalline material 
formed in the second heating cycle is in keeping with the smaller second melt peak in the 
DSC. The recrystallisation occurs over a range of 39 °C and not all of the sample recrystallises 
resulting in a broad and weak recrystallisation peak which is not observable in the DSC 
thermograph. 
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Figure 3.10 - Hot stage microscope heat/cool/heat experiment of crystal 2 at a rate of 10 °C/min: a) start at 
15 °C, b) 110 °C, all material has melted, c) -62 °C, cracks form, d) -77 °C, polarising filter changed to crossed, 
cracks continue to form, e) -90 °C, more cracks have formed, end of cooling, f) 15 °C cracks disappeared, g) 77 
°C, crystals appearing, h) 80 °C, crystal growth, i) 90 °C, crystals continue growing, j)106 °C, crystal growth 
halts, smaller crystals begin to melt, k) 114 °C, melting becomes quicker, affecting the larger crystals, l) 115 °C 
all crystals melted. 
It is not uncommon for a compound to exhibit a metastable amorphous form and a 
crystalline form, but it is much more uncommon for a cocrystal to exhibit a coamorphous 
form, as usually the second component will stabilise one form or the other and thus not allow 
both. Quasi-isothermal DSC measurements can be used to calculate the heat capacity of a 
material and thus compare the relative stability of crystalline and amorphous forms.24,25  
As can be seen from Figure 3.11, pDITFB has the lowest heat capacity of all the samples 
tested. As expected from the previous DSC thermograph, Figure 3.5, showing pDITFB to have 
a melting point of 108 °C, there is a peak  in the heat capacity plot around 380 K from the 
sample melting. After melting the heat capacity is slightly higher as liquids are not as 
thermodynamically stable as crystals.  
The crystals of bisVCap have higher heat capacity than the cocrystal. It is a possibility that 
difference in heat capacity between bisVCap and crystal 2 could be a major part of the driving 
force for the cocrystal formation, as the difference in heat capacity shows crystal 2 to be 
more thermodynamically stable than bisVCap. Both crystals show melting points 
approximately where one would expect from the the previous DSC plots, Figure 3.7 and 
a) b) c) d) 
e) f) g) h) 
i) j) k) l) 
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Figure 3.9. The heat capacity of the liquids is higher than the crystal for both bisVCap and 
crystal 2.26 
The amorphous form of bisVCap has a higher capacity than the crystalline form. There is a 
large change in heat capacity of the amorphous form as it goes through the glass transition. 
The heat capacity starts decreasing again at 318 K, where during the microscope experiment 
it was seen that crystallisation started. The heat capacity of the amorphous form in the quasi-
isothermal DSC never reached the level of the crystalline form as never at any point does the 
whole of the sample crystallise. The amorphous bisVCap after the glass transition has a 
similar heat capacity to the melt of the crystalline bisVCap. This is in keeping with the fact 
that amorphous forms are super cooled liquids, so should have a very similar heat capacity 
to the melt.26  
The coamorphous form of crystal 2 has higher heat capacity than the cocrystalline form. 
Similar to bisVCap, the amorphous form of crystal 2 after the glass transition has a similar 
heat capacity to the melt. Before the glass transition the heat capacity of the coamorphous 
material is very low, approaching that of the crystal, showing the coamorphous form to be 
particularly stable so there is little driving force for recrystallisation.  
 
Figure 3.11 – Heat capacity against temperature from the quasi-isothermal DSC for pDITFB, crystalline 
bisVCap, amorphous bisVCap, crystalline bisVCap/pDITFB and amorphous bisVCap/pDITFB. 
Addition of pDITFB to bisVCap gave a novel cocrystal of a model compound which has 
previously proven challenging to crystallise. The cocrystal is rare as it is also stable as a 
coamorphous form as well as a cocrystalline form. Further investigation into the heat 
0
0.5
1
1.5
2
2.5
3
200 250 300 350 400 450
C
p
 /
 J
 g
-1
 °C
-1
Temperature / K
pDITFB
bisVCap crystal
bisVCap amorphous
cocrystal
coamorphous
3: Cocrystallisation of hydrate inhibitor models 
69 
 
capacity and molecular mobility would give insight into the interactions which dictate the 
stability of the crystalline and amorphous forms of bisVCap and the cocrystal, though more 
in depth analysis is beyond the scope of this thesis. 
3.2.3 Metal cocrystals and complexes 
BisHEP has previously shown the ability to form metal complexes with a zinc and the s-block 
metals1,27 and H2bisVP has been reported in a complex with sodium.27 The model compounds 
6-9 have shown no such capacity for metal binding with the s-block elements or zinc. 
Searching the CSD reveals multiple structures of rare earth metals surrounded by 4 to 8 
pyrrolidone, piperidone or caprolactam molecules. For example, Evans et al.28 reported 
crystal structures of the form shown in Scheme 3.1 with cerium, praseodymium and 
neodymium. This suggests that the lactam functionality might have a higher affinity for the 
rare earth metals than the s-block metals and thus complex more readily. Attempts to form 
metal complexes of model compounds 6-10 with terbium, gadolinium, yttrium, ytterbium, 
lanthanum, aluminium and vanadium were performed. Model compounds and metal salts 
were mixed in a 3:1 molar ratio of model compound:metal salt and dissolved in water. The 
solvent was allowed to evaporate at room temperature. From these experiments a single 
complex was formed. CdCl2 and compound 5, HEPVCap, resulted in a coordination polymer 
discussed in section 3.2.3.1. 
 
Scheme 3.1 – General form of the caprolactam metal complexes reported by Evans et al.28 
As the complexation experiments model compounds 6-10 only resulted in a single novel 
crystal structures compounds 11-16 the structures of which can be seen in Scheme 2.1. The 
details of their synthesis can be found in chapter 2. Compounds 14-16 have major impurities 
of the dimeric model compounds bisVP or bisVCap. The crude products were still tested in 
crystallisation experiments as the potential for tetradentate chelation from the new 
products may result in preferred chelation over the bidentate chelation possible by the side 
products of bisVP and bisVCap. 
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The model compounds 13-16 were mixed with a wide range of metal salts from the s, d and 
f block as well as Al(NO3)3 in water; the full list of metal salts can be found in the experimental 
section 3.3.3. A very large majority of these crystallisation attempts resulted in crystals of 
the metal salt without any ligand complexed or oily mixtures. CdCl2 with Et(OVCap)2 gave a 
novel product which is discussed in section 3.2.3.2. The crude Et(OVP)2/bisVP mixture with 
Y(CF3SO3)3 also gave a novel complex which is detailed in section 3.2.3.3. 
3.2.3.1 Caprolactam/HEP/CdCl2 
In the presence of CdCl2 HEPVCap decomposes to HEP and ε-caprolactam. The 
decomposition of the ether linkage of HEPVCap in the presence of CdCl2 suggests the ether 
link to be unstable to Lewis acids. The fragments then coordinate to the cadmium centres 
giving a crystal, crystal 3, with the formula 3(CdCl2).2(C6H11NO).2(C6H11NO2). The crystal 
structure of crystal 3 is shown in Figure 3.12.  
 
Figure 3.12 – Crystal structure of crystal 3. Hydrogen bonds between the ligands are shown by red dashed 
lines. 
The cadmium centres are linked together into chains by bridging chloride ligands, two shared 
between two metal centres. The CdCl2 chains are linked by two bridging HEP molecules to 
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the same two cadmium centres. Going along a cadmium chain there are three distinct 
cadmium centres. The first has two ε-caprolactam ligands, one above and one below the line 
of the chain. The next along has two HEP ligands bridging to the next chain below, the next 
and final cadmium centre has two HEP ligands bridging to the chain above. After this final 
bridged cadmium centre, the pattern repeats, returning to cadmium with two ε-caprolactam 
ligands. 
There are hydrogen bonds between the carbonyl groups of the ε-caprolactam ligands and 
the hydroxyl groups of the nearest HEP ligands. These hydrogen bonds have O···O distances 
which vary between 2.644(6) - 2.719(7) Å. The Cd-Cl bonds range from 2.542(2) – 2.642(1) Å, 
with all four Cd-Cl bond of each metal centre being different from one another. The distances 
between the cadmium atoms in the chain varies from 2.786 – 3.857 Å with the shorter 
distances occurring between centres ε-caprolactam and centres with HEP and the longer 
distances occurring between to HEP bound centres. The organic ligands demonstrate shorter 
metal-ligand distances than the Cd-Cl bonds, with Cd-ε-caprolactam distances being 
between 2.396(5) – 2.427(5) Å, bonds between cadmium and the carbonyl group of HEP 
being 2.278(4) – 2.338(4) Å and bonds between cadmium and the hydroxyl group of HEP 
being 2.341(4) – 2.356(4) Å. 
3.2.3.2 Caprolactam/ethylene glycol/CdCl2 
Et(OVCap)2 in the presence of CdCl2 decomposes to ε-caprolactam and ethylene glycol. The 
fragments all coordinate to the cadmium metal centres to form crystal 4 with the formula 
2CdCl2, 2(C6H11NO), C2H6O2. The crystal structure of crystal 4 as can be seen in in Figure 3.13. 
The cadmium metal centres are joined to one another by two bridging chloride ions to form 
a chain. The Cd-Cl bond distance vary between 2.548(1) – 2.632 (6) Å with all four bonds to 
each metal centre being of different length. The Cd-Cd distances in the chain are either 
3.725(1) Å or 3.789(1) Å. From the cadmium with the ε-caprolactam ligands, the distance to 
the next two cadmium centres is the same, whilst for cadmium atoms with ethylene glycol 
ligands, the nearest two cadmium centres are different distances away.  
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Figure 3.13 - Crystal structure of crystal 4. Hydrogen bonds between the ligands are shown by red dashed 
lines. 
Going along the cadmium chain, the pendant groups alternate between cadmium with a 
bidentate ethylene glycol ligand and cadmium with two ε-caprolactam ligands. The ε-
caprolactam ligands lie equidistant above and below the chain, though there are two 
different ε-caprolactam coordinated cadmium centres, one with Cd-ε-caprolactam bond 
lengths of 2.417(2) Å and the other with Cd-ε-caprolactam bond lengths of 2.332(2) Å. the 
ethylene glycol binds asymmetrically with one end exhibiting a Cd-O bond length of 2.382(2) 
Å and the other a Cd-O bond length of 2.337(2) Å. There are hydrogen bonds between the 
carbonyl of the ε-caprolactam molecules and the hydroxyl groups of the ethylene glycol. The 
shorter Cd-ε-caprolactam bond, 2.332(2) Å, hydrogen bonds to the side of the ethylene glycol 
with the shorter Cd-O bond, 2.337(2) Å, by a hydrogen bond with an O···O distance of 
2.679(2) Å. The hydrogen bond between the ε-caprolactam with the longer Cd-ε-
caprolactam bond, 2.417(2) Å and the side of the ethylene glycol with the longer Cd-O bond, 
2.372(2) Å, exhibits a longer hydrogen bond with an O···O distance of 2.729(2) Å. 
The ether linkages in both Et(OVCap)2 and HEPVCap are not stable to Lewis acids. In Lewis 
acidic conditions, such as in solution with the Lewis acidic metals used in the crystallisation 
experiments, the ether linkages undergo cleavage, resulting in ε-caprolactam and an alcohol. 
There is no proposed theory for what happens to the two carbon atoms from VCap which 
are not present in the crystal structures. 
3.2.3.3 1,1,3-tri-2-pyrrolidonylbutane/Y(CF3SO3)3 
The crude mixture of Et(OVP)2 and bisVP when mixed with Y(CF3SO3)3 in water resulted in 
crystals of diffraction quality from slow evaporation of the solvent. A complex of Et(OVP)2 
3: Cocrystallisation of hydrate inhibitor models 
73 
 
coordinated to a metal was again not what was achieved, but to differ from the CdCl2 crystal 
structures Y(CF3SO3)3 did not complex with the fragments of a decomposed molecule. Instead 
a completely new ligand had been formed in-situ, the structure of which can be seen in 
Scheme 3.2. The resulting crystal, crystal 5 has the formula C16H35N3O8.3(CF3SO3).H2O and the 
crystal structure of crystal 5 is shown in Figure 3.14 From the two CdCl2 structures, it has 
been seen that the presence of a Lewis acid can break down the ether-VCap links to give free 
ε-caprolactam, thus it is reasonable to assume that Lewis acids could also break down an 
ether-VP link to free pyrrolidone. This free pyrrolidone could then attack the double bond of 
the bisVP resulting in the product in Scheme 3.2. 
 
Scheme 3.2 – Tridentate pyrrolidone ligand from crystal 5. 
The yttrium metal centre is 8-coordinate, with 5 water ligands and two 1,1,3-tri-2-
pyrrolidonylbutane ligands, one bound mono dentate and one bound bidentate. The ligands 
are bound asymmetrically with no ligand being directly opposite another. The bidentate 
ligand O-Y distances are 2.305(3) and 2.315(3) Å whilst the monodentate ligand has an O-Y 
length of 2.277(3) Å. The water ligands O-Y distances range from 2.329(3) – 2.390(3) Å. The 
crystal structure contains chains of 1,1,3-tri-2-pyrrolidonylbutane and yttrium, with the 
1,1,3-tri-2-pyrrolidonylbutane binding bidentate to one yttrium centre then binding 
monodentate to the next yttrium centre. The 1,1,3-tri-2-pyrrolidonylbutane ligand does not 
exhibit any carbonyl based hydrogen bonding as the carbonyls are already taken up by the 
ligand-yttrium coordination bond. The three triflate anions accept hydrogen bonds to their 
sulfonate groups from the water molecules coordinated to the yttrium centre. These 
hydrogen bonds have O···O lengths ranging from 2.686(6) – 2.792(4) Å.  
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Figure 3.14 – Crystal structure of crystal 5, showing the chain of yttrium centres held together by 1,1,3-tri-2-
pyrrolidonylbutane ligands binding to on yttrium centre in a bidentate fashion and another yttrium centre in 
a monodentate fashion. The triflate anions are omitted for clarity. 
In conclusion the ether-lactam link, whilst stable in aqueous solution, is not stable when in 
the presence of certain metal compounds. Mild Lewis acid catalysts with the ability to 
coordinate the lactam carbonyl groups and any resulting alcohols can result in the 
degradation of the ether link. The exact nature of the metal salt does have a notable effect 
on the metal’s efficiency at degrading the ether link as Et(OVCap)2 successfully crystallised 
as a pure organic crystal from solutions containing Cd(CH3COO)2 and Cs(CH3COO)2, though 
CdCl2 resulted in its degradation. Whilst disappointing that the ligands did not function as 
intended, the unexpected reaction of Et(OVP)2 with Y(CF3SO3)3 may introduce new 
opportunities by way of creating new compounds to model PVP and PVCap, containing three 
and not two rings, which would allow for more confirmations and opportunity to chelate in 
a more than bidentate fashion.  
3.2.4 Other crystals 
3.2.4.1 The GRAS list 
In the pharmaceutical industry there is a list of additives which are safe for human 
consumption called the generally regarded as safe (GRAS) list. This list is used to help look 
for cocrystals of drugs that do not need extensive toxicity studies before going to clinical 
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trials. This reduces the chances of making a biologically incompatible cocrystal and increases 
the chance of a drug being accepted for human consumption. As the GRAS list is commonly 
used for cocrystal screening, it was a logical choice for some initial experiments. As PVP is 
commonly used for drug delivery, from being a simple pill binder,29–31 to potentially helping 
controlled release formulations by formulating thermoresponsive delivery systems,32–35 it is 
possible that there are suitable interactions between the models of PVP and drug molecules 
or additives to form cocrystals.  
The potential coformers with the ability to donate hydrogen bonds chosen were (+)-tartaric 
acid, 4-aminobenzoic acid, citric acid, glutamic acid, nicotinamide, nicotinic acid, fumaric 
acid, malonic acid, succinic acid and oxalic acid. All are carboxylic acids so have the ability to 
accept as well as donate hydrogen bonds. This unfortunately increases the chance of single 
component crystallisation as the component has sufficient interaction with itself to make its 
crystallisation favourable. This did not seem to be the case. All crystallisation attempts 
resulted in thick oils. No crystals formed over the course of two years. 
3.2.4.2 Hydrogen bond donors 
All of the model compounds are capable of accepting hydrogen bonds, but not donating 
them to any significant degree. Thus a compound which is hydrogen bond donating, but not 
accepting, should be capable of supplying the lacking hydrogen bond donation interactions 
and form cocrystals with the model compounds. The compounds studied in this context 
were: guanidine, metformin, tannic acid, telluric acid, boric acid and a range of other boronic 
acids.  
Guanidine and metformin (the pharmaceutical name for 1,1-dimethylbiguanide) are both 
available as HCl salts. Chloride ions are strongly hydrogen bond accepting, so exchange to a 
much less hydrogen bond accepting counter ion was undertaken. Hexafluorophosphate is 
not significantly hydrogen bond accepting and is a large and diffuse ion so was chosen as it 
may aid solubility of the salts in non-aqueous solvents and thus allow for a wider solvent 
choice and limit the possible hygroscopicity of the products. The ion exchange was 
performed using AgPF6, as insoluble AgCl is formed and can simply be filtered away, 
preventing reverse ion exchange. Even with an anion as diffuse as hexafluorophosphate, 
both metformin and guanidine were still only soluble in water to any meaningful extent, so 
crystallisations were performed in water. Both coformers with mixed in 1:1 ratios with 6-11 
and allowed to crystallise by evaporation from water. All attempted crystallisations gave 
plate-like and twinned crystals. Recrystallisation by heating and cooling and by redissolving 
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and evaporating slower did not result in crystals of quality suitable for single crystal x-ray 
diffraction.  
Tannic acid is a large polyphenol which is an acid derivative of tannin which is found naturally 
in oak leaves and bark. Whilst the carbonyls of the ester group could technically accept 
hydrogen bonds, the steric bulk of the molecule would make accessing them difficult. Taking 
this into consideration, tannic acid falls into the category of hydrogen bond donor which does 
not accept hydrogen bonds. The large molecular mass of tannic acid makes crystallisation 
challenging, though ease of availability makes it attractive. Tannic acid was mixed with 
compounds 6-11 in a 1:1 molar ratio and then dissolved in water. Solvent evaporation 
resulted in very viscous, brown liquids. No crystal formed over the course of two years.  
Boric acid has previously been reported to cocrystallise with the one of the model 
compounds, bisHEP, as a 1:1 bisHEP:boric acid cocrystal.1 However, no further boric acid 
based co crystals were achieved by crystallisation attempts with boric acid and the other 
model compounds 6-10. 
Telluric acid is analogous in form to boric acid. Instead of boron which is surrounded by three 
hydroxyl groups, telluric acid contains tellurium and is surrounded by six hydroxyl groups. As 
boric acid has shown such promise by crystallising with bisHEP, a similar acid may also prove 
useful. Telluric acid was mixed in a 1:1 ratio with compound 6-10, dissolved in water and the 
solvent was left to evaporate. After 8-9 months, low quality crystals of telluric acid are 
eventually formed in all attempted crystallisations with no trace of any model compound. 
Taking a boronic acid to be of the form RR’BOH where R and R’ can be any group, boric acid 
is the simplest boronic acid. Again, as boric acid can form a cocrystal with bisHEP, it is possible 
that other boronic acids may also cocrystallise with the model compounds. A range of 
monoboronic acids were chosen based on availability: 2-chloropyradine boronic acid, 4-
formylphenyl boronic acid, 2-fluoropyradine, 4-pyradinylphenyl boronic acid, 3-pyridyl 
boronic acid, 4-pyridyl boronic acid, 3-furyl boronic acid, 3-thiophenyl boronic acid, 1,4-
phenyldiboronic acid and tetrahydroxydiboron. All were mixed with compounds 6-11, 
dissolved in water and the solvent was left to evaporate. Two cocrystals were formed by 1,4-
phenyldiboronic acid with bisHEP and tetrahydroxydiboron with bisVCap which are detailed 
in section 4. The crystallisation containing 3-furyl boronic acid and bisHEP gave crystals of 
pure 3-furyl boronic acid which have not been reported in the CSD so the crystal structure of 
3-furanyl boronic acid is shown here in Figure 3.15. 
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Figure 3.15 – Crystal structure 3-furanyl boronic acid, showing the 3-furyl boronic acid dimer and bond to the 
nearest dimers on either side. Hydrogen bonds are shown by red dotted lines. 
The 3-furyl boronic acid molecules are held together in dimers by a cyclic hydrogen bond 
pattern between the hydroxy groups of the boronic acid groups, with each molecule 
donating and accepting a hydrogen bond, these hydrogen bonds have an O···O distance of 
2.7334(2) Å. These dimers are planar. The next dimer along is held close by O-H···O hydrogen 
bonds between the boronic acid groups with O···O distances of 2.726(2) Å. The planes of two 
neighbouring dimers are at 64.78° to each other.  
The hydrogen bonds are easily observable and highlighted by black arrows in the Hirshfeld 
surface fingerprint plot in Figure 3.16. Further out from the trailing diagonal there are two 
more peaks, highlighted by blue arrows, arise from hydrogen bonding interactions. Where 
one dimer donates a hydrogen bond to the neighbouring dimer, the same hydroxyl group 
accepts a hydrogen bond from a C-H of the furan ring. This hydrogen bond has a C···O length 
of 3.366(3) Å which is significantly longer than the O-H···O hydrogen bond so thus appears 
further from the diagonal. 
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Figure 3.16 – Hirshfeld surface fingerprint plot of 3-furyl boronic acid, black arrows point to O-H...O hydrogen 
bond interactions, blue arrows point to C-H...O hydrogen bond interactions. 
3.2.4.3 Peroxide 
In mildly sour systems (pipelines containing small amounts of H2S) hydrogen peroxide can be 
added along with the KHI to interact with the H2S and remove it from the pipeline. Hydrogen 
peroxide is loaded into the polymer mix and it is possible that the hydrogen peroxide 
interacts strongly enough with the polymer that it may crystallise with the model 
compounds. 
A range of crystallisation attempts with compounds 6-9 with molar peroxide ratios 1:2, 1:1 
and 2:1 were performed. A small volume of warm water was used to dissolve any model 
compound which had not dissolved in the peroxide solution and the crystallisation were left 
in the fridge at 5 °C. All bisVCap crystallisations returned solids though none of diffraction 
quality. The other model compounds remained liquid after two years. Whilst an interesting 
concept, interaction with peroxide is not a strong enough driving force to cocrystallise with 
the model compounds.  
3.2.4.4 Analogous compounds 
As the model compounds based on hydrate inhibitors have proven difficult to crystallise, it 
became of interest to try analogous compounds, such as similar ring based carbonyls with 
different heteroatoms as shown in Scheme 3.3. The goal is to find conceptually similar 
molecules that will crystallise quicker and with a higher rate of success at forming cocrystals 
but still have similar functionality and shape. Compounds 18-23 are commercially available. 
Compound 17 was synthesised from thionyl chloride and butanediol by the procedure 
outlined by Gao et al.36  
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Scheme 3.3 – Structure of the compounds analogous to the model compounds based on PVP and PVCap. 
A relatively small range of second components were chosen to attempt to cocrystallise with 
compounds 17-23. Those selected for their hydrogen bond donation: boric acid, 
tetrahydroxydiboron, metformin, guanidine and telluric acid, and the halogen bonding 
compounds: pDITFB, oDITFB, 1,4-diiodobenzene and 1-chloro-(2-iodoethynyl)benzene. All 
crystallisations were performed using a 1:1 molar ratio of components. All halogen bonding 
experiments were performed in a 1:1 volume ratio of acetone:DCM. The boric acid, 
tetrahydroxydiboron, metformin, guanidine and telluric acid crystallisation of compounds 
18-23 were performed in water, whilst compounds 12 was performed in a 1:1 volume ratio 
of acetone:water as 17 is not water soluble. 
Unfortunately no cocrystals were formed. Compound 23 often crystallised as low quality 
single component crystals and pDITFB and 1,4-diiodobenzene also gave crystals of the single 
components. Whilst an interesting idea the right components to form cocrystals with 17-23 
was not found in this short screen. Future work would benefit from a more through screen 
of potential second components, ratios and solvent choices. Though the cost and quantity of 
the compounds may be a barrier to a truly broad cocrystal screen. 
3.2.5 Grinding 
Grinding is a method commonly used in cocrystal screens. The two desired coformers are 
ground together and analysed by PXRD, Raman spectroscopy or IR spectroscopy, to 
determine whether the resulting powder is just a simple mixture with no strong interactions 
between the components or a new material different from its constituent parts.3,37,38 
Grinding is usually performed using a mortar and pestle or a mill, such as a ball mill. It is 
sometimes advantageous to add a small amount of solvent to maximise surface area and aid 
cocrystal formation, this process is called solvent drop grinding or liquid assisted grinding.39 
As the model compounds interact mainly through the carbonyl moiety of the lactam ring, IR 
spectroscopy is ideal to study if the model compounds form new species when ground with 
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a second component. The carbonyl stretch in IR spectroscopy is strong and sensitive to 
changes such as hydrogen bonding and metal coordination so if a cocrystal or other new 
species is formed, the hydrogen bonding interaction of the carbonyl group should be readily 
apparent from the shift in the IR carbonyl peak.  
Compounds 6-8 and 10-12 were used in grinding experiments. As purification of compound 
9 has not been possible it was not chosen for grinding, as the crude mixture results in 
multiple peaks in the carbonyl region, making clear analysis difficult. Compounds 6-8 and 10-
12 were ground together in a 1:1 molar ratio with aluminium nitrate, boric acid, pDITFB, 
guanidinium tetrafluoroborate, nicotinamide, tartaric acid and telluric acid. Grinding was 
performed by hand using a mortar and pestle until a visibly homogeneous mixture was 
formed. The samples were then analysed by IR spectroscopy using an ATR attachment. 
Spectra of the mixtures were overlaid with a spectrum of the pure model compound and the 
position of the carbonyl peaks were compared. The overlay of bisHEP and the ground bisHEP 
samples can be found in Figure 3.17. 
 
Figure 3.17 – Overlay of the IR spectra of bisHEP and bisHEP ground in a 1:1 ratio aluminium nitrate, boric 
acid, DITFB, guanidinium BF4, nicotinamide, tartaric acid and telluric acid. 
The IR carbonyl peak shifts for compounds 6-8 and 10-12 alone and when ground are shown 
in Table 3.1. BisVCap shows no change in the carbonyl peak when ground with any of the 
selected chemicals. To check is the lack of change in the carbonyl peak is truly from a lack of 
interaction or inadequate mixing, bisVCap and aluminium nitrate were mixed in a 1:1 molar 
ratio and ground together using a ball mill. The mixture was milled in 10 min bursts at 20 Hz 
and an IR spectrum recorded after every 10 min milling. The milling was performed for a total 
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of 50 min. As seen in Figure 3.18, even after 50 min of milling, there is no change in the 
carbonyl peak of bisVCap in the IR spectra. This suggests that there is no significant 
interaction between bisVCap and aluminium chloride and the lack of carbonyl peak shift did 
not arise from inadequate mixing.  
 
Figure 3.18 – IR spectra of bisVCap with aluminium nitrate after milling in 10 min increments. 
MEP also showed no significant change in the carbonyl peak with any of the compounds 
tried. Suggesting that there is no significant interaction between MEP and aluminium nitrate, 
boric acid, pDITFB, guanidinium tetrafluoroborate, nicotinamide, tartaric acid or telluric acid. 
There is no carbonyl shift reported for MEP with nicotinamide of guanidinium BF4 as the 
nicotinamide carbonyl peaks and the guanidinium imine peak obscure the MEP carbonyl 
peak. 
HEPVCap did not show any peak shifts larger enough to represent the formation of hydrogen 
bond. When ground with aluminium nitrate the carbonyl peaks broaden too much to 
accurately pick out the signals from both carbonyls, whilst this suggests some interaction, 
compared to the large shifts cause by aluminium nitrate with bisVP, H2bisVCap and bisHEP, 
the broadening of the HEPVCap carbonyl peak is not significant. When ground with tartaric 
acid and nicotinamide the HEPVCap signals are obscured by the carbonyl peaks of tartaric 
acid and nicotinamide so cannot be recorded.  
The carbonyl peak of bisVP show no change within error when ground with telluric acid. With 
boric acid, pDITFB, guanidinium BF4, nicotinamide and tartaric acid there are significant shifts 
between 7-20 cm-1 and with aluminium nitrate there is a large peak shift of 45 cm-1. This 
suggests with tested chemicals, except telluric acid, there is interaction between bisVP and 
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the chemical. BisVP is an oil at room temperature and upon grinding with any of the tested 
compounds thick oils form. These show no birefringence under polarised light and no crystals 
formed over the course of three days.  
  bisVCap bisVP H2bisVCap HEPVCap bisHEP MEP 
model compound 1667 1640 1673 1631 1647 1629 1671 1632 
aluminium nitrate 1667 1641 1628 1588 - 1627 1627 1633 
boric acid 1667 1641 1652 1617 1642 1624 1662 1632 
DITFB 1667 1641 1653 1614 1647 1624 1648 1632 
guanidinium BF4 1666 1640 1666 1598 1643 - 1643 - 
nicotinamide 1667 1641 1657 1614 - - 1661 - 
tartaric acid 1667 1641 1657 1592 - - 1629 1632 
telluric acid 1667 1641 1676 1627 1644 1629 1657 1633 
 
Table 3.1 –Carbonyl peak positions in cm-1 for model compound 1-3 and 5-7 alone and ground in a 1:1 molar 
ratio with aluminium nitrate, boric acid, DITFB, guanidinium BF4, nicotinamide, tartaric acid and telluric acid. 
Dashed indicated that the peak of interest was either obscured or too broad to measure. 
H2bisVCap shows no shift with telluric acid, moderate shifts of 14-17 cm-1 with boric acid, 
nicotinamide and pDITFB and large shifts of 32-42 cm-1 with aluminium nitrate, guanidinium 
BF4 and tartaric acid. This suggests that there is significant interaction between H2bisVCap 
and boric acid, nicotinamide and pDITFB and strong interactions between H2bisVCap and 
aluminium nitrate, guanidinium BF4 and tartaric acid. H2bisVCap is usually an oil at room 
temperature due to absorbed water,40 when ground with any of the chosen chemicals, a 
thick paste which shows no birefringence under polarised light was formed. Even leaving in 
a vacuum desiccator under vacuum for three days did not form any solids. 
The carbonyl peak for bisHEP changes with addition of all of the tested compounds. A 
moderate shift between 9-13 cm-1 is seen with boric acid, nicotinamide and telluric acid, a 
larger shift of 23-28 cm-1 is seen with pDITFB and guanidinium BF4 and large shifts of 42-44 
cm-1 were seen with aluminium nitrate and tartaric acid. This suggests that bisHEP interacts 
with all the compounds tested. BisHEP is a liquid at room temperature and all the ground 
mixtures were also liquids and no solids were observed over the course of three days. 
Slow evaporation experiments of 1:1 ratios compounds 6-8 and 10-12 with aluminium 
nitrate, boric acid, guanidinium tetrafluoroborate, nicotinamide, tartaric acid and telluric 
acid from water and compounds 6-8 and 10-12 with pDITFB in 1:1 volume ratio acetone:DCM 
did not result in any solid product. All remained liquids after six months. 
Whilst grinding experiments do show that interactions between the compounds 7, 8, 10 and 
11 with aluminium nitrate, boric acid, pDITFB, guanidinium tetrafluoroborate, nicotinamide, 
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tartaric acid and telluric acid, it does not guarantee cocrystal formation. Coamorphous 
materials or even solvation of one compound in the other, is driven by intermolecular 
interaction such as hydrogen bonds the same as cocrystal formation. The models of 
crystallisation inhibitors do interact with other compounds, but often inhibit their 
crystallisation, resulting in oils. Whilst meaning cocrystal formation is challenging, the 
difficulty of forming crystals shows the model compounds to exhibit similar crystallisation 
inhibition properties to the polymers, making them good models to study. 
3.3 Experimental 
3.3.1 Macrocycles 
Crystallisation experiments were performed in 2 cm3 glass vials with plastic screw lids. The 
model compounds along with a second component, defined in Table 3.2, were weighed into 
the vial and the vial was filled with 1.5 cm3 of the appropriate solvent. The sample was heated 
and sonicated until everything had dissolved. Crystallisations containing water were left 
open whilst other solvents were left with the lid resting on top of the vial. The samples were 
checked every couple of weeks until either crystals formed, non-crystalline solids formed or 
a thick oil which did not change over the course of a few months was formed.  
Model 
compound 
Model 
compound 
weight / g Macrocycle 
Macrocycle 
weight / g Solvent 
ethyl 
caprolactam 0.0047 SC4 0.050 water 
 0.0095 SC4 0.050 water 
 0.0190 SC4 0.050 water 
 0.0032 SC6 0.050 water 
 0.0063 SC6 0.050 water 
 0.0130 SC6 0.050 water 
 0.0024 SC8 0.050 water 
 0.0047 SC8 0.050 water 
 0.0095 SC8 0.050 water 
 0.0053 SC4 Na salt 0.050 water 
 0.0107 SC4 Na salt 0.050 water 
 0.0213 SC4 Na salt 0.050 water 
 0.0036 SC6 Na salt 0.050 water 
 0.0071 SC6 Na salt 0.050 water 
 0.0146 SC6 Na salt 0.050 water 
 0.0027 SC8 Na salt 0.050 water 
 0.0053 SC8 Na salt 0.050 water 
 0.0107 SC8 Na salt 0.050 water 
 0.0067 
benzyloxycalix 
[5]arene 0.050 
toluene/ 
acetone 
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 0.0087 
4-tert-butyl 
calix[4]arene 0.050 
toluene/ 
acetone 
 0.0100 
cucurbiturils 5, 
6 0.050 dilute HCl 
 0.0100 
cucurbiturils 6, 
7, 8 0.050 dilute HCl 
 0.0088 α-cyclodextrin 0.050 water 
 0.0103 β-cyclodextrin 0.050 water 
 0.0117 γ-cyclodextrin 0.050 water 
ethyl 
pyrrolidone 0.0038 SC4 0.050 water 
 0.0075 SC4 0.050 water 
 0.0150 SC4 0.050 water 
 0.0025 SC6 0.050 water 
 0.0050 SC6 0.050 water 
 0.0100 SC6 0.050 water 
 0.0020 SC8 0.050 water 
 0.0037 SC8 0.050 water 
 0.0075 SC8 0.050 water 
 0.0043 SC4 Na salt 0.050 water 
 0.0084 SC4 Na salt 0.050 water 
 0.0169 SC4 Na salt 0.050 water 
 0.0028 SC6 Na salt 0.050 water 
 0.0056 SC6 Na salt 0.050 water 
 0.0112 SC6 Na salt 0.050 water 
 0.0022 SC8 Na salt 0.050 water 
 0.0042 SC8 Na salt 0.050 water 
 0.0084 SC8 Na salt 0.050 water 
 0.0053 
benzyloxycalix 
[5]arene 0.050 
toluene/ 
acetone 
 0.0109 
4-tert-butyl 
calix[4]arene 0.050 
toluene/ 
acetone 
 0.0100 
cucurbiturils 5, 
6 0.050 dilute HCl 
 0.0100 
cucurbiturils 6, 
7, 8 0.050 dilute HCl 
 0.0071 α-cyclodextrin 0.050 water 
 0.0083 β-cyclodextrin 0.050 water 
 0.0095 γ-cyclodextrin 0.050 water 
bisVCap 0.0090 SC4 0.050 water 
 0.0190 SC4 0.050 water 
 0.0370 SC4 0.050 water 
 0.0070 SC6 0.050 water 
 0.0120 SC6 0.050 water 
 0.0250 SC6 0.050 water 
 0.0050 SC8 0.050 water 
 0.0900 SC8 0.050 water 
 0.0190 SC8 0.050 water 
 0.0101 SC4 Na salt 0.050 water 
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 0.0213 SC4 Na salt 0.050 water 
 0.0416 SC4 Na salt 0.050 water 
 0.0079 SC6 Na salt 0.050 water 
 0.0135 SC6 Na salt 0.050 water 
 0.0281 SC6 Na salt 0.050 water 
 0.0056 SC8 Na salt 0.050 water 
 0.1011 SC8 Na salt 0.050 water 
 0.0213 SC8 Na salt 0.050 water 
 0.0131 
benzyloxycalix 
[5]arene 0.050 
toluene/ 
acetone 
 0.0214 
4-tert-butyl 
calix[4]arene 0.050 
toluene/ 
acetone 
 0.0200 
cucurbiturils 5, 
6 0.050 dilute HCl 
 0.0200 
cucurbiturils 6, 
7, 8 0.050 dilute HCl 
 0.0175 α-cyclodextrin 0.050 water 
 0.0204 β-cyclodextrin 0.050 water 
 0.0233 γ-cyclodextrin 0.050 water 
H2bisVCap 0.0380 SC4 0.050 water 
 0.0750 SC4 0.050 water 
 0.0150 SC4 0.050 water 
 0.0250 SC6 0.050 water 
 0.0500 SC6 0.050 water 
 0.1000 SC6 0.050 water 
 0.0190 SC8 0.050 water 
 0.0330 SC8 0.050 water 
 0.0750 SC8 0.050 water 
 0.0427 SC4 Na salt 0.050 water 
 0.0843 SC4 Na salt 0.050 water 
 0.0169 SC4 Na salt 0.050 water 
 0.0281 SC6 Na salt 0.050 water 
 0.0562 SC6 Na salt 0.050 water 
 0.1124 SC6 Na salt 0.050 water 
 0.0213 SC8 Na salt 0.050 water 
 0.0371 SC8 Na salt 0.050 water 
 0.0843 SC8 Na salt 0.050 water 
 0.0132 
benzyloxycalix 
[5]arene 0.050 
toluene/ 
acetone 
 0.0216 
4-tert-butyl 
calix[4]arene 0.050 
toluene/ 
acetone 
 0.0200 
cucurbiturils 5, 
6 0.050 dilute HCl 
 0.0200 
cucurbiturils 6, 
7, 8 0.050 dilute HCl 
 0.0176 α-cyclodextrin 0.050 water 
 0.0206 β-cyclodextrin 0.050 water 
 0.0235 γ-cyclodextrin 0.050 water 
bisVP 0.0300 SC4 0.050 water 
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 0.0600 SC4 0.050 water 
 0.1190 SC4 0.050 water 
 0.0200 SC6 0.050 water 
 0.0400 SC6 0.050 water 
 0.0790 SC6 0.050 water 
 0.0150 SC8 0.050 water 
 0.0300 SC8 0.050 water 
 0.0600 SC8 0.050 water 
 0.0337 SC4 Na salt 0.050 water 
 0.0674 SC4 Na salt 0.050 water 
 0.1337 SC4 Na salt 0.050 water 
 0.0225 SC6 Na salt 0.050 water 
 0.0449 SC6 Na salt 0.050 water 
 0.0888 SC6 Na salt 0.050 water 
 0.0169 SC8 Na salt 0.050 water 
 0.0337 SC8 Na salt 0.050 water 
 0.0674 SC8 Na salt 0.050 water 
 0.0105 
benzyloxycalix 
[5]arene 0.050 
toluene/ 
acetone 
 0.0171 
4-tert-butyl 
calix[4]arene 0.050 
toluene/ 
acetone 
 0.0200 
cucurbiturils 5, 
6 0.050 dilute HCl 
 0.0200 
cucurbiturils 6, 
7, 8 0.050 dilute HCl 
 0.0140 α-cyclodextrin 0.050 water 
 0.0163 β-cyclodextrin 0.050 water 
 0.0186 γ-cyclodextrin 0.050 water 
H2bisVP 0.0350 SC4 0.050 water 
 0.0710 SC4 0.050 water 
 0.1400 SC4 0.050 water 
 0.0230 SC6 0.050 water 
 0.0470 SC6 0.050 water 
 0.0950 SC6 0.050 water 
 0.0180 SC8 0.050 water 
 0.0360 SC8 0.050 water 
 0.0710 SC8 0.050 water 
 0.0393 SC4 Na salt 0.050 water 
 0.0798 SC4 Na salt 0.050 water 
 0.1573 SC4 Na salt 0.050 water 
 0.0258 SC6 Na salt 0.050 water 
 0.0528 SC6 Na salt 0.050 water 
 0.1067 SC6 Na salt 0.050 water 
 0.0202 SC8 Na salt 0.050 water 
 0.0405 SC8 Na salt 0.050 water 
 0.0798 SC8 Na salt 0.050 water 
 0.0106 
benzyloxycalix 
[5]arene 0.050 
toluene/ 
acetone 
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 0.0173 
4-tert-butyl 
calix[4]arene 0.050 
toluene/ 
acetone 
 0.0200 
cucurbiturils 5, 
6 0.050 dilute HCl 
 0.0200 
cucurbiturils 6, 
7, 8 0.050 dilute HCl 
 0.0141 α-cyclodextrin 0.050 water 
 0.0164 β-cyclodextrin 0.050 water 
 0.0188 γ-cyclodextrin 0.050 water 
HepVCap 0.0375 SC4 0.050 water 
 0.0761 SC4 0.050 water 
 0.1500 SC4 0.050 water 
 0.0246 SC6 0.050 water 
 0.0504 SC6 0.050 water 
 0.1018 SC6 0.050 water 
 0.0193 SC8 0.050 water 
 0.0386 SC8 0.050 water 
 0.0761 SC8 0.050 water 
 0.0421 SC4 Na salt 0.050 water 
 0.0855 SC4 Na salt 0.050 water 
 0.1685 SC4 Na salt 0.050 water 
 0.0277 SC6 Na salt 0.050 water 
 0.0566 SC6 Na salt 0.050 water 
 0.1144 SC6 Na salt 0.050 water 
 0.0217 SC8 Na salt 0.050 water 
 0.0433 SC8 Na salt 0.050 water 
 0.0855 SC8 Na salt 0.050 water 
 0.0126 
benzyloxycalix 
[5]arene 0.050 
toluene/ 
acetone 
 0.0206 
4-tert-butyl 
calix[4]arene 0.050 
toluene/ 
acetone 
 0.0200 
cucurbiturils 5, 
6 0.050 dilute HCl 
 0.0200 
cucurbiturils 6, 
7, 8 0.050 dilute HCl 
 0.0151 α-cyclodextrin 0.050 water 
 0.0176 β-cyclodextrin 0.050 water 
  0.0201 γ-cyclodextrin 0.050 water 
Table 3.2 – Macrocycle crystallisation values and solvents. 
3.3.2 Halogen bonding 
Crystallisation experiments were performed in 2 cm3 glass vials with plastic screw lids. Both 
components were weighed into the vial and the vial was filled with 1.5 cm3 of the appropriate 
solvent. The sample was heated and sonicated until everything had dissolved. Crystallisations 
containing water were left open whilst other solvents were left with the lid resting on top of 
the vial. The samples were checked every couple of weeks until either crystals formed, non-
crystalline solids formed or a thick oil which did not change over the course of a few months 
3: Cocrystallisation of hydrate inhibitor models 
88 
 
was formed. The crystallisation containing the halogen bond donating compounds can be 
found in Table 3.3 . 
Model 
compound 
Model 
compound 
weight / g 
Halogen bond 
donor 
Halogen bond 
donor weight / 
g Solvent 
bisVCap 0.047 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.035 pDITFB 0.050 acetone/DCM 
 0.025 oDITFB 0.050 acetone/DCM 
 0.042 
1,2-
diiodobenzene 0.050 acetone/DCM 
 0.017 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 iodine 0.046 ethanol 
H2bisVCap 0.048 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.035 pDITFB 0.050 acetone/DCM 
 0.025 oDITFB 0.050 acetone/DCM 
 0.042 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.018 
3-chloro-(2-
iodoethynyl)be
nzene 0.050 acetone/DCM 
 0.050 iodine 0.045 ethanol 
bisVP 0.038 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.028 pDITFB 0.050 acetone/DCM 
 0.025 oDITFB 0.050 acetone/DCM 
 0.034 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.018 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 iodine 0.057 ethanol 
H2bisVP 0.038 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.028 pDITFB 0.050 acetone/DCM 
 0.025 oDITFB 0.050 acetone/DCM 
 0.034 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.018 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 iodine 0.057 ethanol 
HepVCap 0.046 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.033 pDITFB 0.050 acetone/DCM 
 0.025 oDITFB 0.050 acetone/DCM 
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 0.041 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.022 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 iodine 0.053 ethanol 
bisHEP 0.035 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.025 pDITFB 0.050 acetone/DCM 
 0.025 oDITFB 0.050 acetone/DCM 
 0.031 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.017 
3-chloro-(2-
iodoethynyl)be
nzene 0.050 acetone/DCM 
 0.050 iodine 0.053 ethanol 
MEP 0.024 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.018 pDITFB 0.050 acetone/DCM 
 0.018 oDITFB 0.050 acetone/DCM 
 0.022 
1,4-
diiodobenzene 0.050 acetone/DCM 
  0.027 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
Table 3.3  – Halogen bond crystallisation values and solvents. 
3.3.3 Metal complexes 
Crystallisation experiments were performed in 2 cm3 glass vials with plastic screw lids. Both 
components were weighed into the vial and the vial was filled with 1.5 cm3 of the appropriate 
solvent. The sample was heated and sonicated until everything had dissolved. Crystallisations 
containing water were left open whilst other solvents were left with the lid resting on top of 
the vial. The samples were checked every couple of weeks until either crystals formed, non-
crystalline solids formed or a thick oil which did not change over the course of a few months 
was formed. The crystallisation containing metal salts can be found in Table 3.4. 
Model 
compound 
Model 
compound 
weight / g Metal salt 
Metal salt 
weight / g Solvent 
bisVCap 0.067 
terbium (III) 
chloride  0.150 water 
 0.078 
terbium (III) 
nitrate  0.150 water 
 0.022 
gadolinium (III) 
chloride  0.050 water 
 0.027 
gadolinium (III) 
nitrate  0.050 water 
 0.032 
yttrium 
triflouromethane
sulfonate  0.050 water 
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 0.037 
ytterbium 
trifluoromethane
sulfonate  0.050 water 
 0.021 
yttrium (III) 
carbonate  0.050 water 
 0.026 
lanthanum (II) 
nitrate  0.050 water 
 0.021 
lanthanum 
chloride  0.050 water 
 0.030 
terbium 
carbonate 0.050 water 
H2bisVCap 0.067 
terbium (III) 
chloride  0.150 water 
 0.078 
terbium (III) 
nitrate  0.150 water 
 0.022 
gadolinium (III) 
chloride  0.050 water 
 0.027 
gadolinium (III) 
nitrate  0.050 water 
 0.032 
yttrium 
triflouromethane
sulfonate  0.050 water 
 0.037 
ytterbium 
trifluoromethane
sulfonate  0.050 water 
 0.021 
yttrium (III) 
carbonate  0.050 water 
 0.026 
lanthanum (II) 
nitrate  0.050 water 
 0.021 
lanthanum 
chloride  0.050 water 
 0.030 
terbium 
carbonate 0.050 water 
bisVP 0.084 
terbium (III) 
chloride  0.150 water 
 0.098 
terbium (III) 
nitrate  0.150 water 
 0.028 
gadolinium (III) 
chloride  0.050 water 
 0.034 
gadolinium (III) 
nitrate  0.050 water 
 0.040 
yttrium 
triflouromethane
sulfonate  0.050 water 
 0.047 
ytterbium 
trifluoromethane
sulfonate  0.050 water 
 0.027 
yttrium (III) 
carbonate  0.050 water 
 0.033 
lanthanum (II) 
nitrate  0.050 water 
 0.027 
lanthanum 
chloride  0.050 water 
 0.037 
terbium 
carbonate 0.050 water 
H2bisVP 0.083 
terbium (III) 
chloride  0.150 water 
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 0.097 
terbium (III) 
nitrate  0.150 water 
 0.028 
gadolinium (III) 
chloride  0.050 water 
 0.034 
gadolinium (III) 
nitrate  0.050 water 
 0.040 
yttrium 
triflouromethane
sulfonate  0.050 water 
 0.046 
ytterbium 
trifluoromethane
sulfonate  0.050 water 
 0.027 
yttrium (III) 
carbonate  0.050 water 
 0.032 
lanthanum (II) 
nitrate  0.050 water 
 0.026 
lanthanum 
chloride  0.050 water 
 0.037 
terbium 
carbonate 0.050 water 
bisHEP 0.078 
terbium (III) 
chloride  0.150 water 
 0.091 
terbium (III) 
nitrate  0.150 water 
 0.026 
gadolinium (III) 
chloride  0.050 water 
 0.031 
gadolinium (III) 
nitrate  0.050 water 
 0.037 
yttrium 
triflouromethane
sulfonate  0.050 water 
 0.043 
ytterbium 
trifluoromethane
sulfonate  0.050 water 
 0.025 
yttrium (III) 
carbonate  0.050 water 
 0.030 
lanthanum (II) 
nitrate  0.050 water 
 0.025 
lanthanum 
chloride  0.050 water 
 0.035 
terbium 
carbonate 0.050 water 
HEPVCap 0.050 
cadmium 
accetate 0.043 water 
 0.050 
cadmium 
chloride 0.034 water 
 0.050 
cadmium 
sulphate 0.039 water 
 0.050 
caesium 
acetate 0.036 water 
 0.050 
caesium 
carbonate 0.061 water 
 0.050 
caesium 
chloride 0.031 water 
 0.050 
caesium 
hydroxide  0.031 water 
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 0.050 
cobalt (II) 
chloride 0.024 water 
 0.050 
cobalt (II) 
nitrate  0.034 water 
 0.050 
cobalt (II) 
sulphate  0.052 water 
 0.050 
copper (II) 
acetate 0.034 water 
 0.050 
copper (II) 
bromide 0.042 water 
 0.050 
copper (II) 
chloride 0.025 water 
 0.050 
copper (II) 
tetrafluorobora
te 0.044 water 
 0.050 ferric chloride 0.030 water 
 0.050 
iron (II) 
bromide 0.040 water 
 0.050 lead (II) nitrate 0.062 water 
 0.050 
lithium 
bromide 0.016 water 
 0.050 lithium iodide 0.025 water 
 0.050 
magnesium 
nitrate  0.028 water 
 0.050 
manganese (II) 
acetate 0.032 water 
 0.050 
nickel (II) 
acetate  0.046 water 
 0.050 
nickel (II) 
chloride  0.024 water 
 0.050 
nickel (II) 
nitrate  0.054 water 
 0.050 
ytterbium 
trifluorometha
nesulfonate  0.116 water 
 0.050 
yttrium (III) 
carbonate  0.067 water 
 0.050 
lanthanum (II) 
nitrate  0.081 water 
 0.050 
manganese 
sulfate  0.032 water 
 0.050 
lanthanum 
chloride  0.066 water 
 0.050 
terbium 
carbonate 0.093 water 
 0.050 
chromium (III) 
nitrate  0.075 water 
 0.050 
chromium (III) 
sulphate  0.073 water 
 0.050 
terbium (III) 
chloride  0.070 water 
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 0.050 
gadolinium (III) 
chloride  0.069 water 
 0.050 
gadolinium (III) 
nitrate  0.084 water 
 1.050 
praseodymium 
(III) nitrate  0.081 water 
 2.050 
erbium (III) 
chloride  0.071 water 
 3.050 
europium (III) 
chloride  0.068 water 
 0.030 
lanthanum (II) 
nitrate  0.145 water 
 0.030 
ytterbium 
trifluorometha
nesulfonate  0.208 water 
 0.030 
yttrium (III) 
carbonate  0.120 water 
 0.030 
terbium 
carbonate 0.167 water 
 0.050 
sodium 
chloride 0.019 water 
 0.050 
neodymium (III) 
nitrate  0.147 water 
 0.050 
potassium 
bromide 0.040 water 
 0.050 
potassium 
carbonate 0.046 water 
 0.050 
potassium 
chloride 0.025 water 
 0.050 
potassium 
hexaflurophosp
hate 0.062 water 
 0.050 
potassium 
nitrate 0.034 water 
 0.050 
sodium 
carbonate 0.036 water 
 0.050 
sodium 
hydrogen 
carbonate 0.028 water 
 0.050 
sodium 
hydrogen 
sulphate 0.040 water 
 0.050 sodium nitrate 0.029 water 
 0.050 
strontium 
nitrate 0.071 water 
 0.050 zinc chloride 0.046 water 
 0.050 zinc acetate 0.061 water 
 0.050 zinc nitrate  0.063 water 
 0.050 calcium nitrate  0.055 water 
 0.050 
strontium 
carbonate 0.067 water 
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 0.050 
caesium 
carbonate 0.109 water 
 0.050 cerium nitrate  0.146 water 
MEP 0.013 
cadmium 
acetate  0.050 water 
 0.011 
cadmium 
chloride 0.050 water 
 0.012 
cadmium 
sulphate 0.050 water 
 0.011 
caesium 
acetate 0.050 water 
 0.019 
caesium 
carbonate 0.050 water 
 0.010 
caesium 
chloride 0.050 water 
 0.010 
caesium 
hydroxide  0.050 water 
 0.008 
cobalt (II) 
chloride 0.050 water 
 0.011 
cobalt (II) 
nitrate  0.050 water 
 0.011 
copper (II) 
acetate 0.050 water 
 0.013 
copper (II) 
bromide 0.050 water 
 0.008 
copper (II) 
chloride 0.050 water 
 0.006 
calcium 
chloride 0.050 water 
 0.014 
copper (II) 
tetrafluorobora
te 0.050 water 
 0.010 
sodium 
hexafluorophos
phate 0.050 water 
 0.009 ferric chloride 0.050 water 
 0.013 
iron (II) 
bromide 0.050 water 
 0.019 lead (II) nitrate 0.050 water 
 0.005 
lithium 
bromide 0.050 water 
 0.004 lithium nitrate 0.050 water 
 0.009 
magnesium 
nitrate  0.050 water 
 0.010 
manganese (II) 
acetate 0.050 water 
 0.015 
nickel (II) 
acetate  0.050 water 
 0.008 
nickel (II) 
chloride  0.050 water 
 0.017 
nickel (II) 
nitrate  0.050 water 
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 0.031 
yttrium 
trifluorometha
nesulfonate  0.050 water 
 0.006 
sodium 
tetrafluorobora
te 0.050 water 
 0.020 
lanthanum (II) 
nitrate  0.050 water 
 0.010 
manganese 
sulfate  0.050 water 
 0.021 
lanthanum 
chloride  0.050 water 
 0.025 terbium nitrate 0.050 water 
 0.023 
chromium (III) 
nitrate  0.050 water 
 0.003 
sodium 
chloride 0.050 water 
 0.022 
terbium (III) 
chloride  0.050 water 
 0.022 
gadolinium (III) 
chloride  0.050 water 
 0.026 
gadolinium (III) 
nitrate  0.050 water 
 0.025 
praseodymium 
(III) nitrate  0.050 water 
 0.009 
erbium (III) 
chloride  0.020 water 
 0.009 
europium (III) 
chloride  0.020 water 
 0.010 
lanthanum (II) 
nitrate  0.020 water 
 0.021 
yttrium (III) 
carbonate  0.050 water 
 0.014 
ytterbium 
trifluorometha
nesulfonate  0.020 water 
 0.029 
terbium 
carbonate 0.050 water 
 0.016 
cobalt (II) 
sulphate  0.050 water 
 0.026 
neodymium (III) 
nitrate  0.050 water 
 0.007 
potassium 
bromide 0.050 water 
 0.008 
potassium 
carbonate 0.050 water 
 0.004 
potassium 
chloride 0.050 water 
 0.011 
potassium 
hexaflurophosp
hate 0.050 water 
 0.006 
potassium 
nitrate 0.050 water 
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 0.006 
sodium 
carbonate 0.050 water 
 0.005 
sodium 
hydrogen 
carbonate 0.050 water 
 0.007 
sodium 
hydrogen 
sulphate 0.050 water 
 0.005 sodium nitrate 0.050 water 
 0.012 
strontium 
nitrate 0.050 water 
 0.008 zinc chloride 0.050 water 
 0.011 zinc acetate 0.050 water 
 0.011 zinc nitrate  0.050 water 
 0.010 calcium nitrate  0.050 water 
 0.012 
strontium 
carbonate 0.050 water 
 0.019 
caesium 
carbonate 0.050 water 
 0.025 cerium nitrate  0.050 water 
 0.023 
chromium (III) 
sulfate 0.050 water 
Et(OVCap)2 0.034 
cadmium 
acetate  0.050 water 
 0.027 
cadmium 
chloride 0.050 water 
 0.031 
cadmium 
sulphate 0.050 water 
 0.028 
caesium 
acetate 0.050 acetone 
 0.048 
caesium 
carbonate 0.050 water 
 0.025 
caesium 
chloride 0.050 water 
 0.025 
caesium 
hydroxide  0.050 acetone 
 0.019 
cobalt (II) 
chloride 0.050 acetone 
 0.027 
cobalt (II) 
nitrate  0.050 acetone 
 0.027 
copper (II) 
acetate 0.050 water 
 0.033 
copper (II) 
bromide 0.050 water 
 0.020 
copper (II) 
chloride 0.050 acetone 
 0.016 
calcium 
chloride 0.050 water 
 0.035 
copper (II) 
tetrafluorobora
te 0.050 acetone 
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 0.025 
sodium 
hexafluorophos
phate 0.050 water 
 0.024 ferric chloride 0.050 acetone 
 0.032 
Iiron (II) 
bromide 0.050 acetone 
 0.049 lead (II) nitrate 0.050 water 
 0.013 
lithium 
bromide 0.050 acetone 
 0.010 lithium nitrate 0.050 acetone 
 0.022 
magnesium 
nitrate  0.050 acetone 
 0.025 
manganese (II) 
acetate 0.050 water 
 0.037 
nickel (II) 
acetate  0.050 water 
 0.019 
nickel (II) 
chloride  0.050 water 
 0.043 
nickel (II) 
nitrate  0.050 acetone 
 0.079 
yttrium 
trifluorometha
nesulfonate  0.050 acetone 
 0.016 
sodium 
tetrafluorobora
te 0.050 acetone 
 0.051 
lanthanum (II) 
nitrate  0.050 acetone 
 0.025 
manganese 
sulfate  0.050 water 
 0.052 
lanthanum 
chloride  0.050 water 
 0.064 terbium nitrate 0.050 acetone 
 0.059 
chromium (III) 
nitrate  0.050 acetone 
 0.009 
sodium 
chloride 0.050 water 
 0.055 
terbium (III) 
chloride  0.050 water 
 0.055 
gadolinium (III) 
chloride  0.050 water 
 0.066 
gadolinium (III) 
nitrate  0.050 acetone 
 0.064 
praseodymium 
(III) nitrate  0.050 acetone 
 0.022 
erbium (III) 
chloride  0.020 water 
 0.022 
europium (III) 
chloride  0.020 water 
 0.025 
lanthanum (II) 
nitrate  0.020 acetone 
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 0.053 
yttrium (III) 
carbonate  0.050 water 
 0.036 
ytterbium 
trifluorometha
nesulfonate  0.020 acetone 
 0.073 
terbium 
carbonate 0.050 water 
 0.041 
cobalt (II) 
sulphate 
heptahydrate 0.050 water 
 0.064 
neodymium (III) 
nitrate  0.050 acetone 
 0.018 
potassium 
bromide 0.050 water 
 0.020 
potassium 
carbonate 0.050 water 
 0.011 
potassium 
chloride 0.050 water 
 0.015 
potassium 
nitrate 0.050 water 
 0.027 
potassium 
hexaflurophosp
hate 0.050 acetone 
 0.016 
sodium 
carbonate 0.050 water 
 0.018 
sodium 
hydrogen 
sulphate 0.050 acetone 
 0.012 
sodium 
hydrogen 
carbonate 0.050 water 
 0.013 sodium nitrate 0.050 water 
 0.031 
strontium 
nitrate 0.050 water 
 0.020 zinc chloride 0.050 acetone 
 0.027 zinc acetate 0.050 water 
 0.028 zinc nitrate  0.050 acetone 
 0.024 calcium nitrate 0.050 acetone 
 0.029 
strontium 
carbonate 0.050 water 
 0.048 
caesium 
carbonate 0.050 water 
 0.064 cerium nitrate  0.050 water 
 0.058 
chromium (III) 
sulfate 0.050 water 
 0.055 
aluminium 
nitrate  0.050 water 
 0.050 
vanadium 
chloride 0.023 water 
 0.050 vanadium oxide 0.027 water 
Pr(OVP)2 0.033 
cadmium 
acetate  0.050 water 
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 0.026 
cadmium 
chloride 0.050 water 
 0.029 
cadmium 
sulphate 0.050 water 
 0.027 
caesium 
acetate 0.050 water 
 0.046 
caesium 
carbonate 0.050 water 
 0.024 
caesium 
chloride 0.050 water 
 0.024 
caesium 
hydroxide  0.050 water 
 0.018 
cobalt (II) 
chloride 0.050 water 
 0.026 
cobalt (II) 
nitrate  0.050 water 
 0.026 
copper (II) 
acetate 0.050 water 
 0.031 
copper (II) 
bromide 0.050 water 
 0.019 
copper (II) 
chloride 0.050 water 
 0.016 
calcium 
chloride 0.050 water 
 0.033 
copper (II) 
tetrafluorobora
te 0.050 water 
 0.024 
sodium 
hexafluorophos
phate 0.050 water 
 0.023 ferric chloride 0.050 water 
 0.030 
Iron (II) 
bromide 0.050 water 
 0.047 lead (II) nitrate 0.050 water 
 0.012 
lithium 
bromide 0.050 water 
 0.010 lithium nitrate 0.050 water 
 0.021 
magnesium 
nitrate  0.050 water 
 0.024 
manganese (II) 
acetate 0.050 water 
 0.035 
nickel (II) 
acetate  0.050 water 
 0.018 
nickel (II) 
chloride  0.050 water 
 0.041 
nickel (II) 
nitrate  0.050 water 
 0.076 
yttrium 
trifluorometha
nesulfonate  0.050 water 
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 0.016 
sodium 
tetrafluorobora
te 0.050 water 
 0.049 
lanthanum (II) 
nitrate  0.050 water 
 0.024 
manganese 
sulfate  0.050 water 
 0.050 
lanthanum 
chloride  0.050 water 
 0.061 terbium nitrate 0.050 water 
 0.056 
chromium (III) 
nitrate  0.050 water 
 0.008 
sodium 
chloride 0.050 water 
 0.053 
terbium (III) 
chloride  0.050 water 
 0.053 
gadolinium (III) 
chloride  0.050 water 
 0.064 
gadolinium (III) 
nitrate  0.050 water 
 0.061 
praseodymium 
(III) nitrate  0.050 water 
 0.022 
erbium (III) 
chloride  0.050 water 
 0.021 
europium (III) 
chloride  0.020 water 
 0.024 
lanthanum (II) 
nitrate  0.020 water 
 0.051 
yttrium (III) 
carbonate  0.020 water 
 0.035 
ytterbium 
trifluorometha
nesulfonate  0.050 water 
 0.070 
terbium 
carbonate 0.020 water 
 0.040 
cobalt (II) 
sulphate 
heptahydrate 0.050 water 
 0.062 
neodymium (III) 
nitrate  0.050 water 
 0.017 
potassium 
bromide 0.050 water 
 0.019 
potassium 
carbonate 0.050 water 
 0.011 
potassium 
chloride 0.050 water 
 0.014 
potassium 
nitrate 0.050 water 
 0.026 
potassium 
hexaflurophosp
hate 0.050 water 
 0.015 
sodium 
carbonate 0.050 water 
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 0.017 
sodium 
hydrogen 
sulphate 0.050 water 
 0.012 
sodium 
hydrogen 
carbonate 0.050 water 
 0.012 sodium nitrate 0.050 water 
 0.030 
strontium 
nitrate 0.050 water 
 0.019 zinc chloride 0.050 water 
 0.026 zinc acetate 0.050 water 
 0.027 zinc nitrate  0.050 water 
 0.023 calcium nitrate 0.050 water 
 0.028 
strontium 
carbonate 0.050 water 
 0.046 
caesium 
carbonate 0.050 water 
 0.061 cerium nitrate 0.050 water 
 0.055 
chromium (III) 
sulfate 0.050 water 
 0.053 
aluminium 
nitrate  0.050 water 
 0.022 
vanadium 
chloride 0.050 water 
 0.026 vanadium oxide 0.050 water 
Et(OVP)2 0.041 
cadmium 
acetate  0.050 water 
 0.032 
cadmium 
chloride 0.050 water 
 0.037 
cadmium 
sulphate 0.050 water 
 0.034 
caesium 
acetate 0.050 acetone 
 0.057 
caesium 
carbonate 0.050 water 
 0.030 
caesium 
chloride 0.050 water 
 0.030 
caesium 
hydroxide  0.050 water 
 0.023 
cobalt (II) 
chloride 0.050 water 
 0.032 
cobalt (II) 
nitrate  0.050 acetone 
 0.032 
copper (II) 
acetate 0.050 water 
 0.039 
copper (II) 
bromide 0.050 water 
 0.024 
copper (II) 
chloride 0.050 acetone 
 0.020 
calcium 
chloride 0.050 water 
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 0.042 
copper (II) 
tetrafluorobora
te 0.050 acetone 
 0.030 
sodium 
hexafluorophos
phate 0.050 acetone 
 0.029 ferric chloride 0.050 acetone 
 0.038 
Iiron (II) 
bromide 0.050 acetone 
 0.058 lead (II) nitrate 0.050 water 
 0.015 
lithium 
bromide 0.050 acetone 
 0.012 lithium nitrate 0.050 acetone 
 0.026 
magnesium 
nitrate  0.050 water 
 0.030 
manganese (II) 
acetate 0.050 water 
 0.044 
nickel (II) 
acetate  0.050 water 
 0.023 
nickel (II) 
chloride  0.050 water 
 0.051 
nickel (II) 
nitrate  0.050 acetone 
 0.094 
yttrium 
trifluorometha
nesulfonate  0.050 acetone 
 0.019 
sodium 
tetrafluorobora
te 0.050 acetone 
 0.061 
lanthanum (II) 
nitrate  0.050 water 
 0.030 
manganese 
sulfate  0.050 water 
 0.062 
lanthanum 
chloride  0.050 water 
 0.077 terbium nitrate 0.050 water 
 0.070 
chromium (III) 
nitrate  0.050 water 
 0.010 
sodium 
chloride 0.050 water 
 0.066 
terbium (III) 
chloride  0.050 water 
 0.065 
gadolinium (III) 
chloride  0.050 water 
 0.079 
gadolinium (III) 
nitrate  0.050 water 
 0.077 
praseodymium 
(III) nitrate  0.050 acetone 
 0.027 
erbium (III) 
chloride  0.020 water 
 0.026 
europium (III) 
chloride  0.020 water 
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 0.030 
lanthanum (II) 
nitrate  0.020 water 
 0.063 
yttrium (III) 
carbonate  0.050 water 
 0.044 
ytterbium 
trifluorometha
nesulfonate  0.020 water 
 0.088 
terbium 
carbonate 0.050 water 
 0.049 
cobalt (II) 
sulphate 
heptahydrate 0.050 water 
 0.077 
neodymium (III) 
nitrate  0.050 water 
 0.021 
potassium 
bromide 0.050 water 
 0.024 
potassium 
carbonate 0.050 water 
 0.013 
potassium 
chloride 0.050 water 
 0.018 
potassium 
nitrate 0.050 water 
 0.032 
potassium 
hexaflurophosp
hate 0.050 acetone 
 0.019 
sodium 
carbonate 0.050 water 
 0.021 
sodium 
hydrogen 
sulphate 0.050 water 
 0.015 
sodium 
hydrogen 
carbonate 0.050 water 
 0.015 sodium nitrate 0.050 water 
 0.037 
strontium 
nitrate 0.050 water 
 0.024 zinc chloride 0.050 water 
 0.032 zinc acetate 0.050 water 
 0.033 zinc nitrate  0.050 water 
 0.029 calcium nitrate  0.050 water 
 0.035 
strontium 
carbonate 0.050 water 
 0.057 
caesium 
carbonate 0.050 water 
 0.076 cerium nitrate  0.050 water 
 0.069 
chromium (III) 
sulfate 0.050 water 
 0.066 
aluminium 
nitrate  0.050 water 
 0.050 
vanadium 
chloride 0.028 water 
 0.050 vanadium oxide 0.032 water 
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Pr(OVP)2 0.039 
cadmium 
acetate  0.050 water 
 0.031 
cadmium 
chloride 0.050 water 
 0.035 
cadmium 
sulphate 0.050 water 
 0.032 
caesium 
acetate 0.050 acetone 
 0.055 
caesium 
carbonate 0.050 water 
 0.028 
caesium 
chloride 0.050 water 
 0.028 
caesium 
hydroxide  0.050 water 
 0.022 
cobalt (II) 
chloride 0.050 water 
 0.031 
cobalt (II) 
nitrate  0.050 acetone 
 0.030 
copper (II) 
acetate 0.050 water 
 0.037 
copper (II) 
bromide 0.050 water 
 0.023 
copper (II) 
chloride 0.050 acetone 
 0.019 
calcium 
chloride 0.050 water 
 0.040 
copper (II) 
tetrafluorobora
te 0.050 acetone 
 0.028 
sodium 
hexafluorophos
phate 0.050 acetone 
 0.027 ferric chloride 0.050 acetone 
 0.036 
Iiron (II) 
bromide 0.050 acetone 
 0.056 lead (II) nitrate 0.050 water 
 0.015 
lithium 
bromide 0.050 acetone 
 0.012 lithium nitrate 0.050 acetone 
 0.025 
magnesium 
nitrate  0.050 water 
 0.029 
manganese (II) 
acetate 0.050 water 
 0.042 
nickel (II) 
acetate  0.050 water 
 0.022 
nickel (II) 
chloride  0.050 water 
 0.049 
nickel (II) 
nitrate  0.050 acetone 
 0.090 
yttrium 
trifluorometha
nesulfonate  0.050 acetone 
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 0.018 
sodium 
tetrafluorobora
te 0.050 acetone 
 0.059 
lanthanum (II) 
nitrate  0.050 water 
 0.028 
manganese 
sulfate  0.050 water 
 0.059 
lanthanum 
chloride  0.050 water 
 0.073 terbium nitrate 0.050 water 
 0.067 
chromium (III) 
nitrate  0.050 water 
 0.010 
sodium 
chloride 0.050 water 
 0.063 
terbium (III) 
chloride  0.050 water 
 0.062 
gadolinium (III) 
chloride  0.050 water 
 0.076 
gadolinium (III) 
nitrate  0.050 water 
 0.073 
praseodymium 
(III) nitrate  0.050 acetone 
 0.026 
erbium (III) 
chloride  0.020 water 
 0.025 
europium (III) 
chloride  0.020 water 
 0.029 
lanthanum (II) 
nitrate  0.020 water 
 0.060 
yttrium (III) 
carbonate  0.050 water 
 0.042 
ytterbium 
trifluorometha
nesulfonate  0.020 water 
 0.084 
terbium 
carbonate 0.050 water 
 0.047 
cobalt (II) 
sulphate 
heptahydrate 0.050 water 
 0.073 
neodymium (III) 
nitrate  0.050 water 
 0.020 
potassium 
bromide 0.050 water 
 0.023 
potassium 
carbonate 0.050 water 
 0.013 
potassium 
chloride 0.050 water 
 0.017 
potassium 
nitrate 0.050 water 
 0.031 
potassium 
hexaflurophosp
hate 0.050 acetone 
 0.018 
sodium 
carbonate 0.050 water 
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 0.020 
sodium 
hydrogen 
sulphate 0.050 water 
 0.014 
sodium 
hydrogen 
carbonate 0.050 water 
 0.014 sodium nitrate 0.050 water 
 0.036 
strontium 
nitrate 0.050 water 
 0.023 zinc chloride 0.050 water 
 0.031 zinc acetate 0.050 water 
 0.032 zinc nitrate  0.050 water 
 0.028 calcium nitrate  0.050 water 
 0.034 
strontium 
carbonate 0.050 water 
 0.055 
caesium 
carbonate 0.050 water 
 0.073 cerium nitrate  0.050 water 
 0.066 
chromium (III) 
sulfate 0.050 water 
 0.063 
aluminium 
nitrate  0.050 water 
 0.050 
vanadium 
chloride 0.026 water 
  0.050 vanadium oxide 0.031 water 
Table 3.4 – Metal crystallisation values and solvents. 
3.3.4 Other cocrystals 
3.3.4.1 The GRAS list 
Crystallisation experiments were performed in 2 cm3 glass vials with plastic screw lids. Both 
components were weighed into the vial and the vial was filled with 1.5 cm3 of the appropriate 
solvent. The sample was heated and sonicated until everything had dissolved. Crystallisations 
containing water were left open whilst other solvents were left with the lid resting on top of 
the vial. The samples were checked every couple of weeks until either crystals formed, non-
crystalline solids formed or a thick oil which did not change over the course of a few months 
was formed. The crystallisation containing the GRAS list compounds can be found in Table 
3.5. 
Model 
compound 
Model 
compound 
weight / g GRAS chemical 
GRAS chemical 
weight / g Solvent 
bisVCap 0.05 oxalic acid 0.023 water 
 0.05 nicotinamide 0.022 water 
 0.05 (+) tartaric acid 0.027 water 
 0.05 citric acid 0.035 water 
 0.05 glutamic acid 0.026 water 
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 0.05 
4-aminobenzoic 
acid 0.025 water 
 0.05 caffeine 0.035 water 
 0.05 citric acid 0.035 water 
 0.05 fumaric acid 0.021 water 
 0.05 malonic acid 0.019 water 
 0.05 succinic acid  0.021 water 
 0.05 nicotinic acid 0.022 water 
H2bisVCap 0.05 oxalic acid 0.023 water 
 0.05 nicotinamide 0.022 water 
 0.05 (+) tartaric acid 0.027 water 
 0.05 citric acid 0.034 water 
 0.05 glutamic acid 0.026 water 
 0.05 
4-aminobenzoic 
acid 0.024 water 
 0.05 caffeine 0.035 water 
 0.05 citric acid 0.035 water 
 0.05 fumaric acid 0.021 water 
 0.05 malonic acid 0.019 water 
 0.05 succinic acid  0.021 water 
 0.05 nicotinic acid 0.022 water 
bisVP 0.05 oxalic acid 0.028 water 
 0.05 nicotinamide 0.027 water 
 0.05 (+) tartaric acid 0.034 water 
 0.05 citric acid 0.043 water 
 0.05 glutamic acid 0.033 water 
 0.05 
4-aminobenzoic 
acid 0.031 water 
 0.05 caffeine 0.028 water 
 0.05 citric acid 0.028 water 
 0.05 fumaric acid 0.017 water 
 0.05 malonic acid 0.015 water 
 0.05 succinic acid  0.017 water 
 0.05 nicotinic acid 0.018 water 
H2bisVP 0.05 oxalic acid 0.028 water 
 0.05 nicotinamide 0.027 water 
 0.05 (+) tartaric acid 0.033 water 
 0.05 citric acid 0.043 water 
 0.05 glutamic acid 0.033 water 
 0.05 
4-aminobenzoic 
acid 0.031 water 
 0.05 caffeine 0.028 water 
 0.05 citric acid 0.028 water 
 0.05 fumaric acid 0.017 water 
 0.05 malonic acid 0.015 water 
 0.05 succinic acid  0.017 water 
  0.05 nicotinic acid 0.018 water 
Table 3.5 – GRAS list crystallisation values and solvents. 
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3.3.4.2 Hydrogen bond donors 
Crystallisation experiments were performed in 2 cm3 glass vials with plastic screw lids. Both 
components were weighed into the vial and the vial was filled with 1.5 cm3 of the appropriate 
solvent. The sample was heated and sonicated until everything had dissolved. Crystallisations 
containing water were left open whilst other solvents were left with the lid resting on top of 
the vial. The samples were checked every couple of weeks until either crystals formed, non-
crystalline solids formed or a thick oil which did not change over the course of a few months 
was formed. The crystallisation containing the hydrogen bond donating compounds can be 
found in Table 3.6. 
Model 
compound 
Model 
compound 
weight / g 
Hydrogen bond 
donor 
Hydrogen bond 
donor weight / 
g Solvent 
bisVCap 0.040 boric acid 0.009 water 
 0.040 boric acid 0.018 water 
 0.040 boric acid 0.009 ethanol 
 0.040 boric acid 0.018 ethanol 
 0.040 boric acid 0.009 methanol 
 0.040 boric acid 0.018 methanol 
 0.050 borax 0.064 water 
 0.040 
tetrahydroxy 
diboron 0.008 water 
 0.040 
benzenedi 
boronic acid 0.019 water 
 0.040 
2-chloro 
pyradine 
boronic acid 0.023 water 
 0.040 
4-formylphenyl 
boronic acid 0.022 water 
 0.040 
2-fluoro 
pyradine 0.020 water 
 0.040 
4-pyradinyl 
phenyl boronic 
acid 0.030 water 
 0.040 
3-pyridyl 
boronic acid 0.018 water 
 0.040 
4-pyridyl 
boronic acid 0.018 water 
 0.040 
3-furyl boronic 
acid 0.016 water 
 0.040 
3-thiophenyl 
boronic acid 0.018 water 
 0.020 tannic acid 0.122 water 
 0.050 telluric acid 0.041 water 
 0.050 
metformin 
tetrafluoro 
borate 0.039 water 
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 0.050 
guanadinium 
tetrafluoro 
borate 0.026 water 
H2bisVCap 0.044 boric acid 0.010 water 
 0.043 boric acid 0.019 water 
 0.039 boric acid 0.009 ethanol 
 0.046 boric acid 0.020 ethanol 
 0.052 boric acid 0.012 methanol 
 0.054 boric acid 0.024 methanol 
 0.046 borax 0.070 water 
 0.045 
tetrahydroxy 
diboron 0.009 water 
 0.045 
benzene 
diboronic acid 0.021 water 
 0.032 
2-chloro 
pyradine 
boronic acid 0.018 water 
 0.040 
4-formylphenyl 
boronic acid 0.021 water 
 0.037 
2-fluoro 
pyradine 0.019 water 
 0.030 
4-pyradinyl 
phenyl boronic 
acid 0.023 water 
 0.043 
3-pyridyl 
boronic acid 0.019 water 
 0.042 
4-pyridyl 
boronic acid 0.020 water 
 0.044 
3-furyl boronic 
acid 0.018 water 
 0.042 
3-thiophenyl 
boronic acid 0.019 water 
 0.020 tannic acid 0.121 water 
 0.050 telluric acid 0.041 water 
 0.050 
metformin 
tetrafluoro 
borate 0.039 water 
 0.050 
guanadinium 
tetrafluoro 
borate 0.026 water 
bisVP 0.058 boric acid 0.016 water 
 0.092 boric acid 0.051 water 
 0.084 boric acid 0.023 ethanol 
 0.084 boric acid 0.047 ethanol 
 0.084 boric acid 0.023 methanol 
 0.115 boric acid 0.064 methanol 
 0.040 borax 0.055 water 
 0.041 
tetrahydroxy 
diboron 0.029 water 
 0.053 
1,4-phenyl 
diboronic acid 0.013 water 
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 0.055 
2-chloro 
pyradine 
boronic acid 0.033 water 
 0.035 
4-formylphenyl 
boronic acid 0.024 water 
 0.038 
2-fluoro 
pyradine 0.024 water 
 0.042 
4-pyradinyl 
phenyl boronic 
acid 0.040 water 
 0.042 
3-pyridyl 
boronic acid 0.023 water 
 0.050 
4-pyridyl 
boronic acid 0.023 water 
 0.041 
3-furyl boronic 
acid 0.025 water 
 0.041 
3-thiophenyl 
boronic acid 0.024 water 
 0.020 tannic acid 0.153 water 
 0.050 telluric acid 0.052 water 
 0.050 
metformin 
tetrafluoro 
borate 0.049 water 
 0.050 
guanadinium 
tetrafluoro 
borate 0.033 water 
H2bisVP 0.110 boric acid 0.030 water 
 0.061 boric acid 0.034 water 
 0.120 boric acid 0.033 ethanol 
 0.123 boric acid 0.068 ethanol 
 0.079 boric acid 0.022 methanol 
 0.110 boric acid 0.061 methanol 
 0.046 borax 0.07 water 
 0.045 
tetrahydroxy 
diboron 0.009 water 
 0.045 
1,4-phenyl 
diboronic acid 0.0212 water 
 0.032 
2-chloro 
pyradine 
boronic acid 0.018 water 
 0.04 
4-formylphenyl 
boronic acid 0.021 water 
 0.037 
2-fluoro 
pyradine 0.019 water 
 0.03 
4-pyradinyl 
phenyl boronic 
acid 0.023 water 
 0.043 
3-pyridyl 
boronic acid 0.019 water 
 0.042 
4-pyridyl 
boronic acid 0.02 water 
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 0.044 
3-furyl boronic 
acid 0.0176 water 
 0.042 
3-thiophenyl 
boronic acid 0.019 water 
 0.020 tannic acid 0.153 water 
 0.050 telluric acid 0.052 water 
 0.050 
metformin 
tetrafluoro 
borate 0.049 water 
 0.050 
guanadinium 
tetrafluoro 
borate 0.033 water 
HepVCap 0.046 boric acid 0.012 water 
 0.048 boric acid 0.012 water 
 0.045 boric acid 0.012 ethanol 
 0.040 boric acid 0.010 ethanol 
 0.039 boric acid 0.010 methanol 
 0.041 boric acid 0.011 methanol 
 0.043 borax 0.059 water 
 0.052 
tetrahydroxydi
boron 0.012 water 
 0.051 
1,4-phenyl 
diboronic acid 0.028 water 
 0.036 
2-chloro 
pyradine 
boronic acid 0.024 water 
 0.050 
4-formylphenyl 
boronic acid 0.031 water 
 0.049 
2-fluoro 
pyradine 0.029 water 
 0.044 
4-pyradinyl 
phenyl boronic 
acid 0.031 water 
 0.042 
3-pyridyl 
boronic acid 0.022 water 
 0.041 
4-pyridyl 
boronic acid 0.021 water 
 0.044 
3-furyl boronic 
acid 0.021 water 
 0.035 
3-thiophenyl 
boronic acid 0.019 water 
 0.020 tannic acid 0.142 water 
 0.050 telluric acid 0.048 water 
 0.050 
metformin 
tetrafluoro 
borate 0.045 water 
 0.050 
guanadinium 
tetrafluoro 
borate 0.031 water 
bisHEP 0.046 borax 0.07 water 
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 0.045 
tetrahydroxydi
boron 0.009 water 
 0.045 
1,4-phenyl 
diboronic acid 0.0212 water 
 0.032 
2-chloro 
pyradine 
boronic acid 0.018 water 
 0.04 
4-formylphenyl 
boronic acid 0.021 water 
 0.037 
2-fluoro 
pyradine 0.019 water 
 0.03 
4-pyradinyl 
phenyl boronic 
acid 0.023 water 
 0.043 
3-pyridyl 
boronic acid 0.019 water 
 0.042 
4-pyridyl 
boronic acid 0.02 water 
 0.044 
3-furyl boronic 
acid 0.0176 water 
 0.042 
3-thiophenyl 
boronic acid 0.019 water 
 0.020 tannic acid 0.142 water 
 0.050 telluric acid 0.048 water 
 0.050 
metformin 
tetrafluoro 
borate 0.045 water 
 0.050 
guanadinium 
tetrafluoro 
borate 0.031 water 
MEP 0.022 boric acid 0.050 water 
 0.031 
tetrahydroxydi
boron 0.050 water 
 0.058 
1,4-phenyl 
diboronic acid 0.050 water 
 0.080 telluric acid 0.050 water 
 0.086 
metformin 
tetrafluoro 
borate 0.050 water 
  0.051 
guanadinium 
tetrafluoro 
borate 0.050 water 
Table 3.6 – Hydrogen bond crystallisation values and solvents. 
3.3.4.3 Analogous compounds 
Crystallisation experiments were performed in 2 cm3 glass vials with plastic screw lids. Both 
components were weighed into the vial and the vial was filled with 1.5 cm3 of the appropriate 
solvent. The sample was heated and sonicated until everything had dissolved. Crystallisations 
containing water were left open whilst other solvents were left with the lid resting on top of 
the vial. The samples were checked every couple of weeks until either crystals formed, non-
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crystalline solids formed or a thick oil which did not change over the course of a few months 
was formed. The crystallisation containing the analogous compounds can be found in Table 
3.7. 
Analogous 
compound 
Analogous 
compound 
weight / g 
Second 
component 
Second 
component 
weight / g Solvent 
2,7-
dioxathiephene
-1-oxide 0.017 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.012 pDITFB 0.050 acetone/DCM 
 0.012 oDITFB 0.050 acetone/DCM 
 0.015 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.019 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 1.310 boric acid 0.023 acetone/water 
 1.310 
tetrahydroxydi
boron 0.033 acetone/water 
 1.310 
1,4-phenyl 
diboronic acid 0.061 acetone/water 
 0.025 telluric acid 0.042 acetone/water 
 0.025 
guanadinium 
tetrafluoro 
borate 0.027 acetone/water 
 0.025 
metformin 
tetrafluoro 
borate 0.045 acetone/water 
caprolactone 0.019 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.014 pDITFB 0.050 acetone/DCM 
 0.014 oDITFB 0.050 acetone/DCM 
 0.017 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.022 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 boric acid 0.027 water 
 0.050 
tetrahydroxy 
diboron 0.039 water 
 0.050 
1,4-phenyl 
diboronic acid 0.073 water 
 0.050 telluric acid 0.101 water 
 0.025 
guanadinium 
tetrafluoro 
borate 0.032 water 
 0.025 
metformin 
tetrafluorobora
te 0.054 water 
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dihydrothiophe
n-3-one 0.017 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.012 pDITFB 0.050 acetone/DCM 
 0.012 oDITFB 0.050 acetone/DCM 
 0.015 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.019 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 boric acid 0.036 water 
 0.050 
tetrahydroxy 
diboron 0.052 water 
 0.050 
1,4-phenyl 
diboronic acid 0.097 water 
 0.050 telluric acid 0.134 water 
 0.025 
guanadinium 
tetrafluoro 
borate 0.042 water 
 0.025 
metformin 
tetrafluorobora
te 0.071 water 
dihydrofuran-
3(2H)-one 0.017 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.013 pDITFB 0.050 acetone/DCM 
 0.013 oDITFB 0.050 acetone/DCM 
 0.015 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.019 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 boric acid 0.036 water 
 0.050 
tetrahydroxydi
boron 0.052 water 
 0.050 
1,4-phenyldi 
boronic acid 0.097 water 
 0.050 telluric acid 0.113 water 
 0.025 
guanadinium 
tetrafluoro 
borate 0.036 water 
 0.025 
metformin 
tetrafluoro 
borate 0.060 water 
2(5H)-
thiophenone  0.017 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.012 pDITFB 0.050 acetone/DCM 
 0.012 oDITFB 0.050 acetone/DCM 
 0.015 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.019 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 boric acid 0.031 water 
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 0.050 
tetrahydroxy 
diboron 0.045 water 
 0.050 
1,4-phenyl 
diboronic acid 0.083 water 
 0.050 telluric acid 0.115 water 
 0.025 
guanadinium 
tetrafluoro 
borate 0.037 water 
 0.025 
metformin 
tetrafluoro 
borate 0.061 water 
6-
hydroxybenzo 
[d][1,3]oxathiol
-2-one 0.029 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.021 pDITFB 0.050 acetone/DCM 
 0.021 oDITFB 0.050 acetone/DCM 
 0.025 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.032 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 boric acid 0.018 water 
 0.050 
tetrahydroxy 
diboron 0.027 water 
 0.050 
1,4-phenyl 
diboronic acid 0.049 water 
 0.050 telluric acid 0.068 water 
 0.025 
guanadinium 
tetrafluoro 
borate 0.022 water 
 0.025 
metformin 
tetrafluoro 
borate 0.036 water 
3-methyl-
2(3H)-benzo 
thiazolone 0.028 
pentafluoro 
iodobenzene 0.050 acetone/DCM 
 0.021 pDITFB 0.050 acetone/DCM 
 0.021 oDITFB 0.050 acetone/DCM 
 0.025 
1,4-
diiodobenzene 0.050 acetone/DCM 
 0.031 
3-chloro-(2-
iodoethynyl) 
benzene 0.050 acetone/DCM 
 0.050 boric acid 0.019 water 
 0.050 
tetrahydroxy 
diboron 0.027 water 
 0.050 
1,4-phenyl 
diboronic acid 0.050 water 
 0.050 telluric acid 0.070 water 
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 0.025 
guanadinium 
tetrafluoro 
borate 0.022 water 
  0.025 
metformin 
tetrafluoro 
borate 0.037 water 
Table 3.7 – Analogous compound crystallisation values and solvents. 
3.3.4.4 Hydrogen peroxide 
Hydrogen peroxide was mixed with the dimers in a 1:1 and 1:2 H2O2 to dimer ratios. The 
minimum amount of water to dissolve or disperse the dimer was added to the mixture. 
Samples were left to slow evaporate or cool in the fridge or freezer. Samples in the freezer 
had 0.2 cm3 of ethanol added to prevent freezing of the water. All combinations are shown 
in Table 3.8. 
Model compound 
Model compound / 
g 30% H2O2 / cm3 Crystallisation type 
bisVCap 0.092 0.037 cooling 5 °C 
 
0.088 0.072 cooling 5 °C 
bisVP 0.102 0.052 cooling 5 °C 
 
0.098 0.099 cooling 5 °C 
H2bisVCap 0.073 0.030 cooling 5 °C 
 
0.082 0.066 cooling 5 °C 
Table 3.8 - Hydrogen peroxide/model compound crystallisations. 
3.3.5 Differential scanning calorimetry 
Differential scanning calorimetry scans were recorded on a TA Q2000. The heat/cool/heat 
cycles were performed using standard aluminium pans containing 3 – 12 mg of sample. 
Standard mode was used. The heat/cool/heat cycles began with a heating cycle at a rate of 
10 °C min-1, then cooling cycle at 50 °C min-1 and finally a second heating cycle at 10 °C min-
1. The quasi-isothermal experiments were performed using t-zero aluminium pans with 
hermetic lids containing 6 – 25 mg of sample. A sapphire was run before each sample to 
allow calibration. 
Sapphire experiments were started at 6.85 °C with a ± 1.00 °C modulation every 120 sec. The 
temperature was held isothermal for 5 min before being raised by 20.00 °C increments to a 
value of 326.85 °C. 
Sample experiments were performed with a ± 1.00 °C modulation every 60 sec. Samples 
were held isothermally for 10 min at each temperature before being raised by 5.00 °C. For 
amorphous material runs, the sample was first heated beyond the melting point and cooled 
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to form the amorphous material. Heating was at a rate of 10 °C min-1 with the sample held 
at the higher temperature for 5 min and cooling at a rate of 10 °C min-1 to the start 
temperature of the experiment. The samples were heated to 150 °C and 120 °C for 
amorphous bisVCap and the coamorphous material respectively. The start and end 
temperatures of the samples can be found in Table 3.9. All experiments were carried out 
twice with fresh samples.  
Sample Start temp. / °C End temp. / °C 
bisVCap crystal -40 160 
bisVCap amorphous -35 160 
pDITFB -80 120 
cocrystal 40 145 
coamorphous -15 85 
Table 3.9 – Start and end temperature for the quasi-isothermal DSC experiments. 
3.3.6 IR Spectroscopy 
Experiments were performed on a Perkin Elmer FTIR spectrum 100 with an attenuated total 
reflectance (ATR) attachment. Data were recorded at a resolution of 2 cm-1 for 16 runs over 
the range 4000 – 600 cm-1. Samples were prepared by grinding together a 1:1 molar ratio of 
the two components using a mortar and pestle for one minute before placing on the ATR 
crystal, applying pressure using the side arm and running the FTIR spectrum. The single 
components were ran for comparison by placing the compound on the ATR crystal applying 
pressure using the side arm and running the FTIR spectrum. Spectral analysis was performed 
using SpekWin32.41 The combinations of chemicals tried can be found in Table 3.10. 
Model compound Second component 
bisVCap aluminium nitrate 
 guanadinium tetrafluoroborate 
 metformin tetrafluoroborate 
 telluric acid 
 nicotinamide 
 tartaric acid 
 SC4 
H2bisVCap aluminium nitrate 
 telluric acid 
 oxalic acid 
 α-cyclodextrin 
 β-cyclodextrin 
 γ-cyclodextrin 
HEPVCap aluminium nitrate 
 guanadinium tetrafluoroborate 
 metformin tetrafluoroborate 
 telluric acid 
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 sodium tetraphenylborate 
 sodium hexafluorophosphate 
 zinc chloride 
 tetrahydroxyboron 
MEP pDITFB 
 oDITFB 
 boric acid 
 calcium nitrate 
 sodium chloride 
 telluric acid 
bisHEP aluminium nitrate 
 guanadinium tetrafluoroborate 
 metformin tetrafluoroborate 
  telluric acid 
Table 3.10 – Combinations of chemicals for grinding and IR analysis. 
3.3.7 Crystallographic data 
Powder x-ray diffraction was performed using a Bruker AXS D8 Advance diffractometer, with 
a Lynxeye Soller PSD Detector and CuKα radiation at a wavelength of 1.5406 Å by Mr Gary 
Oswald. 
Single crystal crystallographic analysis were performed on a Bruker Photon D8 Venture 
diffractometer (ImuS microsource, λMoKα, λ = 0.71073 Å) equipped with a Cryostream 
(Oxford Cryosystems) open-flow nitrogen cryostat, at 120 K. The data collection and 
refinement was kindly carried out by Dr Dmitry S. Yufit.  
Ethyl pyrrolidone/p-sulfonatocalix[4]arene crystal data: Empirical formula C28H20O16S4, 
3(C6H12NO), H3O, 4H2O, space group 𝑃1
−, a = 10.8924(7) Å, b = 16.0836(10) Å, c = 16.7429(11) 
Å, α = 116.186(2)°, β = 94.591(3)°, γ = 94.434(2)°, volume = 2603.2(3) Å3, Z = 2, F(000) = 
1240.0, MoKα (λ = 0.71073) 2θ range for data collection = 4.75 - 58°, data = 13824, 
parameters = 773, goodness-of-fit on F2 = 1.017, R1 = 0.0686, wR2 = 0.1049 
BisVCap/1,4-diiodotetrafluorobenzene crystal data: Empirical formula C16H26N2O2, C6F4I2, 
space group P21/n, a = 21.8250 Å, b = 5.2275(3) Å, c = 23.0386 Å, α = 90.00°, β = 114.280(7)°, 
γ = 90.0°, volume = 2396.0(2)) Å3, Z = 4, F(000) = 1320.0, MoKα (λ = 0.71073) 2θ range for 
data collection = 4.16 - 52°, data = 4716, parameters = 290, goodness-of-fit on F2 = 1.005, R1 
= 0.0895, wR2 = 0.1006 
HEP/ε-caprolactam/CdCl2 crystal data: Empirical formula 3(CdCl2), 2(C6H11NO), 2(C6H11NO2), 
space group Cc, a = 21.4093(9) Å, b = 35.3293(15) Å, c = 18.7193(8) Å, α = 90.00°, β = 
100.388(2)°, γ = 90.0°, volume = 13926.7(10) Å3, Z = 16, F(000) = 8160.0, MoKα (λ = 0.71073) 
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2θ range for data collection = 4.36 - 60°, data = 40562, parameters = 1562, goodness-of-fit 
on F2 = 1.009, R1 = 0.06049, wR2 = 0.0936 
CdCl2/ε-caprolactam/ethylene glycol crystal data: Empirical formula 2CdCl2, 2(C6H11NO), 
C2H6O2, space group P21/c, a = 13.6049(2) Å, b = 14.4911(2) Å, c = 11.9047(2) Å, α = 90.00°, 
β = 110.162(2)°, γ = 90.00°, volume = 2203.19(6) Å3, Z = 4, F(000) = 1288.0, MoKα (λ = 
0.71073) 2θ range for data collection = 4.252 – 60.000°, data = 6412, parameters = 244, 
goodness-of-fit on F2 = 1.033, R1 = 0.0301, wR2 = 0.0511 
1,1,3-tri-2-pyrrolidonylbutane/Y(CF3SO3)3 crystal data: Empirical formula C16H35N3O8, 
3(CF3SO3), H2O, space group P21/n, a = 11.1216(9) Å, b = 23.5054(19) Å, c = 14.4218(12) Å, α 
= 90.00°, β = 91.688(3)°, γ = 90.00°, volume = 3768.5(5) Å3, Z = 4, F(000) = 1928.0, MoKα (λ = 
0.71073) 2θ range for data collection = 4.472 - 58°, data = 10015, parameters = 484, 
goodness-of-fit on F2 = 1.047, R1 = 0.0832, wR2 = 0.1582 
2-Furanylboronic acid crystal data: Empirical formula C4H6BO3, space group P21/n, a = 
9.1128(9) Å, b = 6.9860(7) Å, c = 9.1402(9) Å, α = 90.00°, β = 116.623(4)°, γ = 90.00°, volume 
= 320.19(9) Å3, Z = 4, F(000) =236.0, MoKα (λ = 0.71073) 2θ range for data collection = 4.98 - 
56°, data = 1256, parameters = 82, goodness-of-fit on F2 = 1.061, R1 = 0.0444, wR2 = 0.1113 
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4 Gelling guar 
4.1 Introduction 
Guar is a plant cultivated in India, Pakistan and any other warm climate with a low chance of 
frost. The beans produced from guar are edible, though the gum extracted from them has 
many more uses. Guar gum is a straight chain galactomannan, whose suggested repeat unit 
is shown in Scheme 4.1. Guar gum is used to reduce ice crystal size in ice cream, improve the 
texture of cheese, thicken face creams and toothpastes, bind pills for drug delivery and 
improving the wear of paper to name but a small fraction of its uses.1 In the oil industry guar 
is used to thicken mud to help with drilling, as a surfactant to maintain slurries, as a lubricant 
for a variety of parts and to minimise water loss in certain geological formations.2–4 
 
  
Scheme 4.1 - Repeat unit of guar gum.5  
For many applications, especially as a thickening agent, the guar gum is crosslinked. In the 
presence of water crosslinked guar gum readily swells to form a hydrogel.6 Crosslinking is 
often performed by borate ions either by using boric acid at high pH or borax.  Hydroxyl 
groups in the guar gum react reversibly with the borate ions, losing water and forming a 
guar-borate complex. When this complex reacts with a second chain of guar a crosslink is 
formed, Scheme 4.2. As the steps to form the crosslinks are reversible this is a dynamically 
crosslinked system, so the gel can be broken and reformed easily. New methods of 
crosslinking are of industrial interest, either to reduce cost, vary the properties of the final 
product or change the rate of the crosslinking reaction. 
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Scheme 4.2 - Crosslinking of guar by borate ions. 
As boric acid is a well-established, effective crosslinker of guar,1,6–9 it stands to reason that 
analogous compounds, such as boronic acids and other comparable Lewis acids, like telluric 
acid, may also show similar behaviour. Cocrystals of established crosslinkers, such as boric 
acid cocrystals, may also be capable of crosslinking guar. Perrin10 reported a 2:1 boric 
acid:bisHEP cocrystal, crystal 6. The crystal structure of crystal 6 is shown in Figure 4.1. 
Crystal 6 is made up of two zigzagging, hydrogen bonded boric acid chains with bisHEP 
molecules hydrogen bonded between the two chains every alternating boric acid molecule. 
Crystal 6 should release boric acid in solution which will be able to crosslink guar. The 
hydrogen bonds which hold the cocrystal together could possibly slow the release and 
availability of the boric acid molecules, slowing the rate of gelation. A longer gelation time 
resulting in a similar strength of gel to the normal boric acid crosslinked guar would be of 
great interest in any situation where the gel is required to be shaped using a mould, as the 
solution could be poured before the gel has formed. 
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Figure 4.1 – Crystal packing of crystal 6. Hydrogen bonds are shown by red dashed lines.11 
4.2 Results and Discussion  
4.2.1 Preparing crystal 6 
Crystal 6 was successfully prepared by the grinding method outlined by Perrin10 and the 
structure was confirmed by comparing the experimental powder x-ray pattern of the ground 
sample to a powder x-ray pattern calculated from the single crystal x-ray structure using 
Mercury,12 Figure 4.2. The calculated and experimental patterns do not look the same by 
eye, but a computational fit performed by Prof John Evans, Durham University, revealed the 
experimental pattern to be what would be expected from the crystal with strong 
orientational preference. As crystal 6 forms flat, plate-like needles, Figure 4.3, orientational 
preference in the PXRD pattern is to be expected. As the PXRD pattern for the ground sample 
is what could be expected from the cocrystal and does not show any similarity to the PXRD 
patterns calculated from the crystal structures of boric acid,13,14 the powder was used in 
gelation experiments without further preparation. 
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Figure 4.2 – PXRD plot of the experimental data of crystal 6 made by grinding and the calculated from the 
crystal structure of crystal 6. 
 
Figure 4.3 – Crystals of crystal 6. 
4.2.2 1,4-phenylenediboronic acid/bisHEP cocrystal 
A 1:1 molar ratio of bisHEP and 1,4-phenylenediboronic acid was dissolved in water and the 
solvent was allowed to slowly evaporate over the course of four weeks to give diffraction 
quality crystals of a 1:1 1,4-phenylenediboronic acid:bisHEP cocrystal, crystal 7, with the 
formula C6H8B2O4·C12H20N2O3. The crystal packing of crystal 7 is shown in Figure 4.4.  
The 1,4-phenylenediboronic acid molecules form chains with the bisHEP molecules bridging 
between two chains by accepting hydrogen bonds from the boronic acid groups. In the 1,4-
phenylenediboronic acid chain the torsion between the benzene ring and the boronic acid 
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moiety is 28.35(16)° on the side hydrogen bonding to the bisHEP and 10.48(15)° on the side 
hydrogen bonding to the next 1,4-phenylenediboronic acid molecule. The hydrogen bonds 
between the 1,4-phenylenediboronic acid molecules have O···O distances of 2.810(2) Å and 
2.754(2) Å. In comparison, in pure 1,4-phenylenediboronic acid15 the hydrogen bond O···O 
distances between the 1,4-phenylenediboronic acid molecules are both the same at 2.761(3) 
Å and the torsions at both ends of the 1,4-phenylenediboronic acid molecule are much more 
similar to each other with values of 23.5° and 25.0°. The inclusion of bisHEP decreases the 
symmetry of the 1,4-phenylenediboronic acid molecules seen in the structure of pure 1,4-
phenylenediboronic acid resulting in one longer bond and a twisted 1,4-phenylenediboronic 
acid conformation.   
 
Figure 4.4 – Crystal packing of crystal 7 with hydrogen bonds shown by red dashed lines. 
The hydrogen bonds between the bisHEP and 1,4-phenylenediboronic acid molecules have 
O···O distances of 2.626(2) Å and 2.699(1) Å. These are slightly longer than the lengths of the 
hydrogen bonds between the carbonyl group of bisHEP and  boric acid in crystal 6 which have 
O···O bond lengths of 2.6583(13) Å and 2.6045(13) Å. As the difference in bond length is not 
large, it suggests the strength of the hydrogen bonds between bisHEP with 1,4-
phenylenediboronic acid and boric acid is similar. Crystal 6 and crystal 7 both have bisHEP 
bridging the chains formed be the boronic acids, though the conformation of the bisHEP 
molecules are distinctly different. In crystal 6 the bisHEP molecules are much more U-shaped 
in than the bisHEP molecules in crystal 7.  In crystal 7 the pyrrolidone rings are held close to 
parallel, with the carbonyl groups pointing away from each other, one forward and one back 
from the plane of the molecule shown in Figure 4.5a.  In crystal 6 the pyrrolidone rings lie 
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almost flat to one another within the plane of the molecule shown in Figure 4.5b, with the 
carbonyl groups pointing out to the left and right of the molecule.  
       
Figure 4.5 – Conformation of bisHEP in a) crystal 7 and b) crystal 6. 
The Hirschfeld surface fingerprint plots of bisHEP for both crystal 6 and crystal 7 can be found 
in Figure 4.6. Both plots exhibit a sharp peak in the lower right half of the plot. This is 
characteristic of hydrogen bond accepting behaviour from the carbonyl of the lactam which 
makes bisHEP a strong hydrogen bond acceptor. There are two main differences between 
the Hirshfeld surface fingerprint plots of crystal 6 and crystal 7. The first of which is the larger 
amount of diffuse blue area in the top right of the plot for crystal 7. This arises from more 
space around the molecule as crystal 7 is less densely packed around the bisHEP molecules 
than crystal 6. The second difference it that the plot of crystal 6 also has a small, but 
significant, peak in the top right, which is indicative of hydrogen bond donating behaviour. 
In crystal 6 the bisHEP molecule donates a single C-H···O hydrogen bond to the boric acid 
molecules of left hand side boric acid chain as illustrated in Figure 4.1. This hydrogen bond 
donating interaction is absent in crystal 7.  
 
Figure 4.6 – Hirshfeld surface fingerprint plots of bisHEP in a) crystal 7 and b) crystal 6.  
IR spectra of bisHEP and crystal 7 showed the carbonyl peak of bisHEP to shift from 1668 cm-
1 to 1647 cm-1 upon formation of the cocrystal. The significant decrease in wavenumber 
a) b) 
a) b) 
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arises from the formation of hydrogen bonds forming between the carbonyl group of bisHEP 
and 1,4-phenylenediboronic acid as can be seen in the crystal structure in Figure 4.4. 
DSC of crystal 7 shows small sharp endothermic peaks beginning at 55 °C, which are 
attributed to decomposition of the sample. The decomposition peaks get larger and more 
frequent until 150 °C which was the maximum temperature tested. The decomposition is 
probably due to the unstable nature of the lactam rings in bisHEP. 
Crystal 7 is a novel crystal structure with strong parallels to the previously reported crystal 
6. Though of a similar composition, containing bisHEP and a boronic acid, crystal 6 and crystal 
7 have different stoichiometry and conformation of the bisHEP molecules. The strong 
hydrogen bonds between bisHEP and 1,4-phenylenediboronic acid in crystal 7 may be able 
to delay the availability of 1,4-phenylenediboronic acid to react in solution, affording delayed 
onset reactions.  
4.2.3 ε-caprolactam/boric acid cocrystal 
Slow evaporation of a 1:1 mixture of tetrahydroxydiboron and bisVCap did not result in a 
tetrahydroxydiboron/bisVCap cocrystal, but instead both components underwent Lewis acid 
catalysed cleavage resulting in a ε-caprolactam/boric acid cocrystal, crystal 8, with the 
formula C6H11NO·B(OH)3. The crystal structure of crystal 8 is shown in Figure 4.7. The boric 
acid molecules form a zigzagging, hydrogen-bonded chain, with ε-caprolactam molecules 
hydrogen bonding to the outside. These chains lie parallel to each other forming layers. The 
chains in same layers have no short contact interactions with each other, with the closest 
C···C distance between the pendant ε-caprolactam groups being 4.274(2) Å. Between the 
layers there are short contact interactions between boric acid and ε-caprolactam with C···H 
distances of 3.595(1) Å and 3.519(1) Å. There are no ε-caprolactam to ε-caprolactam or boric 
acid to boric acid short contact interactions between the layers.  
The boric acid to ε-caprolactam hydrogen bonds have a O···O length of 2.564(1) Å and a N···O 
length of 3.035(1) Å. The O-H···O of crystal 8 is particularly short with most similar ε-
caprolactam to hydroxyl group hydrogen bonds in the CSD having O···O lengths of 2.66 – 2.67 
Å.16,17 A sulfonamide benzoic acid/ε-caprolactam cocrystal reported by Bolla et al.18 exhibits 
a very comparable O···O length between the carbonyl of the ε-caprolactam molecule and the 
hydroxyl group of sulfonamide benzoic acid of length 2.556(10) Å. The boric acid chain in 
crystal 8 is held together by two hydrogen bonds, one donating, one accepting, between 
each pair of boric acid molecules. Both hydrogen bonds to the same boric acid molecule 
along have the same length, with different lengths of hydrogen bond to the different boric 
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acid molecules. The O···O length of the hydrogen bonds are 2.657(1) Å to one boric acid 
molecule and 2.707(1) to the other. When compared to the boric acid chain in crystal 6, 
crystal 8 has less variation in bond lengths in the boric acid chain, as crystal 6 has 4 different 
boric acid to boric acid hydrogen bond lengths, ranging from 2.683(1) to 2.750(12) Å. The 
crystal structure of pure boric acid19  also shows more variation in boric acid to boric acid 
hydrogen bond length, with the O···O hydrogen bond distances varying between 2.688(7) Å 
and 2.740(6) Å and no two being the same. In crystal 8 the boric acid molecules are more 
symmetrically bound to one another than in either pure boric acid or crystal 6.  
 
Figure 4.7 - Crystal packing of crystal 8 with hydrogen bonds shown in red. 
The Hirschfeld surface fingerprint plot of ε-caprolactam in crystal 8 can be seen in Figure 4.8. 
There is a strong hydrogen bond accepting peak in the bottom right of the diagram, relating 
to the carbonyl group accepting a hydrogen bond from boric acid. The top left of the graph 
shows a hydrogen bond donating peak, arising from the N-H of the ε-caprolactam donating 
a hydrogen bond to an oxygen atom of the boric acid. The small diffuse blue region between 
the two hydrogen bonding peaks is indicative of a cyclic hydrogen bonding moiety. In this 
case the cyclic hydrogen bonding between the boric acid molecule and the ε-caprolactam 
molecule, as can be seen in Figure 4.7 
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Figure 4.8– Hirschfeld surface analysis of ε-caprolactam in crystal 8. 
DSC of crystal 8 showed the crystal to decompose on heating, as the DSC plot showed many 
overlapping, endothermic peaks. Both boric acid and ε-caprolactam show the beginnings of 
decomposition on heating, so meaningful DSC of analysis is crystal 8 is not possible. IR 
spectroscopy shows the carbonyl peak of ε-caprolactam to shift from 1653 cm-1 to 1623 cm-
1 upon forming the cocrystal. The large shift in the IR carbonyl peak to a lower wavenumber 
is indicative of strong hydrogen bonding behaviour, as was observed in the crystal structure. 
It is preferable to be able to produce crystal 8 directly from its constituent parts, ε-
caprolactam and boric acid, so a larger amount of pure product can be formed and to verify 
reproducibility, as the cleavage of bisVCap and tetrahydroxydiboron may not be complete. 
To attempt direct acquisition of crystal 8, ε-caprolactam and boric acid were accurately 
weighed out in a 1:1 molar ratio and ground together using a ball mill until a homogenous 
powder was formed. This powder was analysed by PXRD, the results of which can be seen in 
Figure 4.9. A powder x-ray pattern of crystal 8 was calculated from the single crystal structure 
using Mercury12 and compared to the experimental PXRD pattern achieved from the ground 
structure. Allowing for a small shift in peaks due to the difference in the temperatures of the 
measurements, single crystal data was recorded at 120 K whilst PXRD was performed at room 
temperature, and changes in intensity due to preferred orientations in the powder the 
calculated and experimental powder patterns are consistent, confirming that grinding is an 
adequate method of forming crystal 8.  
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Figure 4.9– PXRD of crystal 8 calculated from the crystal structure and formed by grinding of the two 
components. 
4.2.4 Gelling guar 
4.2.4.1 Gel tests 
As boric acid is already well researched as a crosslinker of guar, it is used as the control 
experiment to which all others are compared. Bishop et al.7 found that a 10:2000:1 wt/wt/wt 
ratio of guar:water:boric acid with a small amount of NaOH to raise the pH above 9, to be an 
effective recipe to achieve a robust guar gel. For a gel made of 20 cm3 of water, 0.1 g of guar 
and 0.01 g of boric acid, 0.1 cm3 of 2 M NaOH raises the pH enough for gelling to occur. To 
allow direct comparison to the control experiment which uses boric acid as the crosslinker, 
all other potential crosslinking additives were added in 1:1 molar ratio of active 
component:boric acid. The active component for the cocrystals is the boronic acid 
component, other acids are simply added in a 1:1 molecular ratio compared to boric acid. 
Readily available diboronic acids, tetrahydroxydiboron and 1,4-phenylenediboronic acid, 
were tested for their ability to gel guar. Monoboronic acids were not tested as they would 
not be effective in gelling guar. As seen in Scheme 4.2, the boronic acid must react with two 
guar chains to form a crosslink and monoboronic acids only have one reactive group so are 
not capable of creating both sides of the crosslink. Telluric acid was also tested; whilst not a 
boronic acid, it is a Lewis acid of an analogous form to boric acid with a pKa1 of 7.7 compared 
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with boric acid which has a pKa1 of 9.3.20 The three cocrystals, crystals 6-8, were also tested 
for crosslinking ability.  
As expected, the control experiment using boric acid readily formed a gel when mixed with 
a guar/water mixture after 0.01 cm3 of 2 M NaOH was added. Tetrahydroxydiboron and 
telluric acid did not show any capacity for crosslinking. For both tetrahydroxydiboron and 
telluric acid a second experiment using 5 M NaOH, instead of the usual 2 M NaOH, was 
performed to ensure that the compound has been deprotonated. This was not successful 
with either the tetrahydroxydiboron or the telluric acid. Neither tetrahydroxydiboron nor 
telluric acid gelled guar under the conditions tested, so are not effective crosslinkers for guar 
and are not included in any further gelation experiments.  On the other hand, 1,4-
phenylenediboronic acid and crystals 6-8 all readily formed a gel upon the standard gelling 
conditions of guar, water and 0.01 cm3 of 2 M NaOH.  
4.2.4.2 Gelation time 
To test if use of a cocrystal instead of just the boronic acid affects the gelation time an 
inversion test was used. The inversion test is a common visual test for gel formation, if a 
material can support its own weight when the vial the sample is in is inverted, then a gel is 
said to have formed. To make a timed experiment of the inversion test the samples were 
inverted every 30 seconds. When the gel could support itself without collapse for 30 seconds 
it was taken to be fully formed. At first it seemed that the cocrystals 6 and 8 gave a delayed 
crosslinking, as it took the samples containing crystal 6 or crystal 8 longer to pass the 
inversion test than the samples containing pure boric acid.  Repeats of the experiment 
showed this observation not to be reproducible, with boric acid containing samples 
sometimes having a long onset time and cocrystals samples sometimes having a short onset 
time. The samples were prepared, without NaOH as this starts the gelation process, directly 
one after another in the same lab, so there is no notable difference in temperature and the 
mixing procedures, length of shaking and sonication, were kept as similar as possible. The 
only difference is how long the sample had been stood before the NaOH was added. 
Experiments varying how long after the water, crosslinker and guar had been mixed the 
NaOH was added were undertaken. For the first sample, NaOH was added as soon as the 
crosslinker and guar had all completely dissolved in the water. This point is taken to be 0 min. 
For the subsequent samples NaOH was added 10, 20, 30, 40, 50 and 60 min after the 
dissolution of guar and boric acid. The experiments were repeated for boric acid, 1,4-
phenylenediboronic acid  and crystals 6-8. For boric acid, crystal 6 and crystal 8, the 0 min 
addition of NaOH noticeably thickened the mixture but did not result in a gel capable of 
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passing the inversion test. The gelation times for the samples containing boric acid, crystal 6 
or crystal 8 decreased with the time waited before NaOH addition until 50 min, where the 
gelation time for all sample was approximately 2 min. The experiments were repeated twice 
and the averaged data of gelation time against time before NaOH was added for boric acid, 
crystal 6 and crystal 8 is shown in Figure 4.10.  
 
Figure 4.10 – Average gelation time over two experiments of samples containing boric acid, crystal 6 or 
crystal 8 with varying times before addition of NaOH. 
For samples containing 1,4-phenylenediboronic acid  or crystal 7 gelation occurred in under 
a minute regardless of time between mixing and NaOH addition. Samples which had been 
stood for an hour do gel noticeably faster than those at 0 min, as it is difficult to mix the 
sample thoroughly before gelation occurs, resulting in a gel surrounded by unreacted 
solution. Both 1,4-phenylenediboronic acid and crystal 8 behave the same within the scope 
of these experiments.  
The dependency of gelation on the time which NaOH is added is possibly due to 
entanglement of the guar chains in solution, this entanglement would add a further degree 
of physical crosslinking to the chemical crosslinks formed by the boric acid, strengthening 
the gel and shortening the time before the inversion test is passed. Further investigation into 
the time dependence of gelation is beyond the scope of this project. Within the error of the 
experiment there is no difference in gelation time between the cocrystals and boronic acids, 
suggesting that the supramolecular bonds which form the cocrystal are not persistent 
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enough in solution to significantly slow the gelation process. Any differences there may be 
are small and not within the scope of potential utilization in an industry setting for any 
delayed gelation applications. 
4.2.4.3 Gel strength 
Oscillatory stress sweep rheology was used to test the relative strength of the guar gels 
formed with boric acid, 1,4-phenylenediboronic acid  and crystals 6-8. Oscillatory stress 
sweeps were performed using a smooth 25 mm steel geometry and 60 mm smooth Peltier 
steel plate with a gap of 1000 µm. The frequency was fixed at 1 Hz and the stress sweep was 
performed from 0 – 1000 Pa. The samples for rheology were prepared by mixing water, guar 
and crosslinker an hour before adding NaOH to avoid any variations in the gel which may 
arise from the differences in gelation time caused by earlier addition of NaOH. As the samples 
are shaken to thoroughly mix in the NaOH, the gels often have air bubbles, which can lead 
to erratic rheology results. To help reduce errors due to bubbles, multiple samples of the 
same gel were run until reproducible results were produced.  
The plot of the oscillatory stress sweeps for boric acid, crystal 6 and crystal 8 can be found in 
Figure 4.11. All three samples start with a storage modulus between 20.9 and 22.6 log(Pa). 
When compared to the multiple runs of the same samples, this is within the expected 
variance and not a significant difference. The storage modulus for all three samples 
decreases and eventually crosses over with the loss modulus between 225 and 283 Pa. Again 
the difference between repeats of the same sample is greater than the difference between 
samples, so within error the crossing point is the same. The crossover of the storage and loss 
modulus shows a change from a gel with significant solid like character to a sol which behaves 
much more like a liquid. When enough stress is applied the bonds of the crosslinks readily 
break and reform due to the dynamic, non-covalent nature of the crosslinks formed by guar 
and the boronic acids, causing the gel to collapse. After the stress has been removed, the gel 
reforms. 
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Figure 4.11 – Oscillatory stress sweep plot of boric acid, crystal 6 and crystal 8. 
Crystal 7 and 1,4-phenylenediboronic acid also show almost identical behaviour. The 
oscillatory stress sweep plot, Figure 4.12, shows both gels to start at a storage modulus of 
27 log(Pa) and then decrease, crossing the loss modulus at approximately 565 Pa. As seen 
with the boric acid based crosslinkers, there is no difference between 1,4-
phenylenediboronic acid and its crystal 7 outside of experimental error.  
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Figure 4.12 – Oscillatory stress sweep plot of 1,4-phenylenediboronic acid and crystal 7.  
In conclusion the interactions between the components of the cocrystals that promote the 
formation of the cocrystals are not significant enough in solution to affect the boronic acids’ 
ability to gel guar, either in gelation time, or strength of gel. On the other hand 1,4-
phenylenediboronic acid does give stronger gels than boric acid which require more stress 
to go through the gel-sol transition. This could have potential applications where stronger 
guar gels are requires, though the greater expense and less favourable toxicity of 1,4-
phenylenediboronic acid would probably hamper the use of 1,4-phenylenediboronic acid in 
many situations where guar gel is used.  
4.3 Experimental 
4.3.1 Cocrystal synthesis 
Crystal 6 was made by grinding a 1:1 bisHEP:boric acid mixture in a mortar and pestle for one 
minute. Excess bisHEP was removed by pressing the mixture between dry filter papers until 
only an off white solid remained. The sample was characterised by PXRD.  
Crystal 7 was made by dissolving 0.021 g 1,4-phenylenediboronic and 0.045 g bisHEP 
together in water and allowing the water to evaporate at room temperature. Crystals of 
diffraction quality formed within three weeks and analysed by single crystal x-ray 
crystallography. A second sample was formed made by grinding a 1:1 bisHEP:1,4-
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phenylenediboronic acid in a mortar and pestle for one minute. The sample was analysed by 
IR spectroscopy.  
Crystal 8 was made by dissolving 0.008 g of tetrahydroxydiboron and 0.04 g of bisVCap 
together in water and allowing the water to evaporate at room temperature. Single crystals 
of diffraction quality were achieved within three weeks and analysed by single crystal x-ray 
crystallography. A second sample was formed by grinding a 1:1 ratio of ε-caprolactam:boric 
acid in a Retsch MM200 ball mill at 20 Hz for 30 min. The sample was characterised by PXRD.  
IR spectra were performed using a Perkin Elmer FTIR spectrum 100 with an attenuated total 
reflectance (ATR) attachment. Data were recorded at a resolution of 2 cm-1 for 16 runs over 
the range 4000 – 600 cm-1. 
Powder x-ray diffraction was performed using a Bruker AXS D8 Advance diffractometer, with 
a Lynxeye Soller PSD Detector and CuKα radiation at a wavelength of 1.5406 Å by Mr Gary 
Oswald. 
Single crystal crystallographic analyses were performed on a Bruker Photon D8 Venture 
diffractometer (ImuS microsource, λMoKα, λ = 0.71073 Å) equipped with a Cryostream 
(Oxford Cryosystems) open-flow nitrogen cryostat, at 120 K. The data collection and 
refinement was kindly carried out by Dr Dmitry S. Yufit.  
ε-caprolactam/boric acid crystal data: Empirical formula C6H11NO, B(OH)3, space group P21/n, 
a = 6.9008(3) Å, b = 18.7679(8) Å, c = 7.4385(3) Å, α = 90.00°, β = 111.3340(10)°, γ = 90.00°, 
volume = 897.37(7) Å3, Z = 4, F(000) = 376.0, MoKα (λ = 0.71073) 2θ range for data collection 
= 4.34 - 60°, data = 2628, parameters = 165, goodness-of-fit on F2 = 1.056, R1 = 0.0436, wR2 
= 0.0903 
BisHEP/1,4-phenylenediboronic crystal data: Empirical formula C6H8B2O4, C12H20N2O3, space 
group P1
−, a = 10.0731(4) Å, b = 10.2343(4) Å, c = 12.1312(5) Å, α = 112.5470(10)°, β = 
111.5550(10)°, γ = 90.5390(10)°, volume = 1038.42(7) Å3, Z = 2, F(000) = 432.0, MoKα (λ = 
0.71073) 2θ range for data collection = 4.04 – 60°, data = 6065, parameters = 325, goodness-
of-fit on F2 = 1.064, R1 = 0.0684, wR2 = 0.1682 
4.3.2 Gel experiments 
Gelling mixtures were prepared in a 10:2000:1 wt/wt/wt ratio. For the different acids, the 
acid was added in the same molar amount as boric acid. Cocrystals were added to result in 
the same number of moles of boronic acid. The compositions can be found in Table 4.1.  
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Guar and either boric acid, 1,4-phenylenediboronic acid, crystals 6-8, telluric acid or 
tetrahydroxydiboron were dissolved in water, compositions outlined in Table 4.1, by shaking 
for 30 seconds followed by 30 seconds of sonication after which 0.01 cm3 of 2 M NaOH was 
added then the mixture was vigorously shaken for a further 20 seconds. Samples were 
inverted to test for gel formation. 
Guar and either telluric acid or tetrahydroxydiboron were dissolved in water, compositions 
outlined in Table 4.1, by shaking for 30 seconds followed by 30 seconds of sonication after 
which 0.01 cm3 of 5 M NaOH was added then the mixture was vigorously shaken for a further 
20 seconds. Samples were inverted to test for gel formation. 
Crosslinker 
Crosslinker 
/ g 
Guar 
/ g 
Water 
/ cm3 
2 M NaOH 
/ cm3 
5 M NaOH 
/ cm3 
boric acid 0.0010 0.010 2.00 0.01 0 
crystal 7 0.0024 0.010 2.00 0.01 0 
1,4-phenylenediboronic acid 0.0027 0.010 2.00 0.01 0 
crystal 8 0.0065 0.010 2.00 0.01 0 
crystal 9 0.0045 0.010 2.00 0.01 0 
tetrahydroxydiboron  0.010 2.00 0.01 0 
telluric acid  0.010 2.00 0.01 0 
tetrahydroxydiboron  0.010 2.00 0 0.01 
telluric acid  0.010 2.00 0 0.01 
Table 4.1 - Composition of guar gelling experiments. 
Guar and either boric acid, 1,4-phenylenediboronic acid, crystals 6, 7 or 8 were dissolved in 
water, compositions outlined in Table 4.1, by shaking for 30 seconds followed by 30 seconds 
of sonication. 0.01 cm3 of 2 M NaOH was added 0, 10, 20, 30, 40, 50 or 60 minutes after the 
sonication and the sample was vigorously shaken for a further 20 seconds. The vials were 
inverted every thirty seconds after addition of NaOH until the sample could hold its own 
weight for at least 5 seconds or half an hour had passed with no gel forming.    
Samples for rheology were prepared by dissolving guar and either boric acid, 1,4-
phenylenediboronic acid, crystals 6, 7 or 8 in water, compositions outlined in Table 4.1, by 
shaking for 30 seconds followed by 30 seconds of sonication. After one hour 0.1 cm3 of NaOH 
was added and the sample was vigorously shaken for a further 20 seconds. Oscillatory stress 
sweep experiments were performed on a TA Discovery HR-2 hybrid rheometer equipped 
with a smooth 25 mm steel geometry and 60 mm smooth Peltier steel plate. 2 cm3 of gel was 
positioned on the steel plate below the geometry using a spatula. The geometry was lowered 
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to a distance 1000 µm from the plate. The frequency was set at 1 Hz and the stress sweep 
was performed from 0.1 - 1000 Pa at 25 °C. Data was recorded using TRIOS v4.1.0.31739. 
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5 Interactions of sour gas with KHIs 
5.1 Introduction 
Desirable natural gases, such as methane, are found mixed with gases such as hydrogen 
sulfide and carbon dioxide which are referred to as acid gases. After a certain threshold of 
H2S the gas is then classed as a sour gas. This threshold varies by company but the sales 
specification is often 4 ppm of H2S.1,2 Sour gas is often sweetened, in other words the acidic 
elements are removed, before being transported through pipes.3 The presence of acidic 
gases causes corrosion of the pipeline,4 as well as promoting the formation of hydrates.5  
H2S forms hydrates at the lowest partial pressure of all the components in sour gas, at least 
partially due to its size being correct to fit in the hydrate cavities.6 The favourability of H2S 
clathrate formation brings added danger to the system.  As well as the health hazards which 
are always associated with natural gas clathrates, such as flammability and pipe blockages, 
hydrates formed in a sour system are rich in H2S.6 This poses a significant health risk, as H2S 
high acute toxicity, even at low concentrations, so avoiding a significant concentration of H2S 
is necessary to ensure safe working conditions.7 
The presence of H2S changes the polarity of the system and increases the level of moisture 
in the gas.8 The more water there is in the system, the higher the likelihood of it crystallising 
and hydrates forming. There is plenty of evidence that hydrates are more likely to form in 
sour systems than sweet ones. H2S apparently makes the formation of hydrates more 
favourable, though no reason for this, except for favourable size, has been proposed, and it 
seemingly contradicts the theory that more polar molecules make less stable clathrate 
hydrates,9 as well as helping introduce water to form the hydrates. Though there has been 
no research into if there is any effect on the inhibitors. Insight into the interactions between 
sour gas and KHIs could lead to the development of more effect products for use in sour 
systems.   
There has long been a theory in the oil field industry that acid gas interacts with KHI 
effectively inhibiting the inhibitor.6 This theory is based on the observation that in sour 
systems more KHI is required to achieve the desired level of hydrate inhibition. Though often 
taken as fact, no data has been published proving this to be true, making it a topical and 
worthwhile avenue of study. 
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5.2 Results and discussion 
The goal of this chapter is to explore whether the presence of acid gases adversely affects 
KHIs’ ability to inhibit clathrate hydrate formation. For ease of analysis model compounds 6-
9 and compound 11 were studied as well as the KHI polymers 1, 3 and 5. Interactions 
between the model compounds and the acids gases were explored by attempted 
cocrystallisation with acid gases, NMR titrations and IR titrations. 
5.2.1 Crystallisations 
One possibility for the seeming inhibition of the KHIs in sour conditions is that the acid gases 
interact more strongly, or at least comparably, with the KHI than the water does creating 
competitive inhibition. If the interaction is stronger it may be possible to create cocrystals of 
the model compound with the acid gases. Cocrystals of gases have been reported before, 
the most prevalent of which probably being the clathrate hydrates which the KHIs are 
designed to inhibit.5,9,10 Unfortunately the methods to form lab synthesised clathrate 
hydrates require high pressure and thus specialised equipment,11–13 so looking to clathrate 
hydrates as an example of how to form new clathrate structures is not viable. Other clathrate 
structures can be formed in much less demanding conditions. For example hydroquinone 
exhibits clathrate structures with both CO2 and H2S which are formed by bubbling gas 
through a warm supersaturated solution of hydroquinone then allowing the solution to 
slowly cool to room temperature.14,15  
To test the efficiency of the experimental setup a hydroquinone/CO2 crystallisation was 
performed. Hydroquinone and water were placed in a glass vial stoppered with a Suba seal. 
The solution was heated until all of the hydroquinone was dissolved. CO2 was generated by 
allowing dry ice to warm in a sidearm flask, attached to a rubber tube with a syringe and 
needle. The needle was submerged in the hydroquinone solution and an exit needle was 
introduced to allow the gas to bubble through the solution. The exit needle was removed 
before the gas inlet needle to leave the sample under an atmosphere of CO2. The sample was 
placed in a dewar flask filled with boiling water and allowed to cool to room temperature 
over the course of three days. Large needle shaped crystals of hydroquinone/CO2 clathrate, 
crystal 9, were successfully created and analysed by single crystal x-ray diffraction, matching 
the crystal structure found in the literature.14,15 The structure of crystal 9 is shown in Figure 
5.1, showing the hexagonal, hydrogen bonded channels of hydroquinone containing CO2 
molecules. This confirms the experimental setup is adequate to form clathrate structures.  
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Figure 5.1 - Crystal structure of crystal 9 showing hexagonal channels of hydroquinone filled with CO2. 
Hydrogen bonds are shown by red dashed lines. 
Crystallisations were attempted with compounds 6-9 and 11 and the acid gases CO2 and H2S. 
The model compounds, ca. 0.05 g, were dissolved in 0.5 cm3 of acetone, ethanol, methanol 
propan-1-ol, propan-2-ol, acetonitrile and 90 % ethanol in water. The vials were stoppered 
with a Suba seal. CO2 was produced by allowing dry ice to warm in a sidearm flask and H2S 
was produced by dropping HCl into a sidearm flask containing FeS. The acid gases were 
bubbled through the solutions using a rubber tube attached to a syringe and needle by the 
method described for the hydroquinone clathrate. The crystallisations were left in the 
freezer at -20 °C under an atmosphere of acid gas for up to two and a half years. Only one 
sample gave a new crystalline product. After 8 months bisVP in acetone with CO2 formed 
large yellow needle shaped crystals. The crystals were solely bisVP without any CO2 and do 
not further the study into the effects of sour gases on KHIs. The crystal structure of bisVP is 
discussed in further detail in section 2.2.2.  
The interactions between CO2 and H2S and compounds 6-9 and 11 are not sufficient to form 
a clathrate structure of the model compound with a sour gas. In conclusion, crystallisation is 
not an effective method with which to study the interactions between KHIs and their models 
and the acid gases. 
5.2.2 IR and NMR Studies 
To test if there is any significant interaction between the acid gases and the models a series 
of IR spectroscopy studies were carried out. The main functionality in the polymers and their 
models are the lactam rings. The carbonyl groups of the lactam rings are strongly hydrogen 
5: Interactions of sour gas with KHIs 
 
146 
 
bond accepting and the compounds contain no strong hydrogen bond donor groups. This 
allows easy observation by IR spectroscopy of the KHIs and model compounds interacting 
with hydrogen bond donors, as upon hydrogen bonding the carbonyl double bond gains 
more single bond like character, lengthening the bond and shifting the carbonyl stretch band 
to a lower wavenumber. Stronger interactions result in larger changes in the carbonyl stretch 
peak.  
Acetonitrile was chosen as the solvent for these experiments as it is polar enough for 
relatively easy dissolution of the polymers and model compounds, but the lack of a hydrogen 
bond donating group means it will not cause a significant shift in the carbonyl stretch band 
of the studied compounds. IR spectra of the model compounds were recorded in fresh 
acetonitrile and two sour solutions, one containing CO2 and the other H2S, to see if the acid 
gases directly affect the extent of hydrogen bonding interactions of the model compounds 
in water. No quantitative analysis of the exact amount of acid gas dissolved in the sour 
solutions has been possible. Qualitatively IR spectra of the CO2 containing solutions show a 
distinctive and very strong peak at 2343 cm-1 which is characteristic of the asymmetric 
stretch of CO216,17 and the 1H NMR spectrum of the sour acetonitrile shows a peak at 1.07 
ppm from the H2S. Comparison of the IR spectra of the models in acetonitrile without gas, 
with CO2 and with H2S shows that addition of the acid gases did not shift the carbonyl stretch 
bands within the resolution of the experiment. The carbonyl shifts of the model compound 
with and without sour components are shown in Table 5.1. This suggests that the acids gases 
do not directly interact with the model compounds. Though there is no evidence for direct 
interaction, it is possible that the presence of acid gas could affect the interactions of the 
model compounds with water.  
  Carbonyl peak / cm
-1 
Dimer No gas H2S  CO2  
bisVCap 1651 1651 1651 
 1632 1632 1632 
H2bisVCap 1637 1638 1638 
bisVP 1681 1681 1681 
H2bisVP 1682 1682 1682 
bisHep 1684 1684 1684 
Table 5.1 - Positions of the carbonyl peaks in the IR spectra of the compounds 6-9 and 11 dissolved in 
acetonitrile without gas, with CO2 and with H2S. 
To test if the presence of acid gas affects the interactions of the KHIs and model compounds 
with water a series of IR and NMR titrations were performed, involving increasing the 
amount of water in the system and monitoring how the IR and NMR spectra change. IR and 
5: Interactions of sour gas with KHIs 
 
147 
 
NMR titrations have previously been utilised to show the validity of the model compounds 
as models for the KHIs, showing the model compounds to exhibit similar changes in their 
NMR and IR spectra to the polymers when water is added.18,19 To avoid obscuring the peaks 
of interest in the IR spectra Davenport et al.18 chose to use D2O was used instead of H2O. D2O 
was added to an acetonitrile solution of PVCap and a solution of bisVCap. Comparison of the 
changes in carbonyl stretch band showed the model compound, bisVCap, to react in a similar 
manner to the KHI, leading to the conclusion that bisVCap is a suitable model for PVCap. If 
the presence of acid gases affects the KHIs’ interaction with water, a change in the IR and 
NMR titrations should be evident.  
Samples were prepared by dissolving of 0.01 g 1, 3, 5-9 and 11 in acetonitrile. Compounds 1, 
3, 5-9 and 11 were all tested without any gas added, with CO2 and with H2S. For the 
experiments containing either CO2 of H2S, the required gas was bubbled through the solution 
for 1 min before the first spectrum and for 1 min after every three spectra were recorded to 
minimise loss of gas over time. D2O was added at from 0 up to 500 equivalents for the 
experiments with compounds 6-9 and 11 and at 0 up to 250 equivalents of D2O per carbonyl 
group for the experiments with 1, 3 and 5. The carbonyl shifts of the lactam rings were 
followed and plotted against the number of equivalents of water added. There was no 
difference between the sweet and sour systems for any compound that was not within error. 
Note that later points in the titration become more inaccurate as broadening of the carbonyl 
peak makes accurate peak position data difficult. The carbonyl shifts for PVP and PVCap 
without gas, with CO2 and with H2S are shown in Figure 5.2. 
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Figure 5.2 – Positions of the carbonyl peaks of PVP and PVCap upon addition of D2O with and without sour 
gas. 
As D2O is titrated into the KHI or model compound solution the carbonyl band does not 
simply shift but also broadens and changes shape. This peak asymmetry can give information 
on the different levels of hydration of the carbonyl groups as not all will hydrate at the same 
time.20 Band asymmetry of the sweet system was extensively explored by Perrin.19 When 
overlaid the sweet and sour systems show no significant change in peak shape or position, 
PVCap is shown as an example in Figure 5.3. This further suggests that there is no change in 
the interaction of KHIs or the model compounds in sour systems.  As there is no difference 
between the sweet and sour systems and in depth analysis of the peak asymmetry of the 
sour systems would not supply any further information so was not undertaken. 
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Figure 5.3 - Carbonyl peak of PVCap in acetonitrile without acid gas, with CO2 and with H2S with a) 5 
equivalents of water per carbonyl group and b) 100 equivalents of water per carbonyl group. 
As the IR titrations strongly suggest that acid gases do not affect the KHIs’ interaction with 
water, a single series of NMR titrations was performed to check for any differences which 
may have been missed by the IR experiments. BisVCap was chosen for the NMR titrations as 
it is the easiest model compound to synthesise, purify and, as the only solid, the easiest to 
accurately weigh out. The polymers were not chosen as they give much more complicated 
NMR spectra than their low molecular weight models, making analysis by NMR difficult. The 
samples were prepared by dissolving 0.006 g of bisVCap in 0.75 m3 of deuterated acetonitrile. 
a) 
b) 
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D2O was added from 0 to 500 equivalents, with a spectrum being recorded after every 
addition. The spectra of the NMR titration of bisVCap without gas is shown in Figure 5.4. For 
the sample containing CO2, CO2 was bubble through the solution before the first spectrum 
and after every three spectra to avoid loss of gas. 
 
Figure 5.4 - NMR spectra of bisVCap in acetonitrile with increasing amounts of D2O from bottom to top. 
For the titration with H2S, the same method was initially used as for CO2, bubble gas through 
before the first spectrum and every three thereafter. The spectra for the titration with H2S 
show extra peaks, one from the H2S itself at 1.07 ppm, and some small ill-defined peaks from 
the production method of H2S. As the titration continued and more H2S was added more 
peaks appeared eventually obscuring parts of the spectrum and a black powder appeared in 
the sample, possibly FeS which had been pushed into the sample by the flow of gas. To 
prevent this issue, a new sample of bisVCap and acetonitrile was made every three spectra, 
the appropriate amount of D2O was added, then H2S was bubbled through before finally 
recording the next spectrum.  
To check that extra peaks were not caused by the H2S reacting with bisVCap a sample of 
bisVCap in a d-acetonitrile/D2O mix had H2S bubbled through every half hour over a period 
of 2.5 hours to mimic the conditions in the titration. No change was observed in the peaks 
corresponding to the bisVCap and no extra peaks appeared over the course of the 
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experiment. As no reaction seems to be occurring between the bisVCap and H2S and the 
impurities in the NMR do not seem to affect the outcome of the titration, no further action 
was taken.   
As seen in Figure 5.4 a multitude of peaks shift upon addition of D2O, the most significant 
shifts happen to the peaks at 5.27 and 7.16 ppm. The chemical shift in ppm of these peaks 
throughout the titrations with no gas, CO2 and H2S can be found in Figure 5.5. There is no 
significant change between the sweet and sour systems that is not within measurement 
error, suggesting that the acid gases do not affect the interactions of bisVCap with water as 
far as can be observed by NMR. As no significant change was observed in the NMR spectra 
of bisVCap and all IR titrations showed no change upon the addition of acid gas, no further 
NMR titrations were performed.  
 
Figure 5.5 - Chemical shift of the peaks at 5.27 and 7.16 during NMR titrations of bisVCap without acid gas, 
with CO2 and with H2S. 
To summarise, there is no interaction between compounds 6-9 and 11 or the KHIs tested 
with CO2 or H2S observable by IR and NMR spectroscopy. This suggests that the acid gases 
do not affect the way in which KHIs interact with water, so it is likely that sour systems do 
not retard their hydrate inhibiting ability. Acid gases, especially H2S, have long been known 
to promote the formation of clathrate hydrates.5 H2S is commonly referred to as a help 
gas,21,22 even allowing molecules which do not normally form clathrates to do so. H2S forms 
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clathrates at the lowest pressure and highest temperature of any component in natural gas. 
In conclusion, sour gas systems do not inhibit the inhibitor, instead they promote the 
problem. As clathrates form more readily in sour systems more KHI is required to achieve a 
desirable level of hydrate inhibition. This also explains why anti-agglomerants (AAs) are 
generally referred to as unaffected by gas composition.6 AAs do not prevent the formations 
of clathrates but just keep them flowing as a slurry,23 thus faster clathrate formation does 
not greatly change the AA mode of action.  
5.3 Experimental 
5.3.1 Producing sour gas 
Carbon dioxide was produced by placing approximately 5 g of dry ice in a side arm flask and 
covering the top with a rubber bung. Rubber tubing was used to connect the side arm of the 
flask and a syringe and needle. The needle was submerged in the solutions requiring CO2, 
allowing the gas to bubble through the solution. The bung was regularly removed to release 
any build-up of pressure.  
Hydrogen sulfide was produced by slowly dropping dilute hydrochloric acid onto iron (II) 
sulfide. This was done using a dropping funnel full of HCl and side arm flask containing ca. 
0.5 g of FeS. Rubber tubing was used to connect the side arm of the flask and a syringe and 
needle. The needle was submerged in the solutions requiring H2S, allowing the gas to bubble 
through the solution. The bung was regularly removed to release any build-up of pressure. 
All equipment was thoroughly cleaned with bleach before removal from the fume cupboard. 
5.3.2 Crystallisations 
0.1 g of hydroquinone was dissolved in 0.5 cm3 of hot water. The sample was stoppered with 
Suba seals which were pierced with an exit needle and the needle from the CO2 generator. 
The needle from the CO2 generator was submerged in the solution and CO2 was bubbled 
through the solutions 1 min. The exit needle was then removed, followed by the needle from 
the CO2 generator. The sample was left in a Dewar filled with boiling water for three days. 
Large, needle shaped crystals were formed and analysed by single crystal x-ray 
crystallography. 
Single crystal crystallographic analysis was performed on a Bruker Photon D8 Venture 
diffractometer (ImuS microsource, λMoKα, λ = 0.71073 Å) equipped with a Cryostream 
(Oxford Cryosystems) open-flow nitrogen cryostat, at 120 K. The data collection and 
refinement was kindly carried out by Dr Dmitry S. Yufit.  
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Hydroquinone/CO2 crystal data: Empirical formula C6H6O2, 1/12 CO2, space group R-3, a = 
16.4400(14) Å, b = 16.440(14) Å, c = 5.4822(5) Å, α = 90.00°, β = 90.00°, γ = 120.00°, volume 
= 1283.18(19) Å3, Z = 9, F(000) = 538.0, MoKα (λ = 0.71073) 2θ range for data collection = 
4.96 – 0.1320°, data = 901, parameters = 52, goodness-of-fit on F2 = 1.079, R1 = 0.0583, wR2 
= 0.1320  
Compounds 6-9 and 11 were dissolved in 0.5 mL of acetone, ethanol, methanol propan-1-ol, 
propan-2-ol, acetonitrile and 90 % ethanol in water. Details of compounds weight and 
solvent can be found in Table 5.2. The samples were stoppered with Suba seals which were 
pierced with an exit needle and the needle from the CO2 generator. The needle from the CO2 
generator was submerged in the solution and CO2 was bubbled through the solutions 1 min. 
The exit needle was then removed, followed by the needle from the CO2 generator. All were 
placed in the freezer -20 °C and checked for crystals on a monthly basis over the course of 
36 months. 
Dimer Dimer / g Solvent 
bisVCap 0.16 ethanol 
 0.15 methanol 
 0.14 acetone 
 0.15 90% ethanol in water 
 0.15 propan-2-ol 
 0.15 propan-1-ol 
 0.15 acetonitrile 
H2bisVCap 0.34 ethanol 
 0.33 methanol 
 0.37 acetone 
 0.33 90% ethanol in water 
 0.35 propan-2-ol 
 0.31 propan-1-ol 
 0.37 acetonitrile 
bisVP 0.41 ethanol 
 0.36 methanol 
 0.37 acetone 
 0.37 90% ethanol in water 
 0.42 propan-2-ol 
 0.45 propan-1-ol 
 0.44 acetonitrile 
H2bisVP 0.43 ethanol 
 0.38 methanol 
 0.37 acetone 
 0.38 90% ethanol in water 
 0.35 propan-2-ol 
 0.43 propan-1-ol 
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 0.44 acetonitrile 
bisHep 0.13 methanol 
 0.12 ethanol 
 0.11 acetone 
 0.12 90% ethanol in water 
 0.11 propan-2-ol 
 0.12 propan-1-ol 
  0.18 acetonitrile 
Table 5.2 – Composition of CO2 containing crystallisation attempts. 
Compounds 6-9 and 11 were dissolved in 0.5 mL of acetone, ethanol, methanol propan-1-ol, 
propan-2-ol, acetonitrile and 90 % ethanol in water. Details of compounds weight and 
solvent can be found in Table 5.3. The samples were stoppered with Suba seals which were 
pierced with an exit needle and the needle from the H2S generator. The needle from the H2S 
generator was submerged in the solution and H2S was bubbled through the solutions 1 min. 
The exit needle was then removed, followed by the needle from the H2S generator. All were 
placed in the freezer -20 °C and checked for crystals on a monthly basis over the course of 
36 months. 
Dimer Dimer / g Solvent 
bisVCap 0.19 ethanol 
 0.17 methanol 
 0.15 acetone 
 0.16 90% ethanol in water 
 0.15 propan-2-ol 
 0.16 propan-1-ol 
 0.13 acetonitrile 
H2bisVCap 0.36 ethanol 
 0.34 methanol 
 0.35 acetone 
 0.38 90% ethanol in water 
 0.33 propan-2-ol 
 0.31 propan-1-ol 
 0.31 acetonitrile 
bisVP 0.45 ethanol 
 0.57 methanol 
 0.68 acetone 
 0.34 90% ethanol in water 
 0.37 propan-2-ol 
 0.53 propan-1-ol 
 0.32 acetonitrile 
H2bisVCap 0.32 ethanol 
 0.32 methanol 
 0.35 acetone 
 0.34 90% ethanol in water 
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 0.37 propan-2-ol 
 0.41 propan-1-ol 
 0.37 acetonitrile 
bisHep 0.11 methanol 
 0.11 ethanol 
 0.13 acetone 
 0.10 90% ethanol in water 
 0.15 propan-2-ol 
 0.17 propan-1-ol 
  0.14 acetonitrile 
Table 5.3 - Composition of H2S containing crystallisation attempts. 
5.3.3 IR studies 
Experiments were performed on a Perkin Elmer FTIR spectrum 100 using a liquid IR cell with 
CaF2 windows and a 0.05 mm spacer. Data were recorded at a resolution of 1 cm-1 for 16 runs 
over the range 2800 – 1400 cm-1. Spectral analysis was performed using Spekwin32.24 Two 
batches of sour acetonitrile were made, one by bubbling CO2 through the solvent, the other 
by bubbling H2S through the solvent. The acid gases were made as described in section 5.3.1.  
IR titrations with H2S, CO2 and without sour gas, were performed for compounds 1, 3, 5-9 
and 11. 0.01 g of compound was dissolved in 1 cm3 of acetonitrile. For compounds 6-10 water 
was added at 0, 10, 20, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450 and 500 equivalents 
of D2O and spectra were recorded after each addition. For 1, 3 and 5 water was added at 0, 
5, 10, 20, 30, 40, 50, 75, 100, 125, 150, 175, 200, 225 and 250 equivalents of D2O per carbonyl 
group and spectra were recorded after each addition. 
For the sour titrations 0.01 g of 1, 3, 5-9 and 11 were dissolved in 1 cm3 of acetonitrile. H2S 
or CO2 were bubbled through the solution for 1 min before the first spectrum was recorded. 
For compounds 6-9 and 11 water was added at 0, 10, 20, 40, 60, 80, 100, 150, 200, 250, 300, 
350, 400, 450 and 500 equivalents of D2O and spectra were recorded after each addition. For 
1, 3 and 5 water was added at 0, 5, 10, 20, 30, 40, 50, 75, 100, 125, 150, 175, 200, 225 and 
250 equivalents of D2O per carbonyl group and spectra were recorded after each addition. 
After every 5 spectra the acid gas was again bubbled through the solution.  
5.3.4 NMR study 
NMR spectra were recorded on a Varian-Mercury spectrometer, operating at 400 MHz, 
chemical shifts are reported in ppm (δ) relative to residual solvent. 
0.006 g of bisVCap was dissolved in 0.75 cm3 of deuterated acetonitrile. D2O was titrated 
directly into the NMR tube and the tube was inverted to ensure mixing of the D2O. Spectra 
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were recorded at 0, 10, 20, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450 and 500 
equivalents of D2O. 
0.006 g of bisVCap was dissolved in 0.75 cm3 of deuterated acetonitrile. CO2 was bubbled 
through the solution for 1 min before the first spectrum was recorded and after every 3 
spectra. D2O was titrated directly into the NMR tube and the tube was inverted to ensure 
mixing of the D2O. Spectra were recorded at 0, 10, 20, 40, 60, 80, 100, 150, 200, 250, 300, 
350, 400, 450 and 500 equivalents of D2O. 
0.006 g of bisVCap was dissolved in 0.75 cm3 of deuterated acetonitrile. D2O was titrated 
directly into the NMR tube and the tube was inverted to ensure mixing of the D2O. H2S was 
bubbled through the solution for 1 min. A fresh sample of 0.006 g bisVCap in 0.75 cm3 of 
deuterated acetonitrile with H2S bubbled through was prepared after ever 3 spectra. Spectra 
were recorded at 0, 10, 20, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450 and 500 
equivalents of D2O. 
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6 Neutron study of PVCap and butoxyethanol 
6.1 Introduction 
Neutron scattering is a technique comparable to x-ray diffraction. Samples diffract either the 
x-rays or neutrons and structural information about the system can be obtained from the 
diffraction pattern.1 Often x-ray diffraction will be chosen over neutron diffraction as x-rays 
have higher flux and are scattered more strongly since neutrons must hit the nucleus of the 
atom to be diffracted. Moreover x-ray diffraction instrumentation is readily available in the 
home laboratory setting. The amount by which x-rays are diffracted is related to the number 
of electrons of the atom which it hits and hence the atomic number; the higher the atomic 
number of the atom, the stronger the diffraction. This means light atoms, such as hydrogen, 
diffract very weakly and are subject to systematic errors, making analysis requiring hydrogen 
atoms more difficult. In contrast, the amount which neutrons are diffracted is not dependant 
on the mass of that atom. As can be seen in Figure 6.1, the ability to diffract neutrons has no 
correlation with atomic mass. Hydrogen and deuterium in particular, have greatly different 
coherent scattering lengths, hydrogen's being negative, -3.74 fm, whilst deuterium's 
positive, 6.67 fm.2 This allows analysis of high hydrogen systems, by using isotopic 
substitution of hydrogen and deuterium to change the level of contrast and collect multiple 
datasets of the same chemical composition. So whilst less convenient than x-ray diffraction, 
high hydrogen systems, such as studying water, are much more readily studied by neutron 
diffraction. 
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Figure 6.1 – Coherent scattering of atoms sorted by their molecular mass. Plotted from the data of Sears.2 
In a single crystal, a motif is repeated infinitely in all directions which allows for a definitive 
structure to be determined. Defects and disorder in a crystal complicate this process, but the 
order and regularity in the crystal make it possible to solve the structure. By definition 
disordered systems do not have the three dimensional order present in crystals, being either 
amorphous solids or fluids. As there is no order in any direction and as fluid systems are 
dynamic and so constantly changing, no exact structure determination can be achieved. 
Instead an average, statistical overview of the system can be produced, giving information 
on the average nearest neighbours and whether any long range order is present.3 This is done 
by creating a model of the system then refining it against the experimental data. This process 
is often done using modified Monte Carlo based simulations,4 though use of molecular 
dynamic has also been explored.5 Once the modelled data fits the experimental data as 
precisely as possible, the model can be analysed to extract information about the system. 
One such useful plot is the g(r) plot. The g(r) plot shows variations in atomic density at a 
distance r from an atom, giving information on the nearest neighbours in the system as well 
as any longer range structure which may exist. For example, g(r) plots have shown the 
average length of the hydrogen bond between methanol and water,6 the differences in 
intermolecular interactions in different densities of water upon increasing the pressure,7,8 
interactions between the ions in ionic liquids9,10 and how much liquid-like behaviour 
supercritical materials exhibit.11 
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Whilst statistically significant conclusions can be draw from the neutron scattering of 
disordered systems the dynamic nature of the system can make accurate interpretation 
difficult. For example 2-butoxyethanol in water has previously been the focus of a collection 
of small angle neutron studies by D’Arrigo et al.12–14 which resulted in different conclusions 
from analysing the same system. D’Arrigo et al. used a non-linear least-squares fit between 
the simulated and experimental data. For the calculated data they assume that any formed 
micelles would be spherical and that not all of the butoxyethanol would be involved in 
micelle formation. They then calculated how the SANS data would look for different sizes of 
micelle and compared this data to the data from the SANS experiment, adjusting the size of 
the micelles and amount of free butoxyethanol until the calculated and experimental data 
were as close to the same as possible. In all their analyses an acceptable goodness-of-fit was 
achieved. In their earlier papers it was concluded that butoxyethanol does form micelles, 
with a radius corresponding to the length of the butoxyethanol 17 Å.13  The number of 
micelles were at a maximum around 40 °C, but formed as low as 4 °C.13 In a later paper, 
D’Arrigo et al. state that they do not believe that butoxyethanol forms true micelles but 
‘fluctuating micelle-like molecular groupings’.14 This shows that similar analyses of the same 
system do not necessarily give the same results as simulations are not guaranteed to give 
the same result twice and the continuously fluctuating nature of liquid samples makes 
finding a single, definite answer much more challenging than solid systems. 
6.2 Results and discussion 
Previous work in the group15 used neutron diffraction to look at the interactions of bisVCap 
with water in an attempt to glean insight into KHI’s hydration behaviour in solution. To 
further this study it was proposed that neutron diffraction experiments could offer 
information about the synergistic effect that butoxyethanol has on PVCap. Butoxyethanol is 
a weak anti-agglomerant hydrate inhibitor but when added to a pipeline with PVCap the 
resulting hydrate inhibition is greater than the sum of hydrate inhibition of butoxyethanol 
and PVCap alone.16 Two systems were studied: the control system of butoxyethanol/water 
and butoxyethanol/water/PVCap. PVCap is sold for pipeline applications in a 50 wt% solution 
in butoxyethanol so PVCap was added in a 1:1 weight ratio to butoxyethanol to maximise the 
industrial relevance.  
KHIs are added to a pipeline at typically 0.01-5 wt%.17 Whilst a higher concentration of 
butoxyethanol and PVCap is further from industrial relevance, it is necessary for neutron 
diffraction experiments as lower concentrations will make the data impossible to distinguish 
from pure water, especially as neutron diffraction is very highly sensitive to hydrogen so 
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water diffracts strongly. Butoxyethanol was added in 5 mol% to water, which is the highest 
concentration which allows both the butoxyethanol and PVCap to fully dissolve at 6 °C.  This 
temperature was chosen to try and avoid micelle formation of butoxyethanol12–14 and aid 
dissolution of larger amounts of PVCap. PVCap is Flory-Huggins type I polymer18 leading it to 
precipitate out of solution at higher temperatures due to the entropy gain in freeing up 
ordered water molecules along the length of the polymer chain. In the system studied this 
resulted in the amount of polymer used is not being fully soluble at room temperature and 
cooling below 3 °C also resulted in a large enough decrease in solubility to also cause 
precipitation. This leaves a relatively small temperature window, 3-10 °C, in which the 
polymer remains in solution and 6 °C falls in the middle of this temperature range. 
Experiments were run on NIMROD (Near and InterMediate Range Order Diffractometer) at 
the ISIS neutron source with Dr Sam Callear as the local contact. NIMROD is a wide angle 
neutron diffractometer which records data from low to high Q. A wide Q range gives 
information on local environment of a molecule as well as any long range order which may 
occur. Because of its ability to go to a 2θ angle as low as 0.5°, NIMROD is classed as small 
angle neutron scattering (SANS) instrument.19 It is important to have as many data sets to fit 
the simulation to as possible to get a more accurate simulation possible. To do this a range 
of chemically same but isotopically different composition were used. As the systems studied 
were in water, three isotopic versions of water were used, H2O, D2O and HDO. Whilst 
deuterating the polymer is not possible, it was possible to purchase 2-butoxythanol-1,1,2,2-
d4 from QMX Laboratories Ltd. This gave a total of six different combinations of deuterated 
and non-deuterated water and butoxyethanol, all of which were used for the 
butoxyethanol/water experiments as detailed in Table 6.1. Only four combinations of 
deuterated water and butoxyethanol were used for the butoxyethanol/water/PVCap 
experiments due to limited beam time at the neutron source. 
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Water Butoxyethanol PVCap 
H2O H - 
HDO H - 
D2O H - 
H2O D - 
HDO D - 
D2O D - 
H2O H yes 
D2O H yes 
HDO D yes 
D2O D yes 
Table 6.1 – Composition of the NIMROD experiments performed. Where D means 2-butoxythanol-1,1,2,2-d4 
was used and H means that fully protic butoxyethanol was used. 
6.2.1 The simulation process 
Whilst the large difference in scattering lengths between hydrogen and deuterium makes 
neutron scattering ideal to study organic systems, the inelastic scattering of hydrogen adds 
a level of complexity.20 Most elements have small or no inelastic scattering, neutrons hit the 
sample with a certain amount of energy and exit the sample with the same amount of 
energy. Hydrogen on the other hand has a high degree of inelastic scattering, meaning that 
many neutrons which are diffracted by hydrogen either gain or lose energy.21 This changes 
the recorded diffraction pattern and is especially troublesome in the low Q region where the 
inelastic scattering causes a significant increase in f(Q) which obscures the elastic scattering 
at low Q. Thus for meaningful analysis of the data to be performed, the inelastic scattering 
from hydrogen must be removed. The inelastic scattering from hydrogen was removed using 
Gudrun.22 The program uses the composition of the sample, input by the user, to calculate 
the amount of inelastic scattering which should occur and then subtract the calculated 
inelastic scattering from the raw data. This is an iterative process that is repeated until there 
is no change in the output data. A majority of parameters are instrument specific and 
supplied by the Gudrun program itself. Iterations of inelastic scattering removal were carried 
out one at a time until there was not visible change in the output data. This adjusted data 
was then used to refine a model of the system. 
The models of the systems were created using Empirical Potential Structure Refinement 
(EPSR).23,24 Models for the molecules in a system are created and the structure minimised 
using Jmol,25 creating .ato files. The .ato files contain the information on the atoms types and 
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bonding of the molecule, including partial charges, which bonds are capable of rotation, 
bond lengths and the positions of a low energy starting conformation. The starting partial 
charges for the atoms in a molecule are either generated by a program such as MOPAC26 or, 
in the case of the simulations in study, input by hand from the work of Jorgensen et al.27 on 
conformation energetics of organic liquids. The partial charges are refined during the 
iterative process of the simulation, so the exact starting value is only important in as far as 
avoid local energy minima and minimising the time required for the system to equilibrate. 
The molecules are then put in a box in the correct ratio for the sample being analysed using 
the mixato function in EPSR to create a .ato file for the box. The size of the box depends on 
the desired number of molecules and the density, EPSR creates a box which gives the correct 
density with the number of molecules provided. Initially all the molecules are stacked on top 
of one another in the centre of the box, the molecules are then randomised, moved at 
random to somewhere in the box. A function called fmole is then used to ‘shake’ the box, 
reducing the number of molecules which are still occupying the same space. 
EPSR uses a Monte Carlo based simulation, where atoms are moved a random distance in a 
random direction. If the random move increases the energy of the system too greatly, the 
move is rejected, if only a small increase or a decrease in energy is seen, then the move is 
accepted.28 Unlike a purely computational simulation, EPSR has experimental data to 
compare to. The diffraction pattern which would be expected from the model is calculated 
by ESPR and then compared to the experimental diffraction pattern and a goodness-of-fit is 
calculated. As well as measuring the energy of the model and aiming for the lowest energy 
possible, as is done in a standard Monte Carlo simulation, there is also a measure of how 
well the model fits the experimental data. This gives further information on if the model is a 
reasonable representation of reality, as in a pure simulation the chemical intuition of the 
user is relied on, with no experimental data to verify correctness of the model. The more 
different isotopic substitutions which were recorded, the more data there is to refine to, 
resulting in a more accurate model. 
After a few hundred iterations of the Monte Carlo method, the model reaches a stable 
goodness-of-fit and a stable energy level. When the model is stable, the ereq, the energy 
which the system has, can be raised. This inputs energy into the system, allowing the 
molecules to move more and fit better to the experimental data. Older versions of EPSR, 
such as EPSR24, required the ereq to be input by the user, though the most recent version 
of EPSR, EPSR25, increases the ereq automatically, stopping the increase when no further 
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improvement of the goodness-of-fit and energy can be gained. Both EPSR24 and EPSR25 
were tested in this study. 
After the energy level of the simulated data is stable and the goodness-of-fit shows no 
further improvement, the data is then accumulated into an append.xyz file. The append.xyz 
file records the position of every atom in the box for each iteration of the simulation. A 
minimum file size of 3 GB is required for the simulation to be of statistical significance, 
resulting in data from thousands of iterations. The next step is to create a .HISU file from the 
append.xyz file using the xyz2hisu function of the dputils package from Project Aten.29 The 
.HISU file gives the average positions from all of the iterations recorded. The dputils tool, 
pdens, can then be used to make this .HISU file into data readable by the Aten program which 
can used to graphically represent the data. The pdens tool creates two files, a .avg which is 
the average position of the molecule chosen to be the centre of the analysis and a .pdens file 
which gives information on the density of surrounding molecules of a chosen type. The .avg 
file requires three atoms to be picked as the axis of the model. The numbering of the atoms 
are determined upon the creation of the molecule in Jmol and are found in the .ato file for 
the molecule, the numbering for butoxyethanol in the simulations are shown in Figure 6.2. 
The chosen axis atoms are the centre of the analysis. Using butoxyethanol in water as an 
example, atoms 18, 21 and 22, as labelled in Figure 6.2 were chosen as the axis atoms. The 
resulting .avg file can be plot to give Figure 6.3a. The three axis atoms remain still at the 
centre of the model, whilst the rest of the butoxyethanol molecule is free to change 
conformation. The multiple conformations over thousands of iterations are all plot 
simultaneously. The reference atoms in every iteration are perfectly superimposed and the 
rest of the chain is the superimposition of every conformation which occurred in the 
simulation. 
 
Figure 6.2 – Numbering of the butoxyethanol atom file.  
To form a .pdens file, a second molecule type must be chosen. Still using the 
butoxyethanol/water system as an example, either butoxyethanol or water can be chosen 
as the second molecule depending on which interactions are of interest to visualise. For this 
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example water was chosen. As butoxyethanol was chosen as the central molecule and water 
was chosen as the interacting molecule, this will give information on the water surrounding 
butoxyethanol. The .pdens file is plot as translucent blue regions, representing the density 
of the chosen molecule surrounding the axis atoms. The pdens plot of water surrounding 
butoxyethanol is shown in Figure 6.3b. As the whole box is filled with water the .pdens would 
appear as a translucent cube if the data did not cut off at a certain density. The cut off 
parameters in Aten are in terms of density and can be adjusted to show hydration spheres 
arising from a higher density of water surrounding the hydrophilic parts of a molecule.  
                           
Figure 6.3 – a) Visualisation of the .avg file of butoxyethanol, showing the alcohol taken as the axis and the 
range of positions of the rest of the molecule, b) visualisation of the .avg file of butoxyethanol with the 
.pdens file containing information on density of the surrounding water plot as areas of translucent blue. 
  
a) b) 
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6.2.2 Model of butoxyethanol/water 
The model of water was created and minimised using Jmol.25 The model of butoxyethanol 
was created and minimised using Jmol and given full freedom to rotate around every bond. 
The model consists of a cubic box with side measuring 34.96 Å on each side filled with 1045 
water molecules and 55 butoxyethanol molecules with a density of 0.102 atoms Å-3. The 
model can be seen in Figure 6.4. 
 
Figure 6.4 – Simulation box for the butoxyethanol/water simulation with hydrogen atoms omitted for clarity. 
Both EPSR24 and EPSR25 were used to refine the data in two separate simulations. In EPSR24 
the ereq is input by hand and in EPSR25 the ereq is adjusted automatically. Both versions 
gave acceptable energy, -37 kJ mol-1 for both simulations and an acceptable goodness-of-fit, 
R = 0.1 for both simulations. The output data from EPSR25 gave very noisy data for the partial 
atomic distribution functions, g(r) plot, whilst EPSR24 gives smooth curves, as shown in 
Figure 6.5. Noisy partial distributions are usually a result of the simulation not being given 
long enough to equilibrate. Even after two weeks more run time, the EPSR25 data does not 
become any less noisy. This seems to be an issue with this version of EPSR, which at the time 
of writing is still in the beta testing phase. Further analysis of the butoxyethanol/water 
system was performed on the smoother data created by EPSR24. 
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Figure 6.5 – Partial interactions of the hydrogen of the hydroxyl group of butoxyethanol with water and the 
oxygen of the hydroxyl group of butoxyethanol with water. Data refined using EPSR24 is shown in blue, data 
refined by EPSR25 is shown in red. 
After the point at which increasing the ereq no longer improves the goodness-of-fit or the 
energy of the simulation and both remained stable, the fit of the simulation to the 
experimental data was acceptable. Comparison of the experimental data and simulated data 
are shown in Figure 6.6. Only four data sets are shown to allow for direct comparison to the 
butoxyethanol/water/PVCap data. At low Q, Figure 6.6a, the peaks around 2.5 Å-1 in the H2O 
H-butoxyethanol and HDO H-butoxyethanol data are shifted higher in the simulation than 
the experimental data. The D2O D-butoxyethanol simulation also fails to exhibit the ripples 
in the experimental data. The problems in the low Q data arise from the beginnings of 
agglomeration.30,31 Whilst the temperature was chosen to minimise the chances of micelle 
formation, the sample was also made to be as concentrated as possible, which favours 
butoxyethanol forming micelles. EPSR is not designed to study micelle formation, so a better 
fit of the low Q data is not possible with this program. As the real space data, Figure 6.6b, 
has been fitted well and the low Q data is not completely unreasonable, this simulation has 
been taken as the best model for the system which can be made with the current technology.  
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Figure 6.6 – Quality of fit for the EPSR simulation of butoxyethanol/water shown in a) reciprocal space and b) 
real space. The experimental data are shown by dotted red lines whilst the simulated data are shown by solid 
blue lines. 
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Figure 6.7 shows the .avg and .pdens analyses of the butoxyethanol/water data. In Figure 
6.7a the centre of the analysis is the hydroxyl group of the butoxyethanol, atoms 18, 21 and 
22. Two hydration spheres can be seen, a larger partial ellipsoid around the oxygen side of 
the hydroxyl group and a smaller partial ellipsoid around the hydrogen side.  This shows the 
hydrogen bonding nature of the alcohol group, resulting in a higher density of water around 
the hydrogen bond donating and hydrogen bond accepting sides of the hydroxyl group. In 
Figure 6.7b the ether group of the butoxyethanol is taken as the centre of the model, atoms 
11, 14 and 15. By the time the density cut offs have been expanded far enough to see a 
hydration sphere around the oxygen of the ether, the hydration sphere around the hydroxyl 
group is already visible. This shows that the ether group in butoxyethanol is much less 
efficient than the alcohol group at ordering the surrounding water molecules. This is because 
the ether group is much less polar and less capable of hydrogen bonding.  
 
Figure 6.7 – Hydration sphere around butoxyethanol in the butoxyethanol/water simulation plotted using 
Aten with the axis set as a) the hydroxyl group, atoms 18, 21 and 22 and b) the ether group, atoms 11, 14 and 
15. 
Whilst the low Q data was not fit perfectly using EPSR, the EPSR model of butoxyethanol in 
water resulted in a graphic representation of the hydration of butoxyethanol which makes 
chemical sense. The hydroxyl group is proven to be more hydrophilic that the ether group as 
would be expected and smooth hydration spheres were created similar to previous work on 
methanol.6 
6.2.3 Model of butoxyethanol/water/PVCap 
The butoxyethanol and water molecules from the butoxyethanol/water simulation were 
used for the simulation of the butoxyethanol/water/PVCap system and a model of PVCap 
was created using Jmol. As Jmol cannot minimise a structure as large as PVCap, a monomer 
unit was made, minimised and attached to 21 other monomer units. Capping methyl groups 
were added to the ends of the polymer. This gave a polymer with a molecular weight of 3082 
a) b) 
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Da which is within the molecular weight range of the sample of PVCap used as specified by 
the supplier. The model of PVCap was given freedom to rotate along the backbone and the 
side groups were able to rotate. Rotations in the rings were not included. The fused nature 
of the rings and the Monte Carlo system used by EPSR would result in a large majority of 
moves being rejected, leading to almost no movement whilst greatly increasing the 
computational cost of the simulation.  
A cubic box filled with 1045 water molecules and 55 butoxyethanol molecules and 2 PVCap 
molecules was created. The sides of the box are 37.02 Å and the simulation has a density of 
0.106 atoms Å-3. The model can be seen in Figure 6.8. A larger box, containing more than two 
polymer atoms, would be more statistically significant but the initial untangling of the 
polymer chains was not possible when more than two polymer chains were present, leaving 
two as the maximum number of polymer chains which could be simulated.  
   
Figure 6.8 - Simulation box for the butoxyethanol/water/PVCap simulation, a) with hydrogen atoms omitted 
for clarity, b) with hydrogen atoms and water molecules omitted for clarity. 
Using EPSR24 where the ereq was increased by hand there was an issue that as the goodness-
of-fit improved, the energy of the system would increase massively, typically the energy 
increased to a value greater than 500 kJ mol-1, for comparison the butoxyethanol/water data 
had an energy value of -37 kJ mol-1. This is possibly due to the beginnings of phase separation 
of the system at higher ereq. Attempts to apply restrictions on the distance between water 
atoms based on previous data gathered on water24 to allow a lower increase in ereq did not 
solve the problem as it did not reduce the required ereq. The automated ereq increase in 
EPSR25 successfully achieved an acceptable goodness-of-fit, R = 0.02, without the energy 
increasing an unreasonable amount, the energy of the system equilibrated at -40 kJ mol-1. 
During the accumulation of the append.xyz file the energy does start to increase, but does 
not reach into the positive and the fit of the simulation to the experimental data is acceptable 
a) b) 
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as seen in Figure 6.9. Similarly to what was seen in for the butoxyethanol/water partial 
distribution data from EPR25 in Figure 6.5, the partial distribution data of 
butoxyethanol/water/PVCap is noisy. As a reasonable fit and energy level has not been 
possible with EPSR24, the EPSR25 data was used, even though the partial distribution data is 
not as clean as would be preferable. 
The simulated low Q data in Figure 6.9a is much closer to the experimental data than it was 
for the butoxyethanol/water simulation. The peak around 2.5 Å-1 in the H2O H-butoxyethanol 
and HDO H-butoxyethanol data are still shifted slightly higher in the simulation than the 
experimental data, but by much less than the butoxyethanol/water simulation. The D2O D-
butoxyethanol simulation shows fewer peaks than the experimental data, but does exhibit 
some ripples which is closer to the experimental data than the butoxyethanol/water 
simulation. In the real space data in Figure 6.9b the peaks at 1 Å in the simulated data are 
not exactly the same, with variances in intensity unlike the butoxyethanol/water simulation 
where the simulated data matched the experimental data very well. Ever though the low r 
data of the butoxyethanol/water/PVCap data seems less well fit than the 
butoxyethanol/water data, all over, the fit looks slightly better than that of the 
butoxyethanol/water simulation which is reflected in the lower R value. 
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Figure 6.9 - Quality of fit for the EPSR simulation of butoxyethanol/water/PVCap shown in a) reciprocal space 
and b) real space. The experimental data are shown by dotted red lines whilst the simulated data are shown 
by solid blue lines. 
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To allow comparison to the butoxyethanol/water simulation, the pdens analyses were 
performed using butoxyethanol as the central molecule with either the hydroxyl or ether 
groups set as the axis atoms and water was selected as the molecule for the .pdens. As seen 
in Figure 6.10, the smooth hydration spheres apparent in the butoxyethanol/water 
simulation did not occur. There is no way to adjust the cut-off parameters to create a 
meaningful hydration sphere. When the alcohol is set as the axis, Figure 6.10a, either the 
box is completely filled with blue, or when the cut-off parameters are adjusted fragmented 
blue polygons are seen a long distance from the central butoxyethanol. When the ether 
group is set as the axis, there is no change to the hydration sphere when the cut off 
parameters are adjusted, it continues to be a complete shell. Neither scenario is chemically 
reasonable and, as one shows all of the water molecules to be far away from the central 
butoxyethanol molecule and the other shows the water molecules to be very close, the plots 
are not even consistent with each other. Even though an acceptable goodness-of-fit was 
reached with the simulation, the simulation is not made to deal with polymers and this is 
reflected in the output data.  
 
Figure 6.10 - Hydration sphere around butoxyethanol in the butoxyethanol/water/PVCap simulation plotted 
using Aten with the axis set as a) the hydroxyl group, atoms 18, 21 and 22 and b) the ether group, atoms 11, 
14 and 15. 
6.2.4 Partial atomic distribution functions 
Partial atomic distribution functions give information on the distances between two selected 
atom types. The plot consists of g(r) against radius (r). A peak in g(r) indicates a large number 
of atoms at that distance and often indicates bond. For example in water, as can be seen in 
a) b) 
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Figure 6.11, the O-H line shows a peak at 1.8 Å which is the O···H length of the hydrogen 
bond between two water molecules.32 The next broad peak along, at 3.3 Å is the second 
hydration sphere of water. 
Compared to the neutron diffraction work on water by Soper6–8 the partial distribution 
function between the H-H, O-H and O-O for the water molecules for both the 
butoxyethanol/water and butoxyethanol/water/polymer data are both what would be 
expected from a system mainly comprising of water. The peaks below 4 Å are quite well 
defined and typical of the hydrogen bonding in water. In the butoxyethanol/water data, at 4 
Å and above, the peaks seen by Soper are still present, yet relatively broad. This would 
indicate that the there is less order in the second hydration sphere of water when 
butoxyethanol is present than when it is absent. The butoxyethanol/water/PVCap data has 
a peak in the O-O plot at 5.5 Å instead of the expected 4.5 Å. This could possibly be due to 
the second hydration sphere being further disrupted by the presence of the polymer, though 
as there is no shift in the peaks in either the H-H or H-O plot is it more likely that it is an 
inaccuracy in the simulation.  
 
Figure 6.11 - Partial interactions of water with water. Data for the butoxyethanol/water simulation is shown 
in blue and data for the butoxyethanol/water/PVCap simulation is shown in red. 
Comparison of the partial distributions of the alcohol and ether groups of butoxyethanol with 
water in both the butoxyethanol/water and butoxyethanol/water/PVCap simulations can be 
found in Figure 6.12. Both data sets are identical, apart from the spikes resulting from the 
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rough fit of the butoxyethanol/water/PVCap data from EPSR25, suggesting that within the 
limitations of the techniques used, there is no observable difference between the 
interactions between butoxyethanol and water with or without the addition of PVCap 
suggesting there is no change in the interactions between butoxyethanol with water within 
the scope of the technique and analysis used. The hydroxyl group of butoxyethanol exhibits 
hydrogen bonding with and O···O length of 2.8 Å to the first hydration shell of water. This is 
slightly longer than the 2.7 Å observed between water molecules, suggesting that the 
hydroxyl group of the butoxyethanol interacts with water with similar strength as water 
molecules interacting with each other. The ether oxygen atom shows weak bonding to the 
surrounding water, showing shoulders in the plot opposed to peaks, which are often 
indicative of little or no bonding network between the species.7 
 
Figure 6.12 - Partial interactions of the oxygen atom of the ether of butoxyethanol with water, the hydrogen 
of the hydroxyl group of butoxyethanol with water and the oxygen of the hydroxyl group of butoxyethanol 
with water. Data for the butoxyethanol/water simulation is shown in blue and data for the 
butoxyethanol/water/PVCap simulation is shown in red. 
Figure 6.13 shows the partial distribution functions of the carbonyl oxygen atoms with water 
and the lactam nitrogen atoms with water. There is no strong interactions observable in the 
plot. There is a small shoulder at 2.8 Å in the polymer O – water O plot, but it is much too 
weak to conclude that it arises from any significant hydrogen bonding behaviour.  
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Figure 6.13 – Partial interactions of the oxygen atom of the carbonyls of PVCap with water and the nitrogen 
atoms of the lactam rings with water.  
In conclusion SANS is not a viable method to look at this system. The concentration of 
polymer is too low to significantly differentiate the sample from pure water and the Monte 
Carlo based simulation technique is inadequate to analyse polymers. Simulations containing 
the polymer resulted in meaningless polygons in the pdens analysis of density and noisy data 
in the g(r) vs r plots. The butoxyethanol/water data gave chemically intuitive hydration 
spheres showing how it interacts with water in solution, though it was not at a high enough 
concentration to reliably conclude if the broadening of the peaks related to the second 
hydration sphere of water in the g(r) vs r plot of water are evident of the structure of bulk 
water being disrupted.    
6.3 Experimental 
Small angle neutron scatting experiments were performed on the Near and InterMediate 
Range Order Diffractometer (NIMROD) at the ISIS spallation source, in collaboration with Dr 
Samantha Callear. The beam size was set to 30 mm by 30 mm and titanium/zirconium cans 
with a 1 mm wide cavity were used along with a sample changer.   
Water, D2O and 2-butoxyethanol were purchased from Sigma Aldrich and the 2-
butoxythanol-1,1,2,2-d4 was bought from QMX Laboratories Ltd., all were used as supplied. 
The PVCap (Mw ~3000 Da) was supplied by Ashland Inc. in a 1:1 weight ratio solution with 
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butoxyethanol. The PVCap was extracted from the butoxyethanol by repeated washing with 
ether until a white powder was achieved and seen to be pure by 1H NMR spectroscopy. 
The 2-butoxyethanol was added at 5 mol% with respect to the water. The amount of PVCap 
used was the same weight as the non-deuterated 2-butoxyethanol, to get as close to 
industrial relevance as possible. The same weight of PVCap was used with the deuterated 2-
butoxyethanol to keep the number of moles the same.  
Compositions, temperature and time of collection are detailed below in Table 6.2, where H 
represents fully protic 2-butoxyethanol and D represents 2-butoxythanol-1,1,2,2-d4. 
Water Butoxyethanol PVCap Hours of Data Collected 
H2O H - 6 
HDO H - 6 
D2O H - 6 
H2O D - 6 
HDO D - 6 
D2O D - 6 
H2O H yes 5 
D2O H yes 5 
HDO D yes 6 
D2O D yes 6 
Table 6.2 - Composition, deuteration and hours of data collect of the NIMROD experiments. 
Samples were syringed into the cans to avoid any air bubbles.  Samples were prepared in a 
water bath maintained between 3 and 10 °C by careful monitoring and addition of small 
amounts of ice to prevent the precipitation which occurs above and below these 
temperatures. All syringes and sample cans were cooled to this temperature to prevent 
precipitation in the equipment. The 2-butoxyethanol and PVCap sample was slowly syringed 
in parts whilst being held in hot water to reduce viscosity. The samples were then screwed 
onto the sample changer and lowered into the beam.   
Analysis of the raw data was completed using Gudrun4. Simulations and modelling were 
performed using EPSR24 and EPSR25. Modelling of the simulations was performed using 
Project Aten.29   
  
6: Neutron study of PVCap and butoxyethanol 
179 
 
6.4 References 
(1)  Thermal Neutron Scattering; Egelstaff, P. A., Academic Press: London, New York, 
1965. 
(2)  Sears, F. Neutron News 1992, 3 (3), 26–37. 
(3)  Feigin, L. A.; Svergun, D. I.; Taylor, G. W. In Structure Analysis by Small-Angle X-Ray 
and Neutron Scattering; Taylor, G. W., Ed.; Springer US: Boston, 1987; 25–55. 
(4)  McGreevy, R. L.; Pusztai, L. Mol. Simul. 1988, 1 (6), 359–367. 
(5)  Tavagnacco, L.; Brady, J. W.; Bruni, F.; Callear, S.; Ricci, M. A.; Saboungi, M. L.; Cesàro, 
A. J. Phys. Chem. B 2015, 119 (42), 13294–13301. 
(6)  Dixit, S.; Soper, A. K.; Finney, J. L.; Crain, J. Eur. Lett. 2002, 59 (3), 377–383. 
(7)  Soper, A. K. Chem. Phys. 2000, 258 (2–3), 121–137. 
(8)  Soper, A. K.; Ricci, M. A. Phys. Rev. Lett. 2000, 84 (13), 2881–2884. 
(9)  Norman, S. E.; Turner, A. H.; Youngs, T. G. A. RSC Adv. 2015, 5 (82), 67220–67226. 
(10)  Hardacre, C.; Holbrey, J. D.; Mullan, C. L.; Youngs, T. G. a; Bowron, D. T. J. Chem. Phys. 
2010, 133, 1–7. 
(11)  Bernabei, M.; Ricci, M. A. J. Phys. Cond. Matt. 2008, 20, 1–8. 
(12)  D’Arrigo, G.; Teixeira, J.; Giordano, R.; Mallamace, F. J. Chem. Phys. 1991, 95 (4), 2732-
2737. 
(13)  D’Arrigo, G.; Giordano, R.; Teixeira, J. Phys. Scr. 1992, T45, 248–250. 
(14)  D’Arrigo, G.; Giordano, R.; Teixeira, J. J. Mol. Struct. 1997, 404, 319–334. 
(15)  Perrin, A. The chemistry of low dosage clathrate hydrate inhibitors, University of 
Durham, 2015. 
(16)  Cohen, J. M.; Wolf, P. F.; Young, W. D. Energy Fuels 1998, 12, 216–218. 
(17)  Perrin, A.; Musa, O. M.; Steed, J. W. Chem. Soc. Rev. 2013, 42 (5), 1996–2015. 
(18)  Meeussen, F.; Nies, E.; Berghmans, H.; Verbrugghe, S.; Goethals, E.; Prez, F. Du. 
Polymer 2000, 41, 8597–8602. 
6: Neutron study of PVCap and butoxyethanol 
180 
 
(19)  Bowron, D. T.; Soper, A. K.; Jones, K.; Ansell, S.; Birch, S.; Norris, J.; Perrott, L.; Riedel, 
D.; Rhodes, N. J.; Wakefield, S. R.; Botti, A.; Ricci, M.; Grazzi, F.; Zoppi, M. Rev. Sci. 
Instrum. 2010, 81 (3), 33905. 
(20)  Wignall, G. D.; Bates, F. S. J. Appl. Cryst. 1987, 20 (1), 28–40. 
(21)  Hauser, W.; Feshbach, H. Phys. Rev. 1952, 87 (2), 366–373. 
(22)  McLain, S. E.; Bowron, D. T.; Hannon, A. C.; Soper, A. K. Oxford 2014. 
(23)  Soper, A. K. Phys. Rev. B 2005, 72 (10), 104204. 
(24)  Soper, A. K. Mol. Phys. 2001, 99 (17), 1503–1516. 
(25)  Hanson, R. M.; Prilusky, J.; Renjian, Z.; Nakane, T.; Sussman, J. L. Isr. J. Chem. 2013, 
53, 207–216. 
(26)  Stewart, J. J. P. Stewart Computational Chemistry: Glasgow 2016. 
(27)  Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. J. Am. Chem. Soc. 1996, 118 (15), 
11225–11236. 
(28)  Mooney, C. Z. Monte Carlo Simulation.; Sage Publications: Thousand Oaks, London, 
New Delhi, 1997. 
(29)  Youngs, T. G. A. J. Comput. Chem. 2009, 31 (3), 239–648. 
(30)  Gapiński, J.; Szymański, J.; Wilk, A.; Kohlbrecher, J.; Patkowski, A.; Hołyst, R. Langmuir 
2010, 26 (12), 9304–9314. 
(31)  Lin, Y.; Alexandridis, P. J. Phys. Chem. B 2002, 106 (47), 12124–12132. 
(32)  Soper, A.; Benmore, C. Phys. Rev. Lett. 2008, 101 (6), 65502.
7: Coamorphous materials 
 
181 
 
7 Coamorphous materials 
7.1 Introduction 
A major challenge in the development of drugs is the bioavailability of the active 
pharmaceutical ingredient. One of the main issues affecting bioavailability is the solubility of 
the drug in water.1 Cocrystals, salt formation and metastable polymorphs have been among 
the methods employed to help drug solubility.2 Another method is to prevent the drug from 
crystallising, keeping it in an amorphous state. As the amorphous state is less 
thermodynamically stable than the crystal, this often can lead to an increase in solubility in 
a range of solvents, most importantly for drugs, water.3  
Often trying to create an amorphous state of a pure compound is challenging, with either 
crystals forming regardless of preparation method, or conversion to the more stable crystal 
structure over time.4 One way to help prevent this is the addition of a second component to 
create a coamorphous mixture. Similar in concept to cocrystals,5,6 coamorphous materials 
introduce a second component to change the drug’s interactions, but unlike cocrystals, the 
goal is to disrupt favourable interactions which promote crystal formation instead of 
introducing more interactions to help crystals form.7 
One of the many applications of PVP has been in drug formulation.8–10 Often as a binding and 
bulking agent when making pills or for potentially creating delayed release formulation based 
on its thermal behaviour. Another use of PVP in drug formulation is its ability to stabilise 
amorphous forms of drugs.11,12  Though PVP is effective at stabilising the amorphous form of 
a range of drugs, polymer stabilisers are often used in high loading.13 Whilst high loading isn’t 
necessarily a problem for drugs with a small therapeutic index, drugs which require a larger 
dosage would either need pills too large to easily swallow or multiple pills per dose, neither 
of which are preferable for the patient. The other main disadvantage of PVP is that it is 
hygroscopic.14 This reduces the shelf life of the product, either by water promoted 
degradation of the drug, or because water can cause a plasticising effect in pills, aiding 
molecular mobility and crystallisation.15 So whilst PVP is perfectly adequate, a less 
hygroscopic, lower loading alternative would be preferable. Pyrogallol,16 amino acids17,18 and 
mixtures of two drugs19–21 have all been previously been shown to be effective in stabilising 
the amorphous form of pharmaceuticals. The model compounds of PVP and PVCap shown in 
Scheme 2.1, may be also prove effective as low molecular weight alternatives to PVP in 
amorphous drug formulations. 
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7.2 Results and Discussion 
7.3 Coamorphous screening 
7.3.1 ROY 
ROY (5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile, Scheme 7.1) is a highly 
polymorphic compound which is a precursor for the antipsychotic drug olanzapine. ROY is 
named after the colours of its polymorphs: red, orange and yellow. Due to its large number 
of polymorphs, ROY has been the focus of much study with significant effort expended in 
seeking new polymorphs or controlling solid form using novel methods of crystallisation.22,23 
Whilst of academic interest, the high crystallinity of compounds such as ROY can be 
disadvantageous in a pharmaceutical setting do to the low solubility of its crystal forms. 
Corner et al.16  found pyrogallol to be a suitable candidate to stabilise the amorphous form 
of ROY offering a small molecule alternative to the commonly used PVP. As the model 
compounds of the KHIs have shown themselves to be particularly apt at preventing a wide 
range of substances crystallising, it is possible that they may make coamorphous phases with 
ROY. 
Compounds 1, 3, 6-11 and VCap were all ground using a mortar and pestle in a 1:1 molar 
ratio with ROY. The grinding ensures that both components were thoroughly mixed, as 
differences in melting point can make mixing difficult in the melt. The samples were placed 
on a microscope slide and covered with a thin, glass cover slide then heated in the hot stage 
microscope until all material had melted. The samples were then removed from the hot stage 
and allowed to cool at room temperature overnight.  The cooled samples were examined 
under a microscope fitted with cross polarising filters to check if any crystals had formed on 
cooling. Pictures of the microscope slides and crossed polarised microscope images can be 
found in Figure 7.1. 
As expected the reference sample of ROY without any second compound readily crystallises. 
It is interesting to note that under the conditions used, ROY crystallises into three distinctive 
blocks of different colour suggesting that at least three different forms can be made from 
cooling the melt in this way. The cross polarised microscope image shows there is possibly 
more than three forms in the sample. This has been previously reported by Chen et al.24 who 
observed that cooling ROY from the melt results in four polymorphs forming. They reported 
the Y04 forms first and cross-nucleates allowing different, faster growing forms to crystallise, 
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resulting in a mixture of polymorphs from the same cooling crystallisation. Further analysis 
into the polymorphism of ROY is beyond the scope of this study.  
   
   
   
 
  
Figure 7.1 – Polarised light microscope images of ROY samples cooled overnight with photos of the 
microscope slide in the bottom right corner. Samples are: a) ROY, b) ROY and PVP, c) ROY and PVCap, d) ROY 
and VCap, e) ROY and bisVCap, f) ROY and H2bisVCap, g) ROY and bisVP, h) ROY and H2bisVCap, i) ROY and 
bisHEP, j) ROY and HEPVCap. 
PVP with ROY was tested as an example of what, according to literature,11,12 should be an 
effective coamorphous material. There are areas of different colours suggesting that 
different phases may exist, though none of the phases show birefringence so are not 
crystalline. PVCap is not used as an amorphous stabiliser in the pharmaceutical industry. This 
is possibly due to the fact that PVP is an adequate and affordable amorphous stabiliser whilst 
PVCap is more expensive. As PVP is known to prevent drug recrystallisation,11,12 it stands to 
reason that PVCap may also be effective. The PVCap/ROY sample does remain amorphous 
a) b) 
d) 
g) 
j) 
h) 
e) 
i) 
f) 
c) 
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and of a single phase, similarly the unsaturated model for PVCap, bisVCap, also gives an 
amorphous mixture. 
Apart from bisVCap, the other model compounds do not seem to be effective in preventing 
ROY crystallising over time. Though no quantitative analysis has been performed, it is worth 
noting that ROY shows a very significant amount of crystallisation within a couple of minutes 
of being removed from the heat whilst all model compounds slowed the crystallisation. 
BisHEP slowed down the crystallisation the least, with crystals beginning to form within half 
an hour whilst the other models did not show any signs of crystallisation within the next 
couple of hours. After 22 hours however, there were crystals present in all the samples which 
include compounds 7-11. Compounds 7-11 resulted in different combinations of crystal 
habitats and amorphous regions. In depth analysis of which polymorphs form is beyond the 
scope of this project, whilst interesting to note that the crystallisation behaviour is changed 
by the additive, the fact that the additives did not successfully stabilise the amorphous phase 
is the important information for this study. 
None of the samples changed any further after two months of storage at room temperature, 
suggesting all crystallisation was complete within the first 24 hours and those which did not 
crystallise are stable at least on a two month time scale.  
7.3.2 BisVCap and bisVP with a range of drugs 
As bisVCap showed potential as an amorphous phase stabiliser for ROY, further experiments 
were performed with other drugs. Even though bisVP did not effectively prevent ROY from 
crystallising, as the equivalent model to bisVCap of PVP, which is the commercially used 
stabiliser, bisVP was also screened with the same range of drugs. Thirteen drugs were chosen 
based on easy availability and relative heat stability, for example no β-lactam rings, for initial 
screening to see if any would form a coamorphous phase with bisVCap or bisVP. The drugs 
chosen, shown in Scheme 7.1, were benzocaine, caffeine, carbamazepine, carisoprodol, 
dopamine, ethionamide, ibuprofen, isoniazid, metformin, mexiletine, tolfenamic acid, 
valsartan and ROY is included here for completeness.   
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Scheme 7.1 – Structures of the drug molecules. 
The drugs were ground together in a 1:1 mol ratio using a mortar and pestle with bisVCap 
and with bisVP before being heated in a hot stage microscope until all material had melted 
and allowed to cool at room temperature. Pictures were taken using a camera attached to a 
polarised light microscope the next morning and two weeks after melting to see if any 
crystallisation had occurred. The pictures can be found in Figure 7.2. One of the first samples 
which can be rejected as a candidate of interest is valsartan, which even on its own, remains 
amorphous, suggesting that it is either not heat stable, particularly hydroscopic when in the 
melt or forms a stable amorphous form on its own. The amorphous samples using bisVP all 
become viscous fluids, like bisVP itself, creating what could be described as a solution, not 
as an amorphous solid. As creating a solution was not the aim, bisVP is rejected as a potential 
stabiliser. Out of the remaining samples, bisVCap with benzocaine, caffeine and metformin 
can be rejected from this experiment alone, as they crystallise overnight. BisVCap with 
carbamazepine, carisoprodol, dopamine, ethionamide, ibuprofen, isoniazid, mexiletine and 
tolfenamic acid all result in materials which appear amorphous by polarised light microscopy 
after 18 hours at room temperature. 
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Drug Overnight cooling Overnight cooling 
with bisVCap 
Overnight cooling 
with bisVP 
2 weeks 2 weeks with 
bisVCap 
2 weeks with bisVP 
ROY 
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Caffeine 
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Drug Overnight cooling Overnight cooling 
with bisVCap 
Overnight cooling 
with bisVP 
2 weeks 2 weeks with 
bisVCap 
2 weeks with bisVP 
Isoniazid 
      
Metformin 
      
Mexiletine 
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Drug Overnight cooling Overnight cooling 
with bisVCap 
Overnight cooling 
with bisVP 
2 weeks 2 weeks with 
bisVCap 
2 weeks with bisVP 
Valsartan 
      
Figure 7.2 – Cooling of the melts of a range of drugs with and without bisVCap and bisVP overnight and after two weeks
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7.4 Differential scanning calorimetry  
DSC is commonly employed to establish if a melted material recrystallises when cooled and 
reheated. The components are mixed in the desired ratio and then heated until everything 
has melted. The molten mixture is then cooled, often to the limits of the machine being used, 
before being heated past the melting point again. On the first heating cycle either one or 
more endothermic peaks corresponding to the melting of the sample should be observed. 
Two peaks would occur at the melting points of the two separate components. A single 
melting point happens if both of the components share a melting point, form intermolecular 
interaction upon mixing such as cocrystalline materials or if the higher melting component is 
soluble in the molten lower melting component. More than two peaks corresponding to 
melting points may also be possible if one or both of the components have multiple 
polymorphs as polymorphs can have different melting points to one another. For an 
amorphous mixture there should be no exothermic peak from recrystallisation upon cooling 
or reheating. The second heating cycle should show a glass transition of the amorphous 
material and no melting peak, as there should be no crystalline material present to melt. 
Out of the drug/bisVCap combinations which appeared amorphous by polarised light 
microscopy, more failed as this stage. Dopamine shows an endothermic peak in the second 
heating cycle corresponding to melting. As no recrystallisation was observed in the hot stage 
microscope experiment which only heated the sample once, it is possible that 
recrystallisation occurred during the second heating cycle. As dopamine recrystallises during 
the heat/cool/heat DSC experiment, it is not a suitable material for a coamorphous drug 
formulation with bisVCap. Ethionamide, tolfenamic acid, mexilitine and ibuprofen show 
collections of sharp and overlapping endothermic peaks on heating, which arise from 
decomposition of the sample. Ethionamide and mexilitine both decompose soon after their 
melting points as seen in the DSC thermographs of the individual components, so 
decomposition of these two samples is not surprising. Ibuprofen and tolfenamic acid on the 
other hand are stable significantly above their melting points as was observed in the DSC 
thermographs of the single components. The decomposition of the ibuprofen/bisVCap and 
tolfenamic acid/bisVCap mixtures on heating whilst the single components do not 
decompose on heating to the same temperature suggests that the interaction with bisVCap 
promotes degradation of the sample. The exact nature of this decomposition has not been 
explored further, though it is sufficient to say that bisVCap is not an appropriate additive for 
these drugs. The DSC plot of tolfenamic acid and bisVCap/tolfenamic acid are shown in Figure 
7.3 to highlight the decomposition upon heating bisVCap/tolfenamic acid. 
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Figure 7.3 – The first heating cycles of the heat/cool/heat DSC thermographs of tolfenamic acid and 
bisVCap/tolfenamic acid, exotherm up. 
Carisoprodol, carbamazepine, isoniazid and ROY all had DSC thermographs lacking 
decomposition, recrystallisation or endothermic peaks in the second heating cycle 
corresponding to the melting of a crystalline material. The DSC thermographs can be seen in 
Figure 7.4. All four thermographs show an endothermic peak on heating which corresponds 
to the sample melting. On cooling there are not exothermic peaks which would arise from 
recrystallisation of the sample, suggesting that no recrystallisation on cooling occurs. During 
the second heating cycle all the thermographs show an exothermic step which relates to the 
glass transition. No other feature is visible in the second heating cycle. The lack of exothermic 
peak from a recrystallisation event and the lack of endothermic peak in the second heating 
cycle shows carisoprodol, carbamazepine, isoniazid and ROY in 1:1 ratios with bisVCap to be 
amorphous within the scope of the DSC experiment. 
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Figure 7.4 – Heat/cool/heat DSC plots of a) bisVCap/carbamazepine, b) bisVCap/carisoprodol, c) 
bisVCap/isoniazid and d) bisVCap/ROY, exotherm up.  
To further verify the DSC results, the same heat/cool/heat cycles which were performed in 
the DSC experiments were reproduced using a hot stage attached to a polarised light 
microscope.  This adds visual verification that no crystallisation has occurred when 
carisoprodol, carbamazepine, isoniazid and ROY were mixed in a 1:1 molar ratio with 
bisVCap. The results of the microscope experiments can be seen in Figure 7.5, Figure 7.6, 
Figure 7.7 and Figure 7.8. No crystallisation was seen in any sample in the microscope images 
further evidencing the formation of an amorphous phase.  
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Figure 7.5 – Heat cool heat cycle of bisVCap and carbamazepine in a 1:1 ratio under a cross polarised filter 
    
Figure 7.6 – Heat cool heat cycle of bisVCap and carisoprodol in a 1:1 ratio under a cross polarised filter 
    
Figure 7.7 – Heat cool heat cycle of bisVCap and ROY in a 1:1 ration under a cross polarised filter 
    
Figure 7.8 - Heat cool heat cycle of bisVCap and isoniazid in a 1:1 ration under a cross polarised filter 
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7.5 Effective ratio 
One major problem with PVP as an amorphous stabiliser is the large amount required for 
stabilisation of the amorphous phase. This often leads to very large pills or dosages which 
consist of multiple tablets. This is not ideal for the end user. If an amorphous stabiliser can 
work with a lower loading it could help the development of pills which are much easier to 
swallow. Thus further hot stage microscope and DSC experiments of the short listed drugs, 
carisoprodol, carbamazepine, isoniazid and ROY, were performed with increasing 
drug:bisVCap ratios to determine the highest effective ratio. 
For the microscope experiments the drugs and bisVCap were ground in the desired ratio, 
heated until all the sample had melted then cooled back to room temperature and analysed 
by polarised light microscopy. Carbamazepine, carisoprodol, isoniazid and ROY all showed 
no visible crystallisation at a 2:1 drug:bisVCap molar ratio. Carisoprodol also did not show 
any visible crystallisation at a 3:1 carisoprodol:bisVCap ratio. At 3:1 drug:bisVCap ratio 
carbamazepine, isoniazid and ROY all formed crystals overnight and carisoprodol formed 
crystals overnight from a 4:1 ratio. Heat/cool/heat DSC experiments were performed for the 
ratios which did not form crystals in the hot stage microscope experiments. Similar to the 
1:1 ratios, no recrystallisation event or melt during the second heating cycle is present in the 
DSC plots for 3:1 carisoprodol:bisVCap, 2:1 carbamazepine:bisVCap, 2:1 isoniazid:bisVCap or 
2:1 ROY:bisVCap. This suggests that bisVCap is still an effective crystallisation inhibitor at 
these ratios.  
The final experiment to prove amorphousness is PXRD, which should show no Bragg peaks 
as there should be no crystalline material to diffract. The amorphous samples were prepared 
18 hours before the PXRD experiments were run by melting the two components together 
and allowing the samples to cool to room temperature overnight. Carbamazepine:bisVCap 
2:1 and 1:1 and carisoprodol:bisVCap 3:1, 2:1 and 1:1 showed no Bragg peaks in the powder 
patterns, Figure 7.9, showing that these materials are amorphous by x-ray diffraction. The 
1:1 ratio of ROY:bisVCap did not exhibit any Bragg peaks so is amorphous by x-ray diffraction. 
The 2:1 ratio of ROY:bisVCap on the other hand is largely amorphous but has some small 
Bragg peaks and the material has begun to crystallise overnight. 
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Figure 7.9 – PXRD plot of a) carbamazepine with bisVCap in a 1:1 and 2:1 molar ratio, b) carisoprodol with 
bisVCap in a 1:1 and 2:1 molar ratio, c) isoniazid with bisVCap in a 1:1 and 2:1 molar ratio, d) ROY with 
bisVCap in a 1:1 and 2:1 molar ratio. 
Neither isoniazid:bisVCap 2:1 or isoniazid:bisVCap 1:1 are amorphous by PXRD as both 
exhibit Bragg peaks in their PXRD plots. Both the 2:1 and 1:1 ratios gave powder patterns 
consistent with being the same crystal form to one another. Comparison to powder patterns 
calculated from the literature crystal structures of isoniazid25 and bisVCap26 using Mercury27 
shows the crystalline material to be a mixture of isoniazid and bisVCap, Figure 7.10. 
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Figure 7.10 – PXRD plot of isoniazid with bisVCap in a 1:1 and 2:1 molar ratios and the powder diffraction 
patterns calculated from the crystal structures of isoniazid25 and bisVCap.26 
After four weeks of being stored at room temperature, all samples except for 1:1 
carisoprodol:bisVCap showed Bragg peaks in their PXRD plots, showing that over time they 
revert to the more thermodynamically stable crystalline forms. The coamorphous form of 
1:1 carisprodol:bisVCap is stable over the course of a month, which shows great promise for 
drug formulation. 
7.6 IR spectroscopy 
To see if any insight could be gleaned into how the amorphous form is stabilised, IR spectra 
were recorded of carisoprodol, carbamazepine, isoniazid, ROY and bisVCap, as well as the 
1:1, 2:1 and for carisoprodol 3:1 drug:bisVCap mixtures ground and melted together. As 
carisoprodol, carbamazepine, isoniazid and bisVCap all contain carbonyl groups, the carbonyl 
region was focused upon to look for any changes. ROY contains a nitrile group and ROY and 
isoniazid contain amine groups, which were also focused on to look for any significant 
interactions.  
For all four drugs, when just ground with bisVCap, no significant changes in the IR spectra 
were observed, with the spectra being a mix of the spectra of the single components with no 
shifts in the peaks of interest, as highlighted in Figure 7.11 and Figure 7.12. Upon melting 
and cooling there are observable changes for carbamazepine, carisoprodol and isoniazid. For 
carisoprodol, Figure 7.11, when the sample is melted and cooled the carbonyl peaks of 
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bisVCap at 1622 cm-1 and 1640 cm-1 become much broader and less well defined. This is 
indicative of amorphous materials as there are many different conformations and 
environments in which the molecules reside, creating broad peaks which are an average of 
all the possible environments in the amorphous material.17,20,28,29 The carbonyl peak for the 
carisoprodol broadens and also shifts from 1690 cm-1 to 1708 cm-1. This suggests that the 
carbonyl bonds are becoming stronger so less involved in any intermolecular bonding and 
that the hydrogen bonding which normally holds the crystal structure together is being 
disrupted. The bands between 3475 – 3180 cm-1 which are associated with the N-H stretches 
of the carbamate groups, become a single broad peak in the spectrum of the cooled sample 
after melting, where in pure carisoprodol there were four sharp, distinct peaks, which 
suggests a change in bonding. Upon increasing the ratio of carisoprodol:bisVCap from 1:1 to 
2:1 to 3:1 there is no significant change in the wavenumber of any of the peaks. From the 
changes in the IR spectra of carisoprodol with bisVCap, it can be said that there are changes 
in the local environment and interaction of the carisoprodol molecules which affect the 
crystallisation. 
Figure 7.11 – IR spectra of bisVCap, carisoprodol and a 1:1 molar ratio of carisoprodol:bisVCap ground and 
melted. 
Similarly both carbamazepine and isoniazid, Figure 7.12 and Figure 7.13 respectively, show a 
large degree of broadening of the carbonyl peaks in the spectra of the cooled samples after 
melting and no change in the ground sample. The spectra of cooled melts of samples of 
carbamazepine:bisVCap and isoniazid:bisVCap showed no change between the 1:1 and 2:1 
ratios. On the other hand, ROY exhibits no change in peaks in the IR spectra in the ground or 
melted samples at either a 1:1 or 2:1 ROY:bisVCap ratio. Even when melted and cooled, the 
spectrum for ROY/bisVCap is a mixture of the bisVCap and ROY spectra, with no shifts in the 
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peaks of interest. This suggests that unlike carbamazepine, carisoprodol and isoniazid, which 
see significant changes to the local environment, the stabilisation of the amorphous form in 
ROY/bisVCap arises from a bulk property, not from local intermolecular interactions. 
  
Figure 7.12 - IR spectra of bisVCap, carbamazepine and a 1:1 molar ratio of carbamazepine:bisVCap ground 
and melted and cooled. 
 
Figure 7.13 - IR spectra of bisVCap, isoniazid and a 1:1 molar ratio of isoniazid:bisVCap ground and melted. 
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7.7 Dynamic vapour sorption 
One of the biggest issues with PVP as an amorphous stabiliser is its hydroscopicity.14 If 
bisVCap is significantly less hydroscopic than PVP, then it is a promising candidate for future 
pharmaceutical applications. DVS was used to compare the water uptake of bisVCap and PVP 
and the data is presented in section 2.2.1. As seen in Figure 2.2, bisVCap is not hydroscopic, 
absorbing only 0.05 water molecules per molecule of bisVCap, or 0.0025 water molecules 
per carbonyl moiety at 90 %RH. PVP on the other hand, absorbs 2.5 water molecules per 
carbonyl group which is orders of magnitude more than bisVCap. This suggests bisVCap may 
be a desirable amorphous stabiliser which will not absorb much atmospheric water. 
As amorphous forms are more soluble than crystal forms due to their thermodynamic 
instability, it is possible that the amorphous form of bisVCap could absorb much more water 
than the crystalline form. The DVS plot for crystalline bisVCap, Figure 7.14a, shows a mass 
increase of 0.35 %. The amorphous bisVCap, Figure 7.14b, shows a larger mass increase of 
1.2 % which corresponds to 0.18 water molecules per molecule of bisVCap. Whilst the 
amorphous bisVCap does absorb more water than the crystalline bisVCap, the small increase 
in mass and lack of hysteresis in the DVS plot suggest that amorphous bisVCap is also not 
hydroscopic. Amorphous bisVCap absorbs much less water than PVP, making it an acceptable 
additive to stabilise amorphous materials whilst avoiding plasticisation due to water.  
  
Figure 7.14 - DVS plot of a) crystalline bisVCap and b) amorphous bisVCap. 
In conclusion, bisVCap has the capability to stabilise the amorphous form of a range of drugs. 
Carisoprodol in particular showed promise, with a low loading of bisVCap and a long shelf 
life. BisVCap is also much less likely to absorb water than PVP, which would prolong the shelf 
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life of any pills formulated with it. Future experiments would need to include more in-depth 
analysis of the lifetime of the amorphous forms, toxicity testing to see if bisVCap is safe for 
human consumption, experiments into the physical properties of the amorphous forms and 
which method of pill formation would work best, as well as the solubility of the amorphous 
forms. 
7.8 Experimental 
7.8.1 Differential scanning calorimetry 
Differential scanning calorimetry scans were recorded on a TA Q2000 using standard 
aluminium pans containing 3 – 12 mg of sample. Standard mode was used. The 
heat/cool/heat cycles began with a heating cycle at a rate of 10 °C min-1, then cooling cycle 
at 10 °C min-1 and finally a second heating cycle at 10 °C min-1. 
7.8.2 Dynamic vapour sorption 
DVS was performed using an SMS DVS-1 with a 10 %RH step between humidity values with 
equilibrium achieved at 0.01% weight change before moving to the next step. Methods 
began at the humidity of the room at ambient which was measured by a Rotronic A/H 
hygrometer. The humidity was then increased to 90%RH before cycling to 0%RH, to 90%RH, 
to 0%RH. Samples weighing between 5-20mg were used. 
7.8.3 Hot stage microscopy 
A Linkam LTS420 heating stage attached to a Olympus XC50 microscope was used to heat 
the samples. Samples were placed on a glass microscope slide with a thin glass cover slide. 
For the amorphous material screening compounds were ground together as detailed in Table 
7.1 and heated at 30 °C min-1 until the all of the sample had melted. Samples were then 
removed from the hot stage and allowed to cool. 
Model compound Weight / g Drug Weight / g 
bisVCap 0.08 benzocaine 0.05 
 0.07 caffeine 0.05 
 0.06 carbamazepine 0.05 
 0.03 carbamazepine 0.05 
 0.02 carbamazepine 0.05 
 0.05 carisoprodol 0.05 
 0.03 carisoprodol 0.05 
 0.02 carisoprodol 0.05 
 0.01 carisoprodol 0.05 
 0.09 dopamine 0.05 
7: Coamorphous materials 
 
201 
 
 0.08 ethionamide 0.05 
 0.07 ibuprofen 0.05 
 0.10 isoniazid 0.05 
 0.05 isoniazid 0.05 
 0.03 isoniazid 0.05 
 0.11 metformin 0.05 
 0.08 mexiletine 0.05 
 0.05 tolfenamic acid 0.05 
 0.03 valsartan 0.05 
 0.05 ROY 0.05 
 0.03 ROY 0.05 
 0.02 ROY 0.05 
bisVP 0.07 benzocaine 0.05 
 0.06 caffeine 0.05 
 0.05 carbamazepine 0.05 
 0.04 carisoprodol 0.05 
 0.07 dopamine 0.05 
 0.07 ethionamide 0.05 
 0.05 ibuprofen 0.05 
 0.08 isoniazid 0.05 
 0.09 metformin 0.05 
 0.06 mexiletine 0.05 
 0.04 tolfenamic acid 0.05 
 0.03 valsartan 0.05 
  0.04 ROY 0.05 
Table 7.1 – Compositions of model compound drug mixtures. 
BisVCap was ground in 1:1 molar mixture, as detailed in Table 7.1 with carbamazepine, 
carisoprodol, isoniazid and ROY. The carbamazepine/bisVCap sample was heated from room 
temperature to 170 °C at a rate of 10 °C min-1, cooled at °C min-1 to -40 °C, then heated at 10 
°C min-1 to 165 °C min-1. The carisoprodol/bisVCap sample was heated from room 
temperature to 150 °C at a rate of 10 °C min-1, cooled at °C min-1 to -75°C, then heated at 10 
°C min-1 to 145 °C min-1. The isoniazid/bisVCap sample was heated from room temperature 
to 175 °C at a rate of 10 °C min-1, cooled at °C min-1 to -100 °C, then heated at 10 °C min-1 to 
125 °C min-1. The ROY/bisVCap sample was heated from room temperature to 150 °C at a 
rate of 10 °C min-1, cooled at °C min-1 to -90 °C, then heated at 10 °C min-1 to 155 °C min-1. 
7.8.4 Infrared spectroscopy 
Experiments were performed on a Perkin Elmer FTIR spectrum 100 with an attenuated total 
reflectance (ATR) attachment. Data were recorded at a resolution of 2 cm-1 for 16 scans over 
the range 4000 – 600 cm-1. Samples were run by placing on the ATR crystal and applying 
pressure using the side arm. Spectral analysis was performed using SpekWin32.30 
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Ground samples were prepared by grinding together in the desired ratio of the two 
components using a mortar and pestle for one minute. Melted samples were prepared by 
grinding together in the desired ratio of the two components using a mortar and pestle for 
one minute before placing the ground material into 5 mL glass vial with a plastic screw lid. 
After the lid was secured the sample was heated above the melting point of the highest 
melting component until everything had melted using a stirrer hotplate and appropriate 
heating block. 
7.8.5 Crystallographic analysis 
X-ray powder diffraction patterns were recorded on a PANalytical Empyrean diffractometer 
using Cu Kα radiation (λ = 1.54 Å), tube voltage of 40 kV and 40 mA current. Intensities were 
measured from 2° to 40° 2θ. Soller silts and an incident beam divergent slit of 
1
8
°, anti-scatter 
slit of 
1
4
° and diffracted beam anti-scatter slit of 7.5 mm. 
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Conclusion 
The initial aim of the work was to study how low molecular weight models of polymeric 
kinetic hydrate inhibitors used in the oil industry interact with a range of materials to 
hopefully discover some insight into how KHIs prevent crystallisation. If a mechanism of 
hydrate inhibition can be proven then new, more effective inhibitors can be designed. 
Small molecules containing lactam functionalities were synthesised to model PVP, PVCap and 
copolymers thereof. A wide range of compounds were used to try and cocrystallise the 
model compounds, with only a few successes, suggesting that the models are effective at 
inhibiting crystallisations, like the polymers they are designed to mimic which suggest that 
they are reasonable models to study the polymers.  
The effects of sour gas on the KHIs was explored. There was no observable difference in 
sweet and sour systems of the KHIs and their models interactions with water. The increased 
clathrate hydrate in formation in sour pipelines is more likely due to an increase in clathrate 
formation than a decrease in KHI efficiency.  
Cocrystals of boric acid and 1,4-phenyldiboronic acid with the model compounds were 
effective at gelling guar. Though no change in the kinetics or final products was observed 
with the pure boronic acid or cocrystals. There are no strong enough interactions between 
the components of the cocrystals in solution to change the gel onset time, meaning that 
there is no industrial advantage to using cocrystals to gel guar. 
Neutron diffraction of PVCap and butoxyethanol in water was not completely successful. 
Systems which did not contain any polymer gave sensible results, giving smooth and 
plausible hydration sphere. The polymer containing system on the other hand, resulted in 
meaningless fluctuations in water density. Neither the technique nor the simulation program 
were designed to handle polymers and the system investigated was beyond capabilities of 
the technique so far. 
BisVCap has shown potential as an amorphous stabiliser for a selection of drugs. The 
amorphous forms of carbamazepine, carisoprodol and ROY were all stabilised by bisVCap 
added in a stoichiometric ratio. Carbamazepine was particularly stable over time and showed 
good potential for drug formulation. 
 206 
 
Future Work 
Halogen bonding coformers have shown potential at cocrystallising with the KHI model 
compounds. Only a small number of commercially available halogen bonding components 
have been tested. There is potential that other strong halogen bond donors will also 
cocrystallise with the model compounds. 
Synthesis of ether containing model compounds which are stable to Lewis acidic conditions 
may lead to a variety of new ligands for heavy metals. Adding a second carbon between the 
lactam ring and the oxygen, similar to HEP, should help the ether linkage be more stable in 
acidic conditions, as bisHEP is stable to metals when Et(OVCap)2 and HEPVCap are not. 
Further research into the potential of bisVCap as an amorphous stabiliser for drugs should 
also be undertaken. The shelf life of the amorphous mixture, the processability of the 
coamorphous materials and the toxicity of bisVCap would require investigation before a drug 
delivery system could be implemented.  
The polymorphs of ROY which crystallise from melts with the model compounds are also of 
interest. Different polymorphs seem to form depending on which model compound was 
added. Also the polymorphs are not necessarily touching, which differ from the cross 
polymorph nucleation observed in the cooling of the melt of pure ROY. 
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Appendix 
Synthesis of ethylcaprolactam 
Ethylcaprolactam was produced by hydrogenating vinylcaprolactam using hydrogen balloon and 5 % 
Pd/C catalyst to give a yellow liquid. 
 
VCap (2.00 g, 14.4 mmol) was dissolved in ca. 50 mL of methanol. 0.05 g of 5 % active palladium on 
activated carbon was added. A hydrogen balloon and exit needle were used to purge the reaction for 
one minute before the exit needle was removed. The mixture was stirred at 55 °C for 6 hours. Every 
hour the exit needle was introduced to relieve pressure, once the exit needle was removed the 
reaction vessel was shaken to assure good accessibility of the hydrogen. After the 4 hours, the reaction 
was turned off and allowed to cool to room temperature. The solution was then filtered through 
Celite. The methanol evaporated under vacuum leaving a yellow liquid. This liquid was then 
thoroughly mixed with 40 cm3 of ether which was the evaporated under vacuum. The addition of ether 
and evaporation was repeated 3 times. The resulting yellow liquid was left in a vacuum desiccator 
under vacuum overnight. 
1H NMR (400 MHz, CDCl3) δ 3.42 (q, J = 8.0 Hz, 2H), 3.34-3.32 (m, 2H), 2.52-2.49 (m, 2H), 1.75-1.31 (m, 
6H), 1.10 (t, J = 8.0 Hz, 3H) 
13C {1H} NMR (101 MHz, CDCl3) δ 175.52, 50.35, 49.12, 42.92, 37.19, 29.95, 28.74, 23.37, 13.16  
Synthesis of 1,3,2-dioxathiepene-2-oxide 
The method of creating vicinal diol cyclic sulfates by Gao et al.1 was used to synthesise 1,3,2-
dioxathiepene-2-oxide, compound 12, Scheme 3.3. The product was prepared in a yield of 47 %. 
Compound 12 is a liquid at room temperature, the oxidised analogue 1,3,2-dioxathiepene-2,2-dioxide 
is a solid at room temperature as described by Gao et al.1. Crystallisations experiments were 
performed using compound 12 and can be found in section 3.2.4.4. 
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Butane-1,4-diol (2.04 cm3, 34.0 mmol) was added to chloroform (20 cm3) at room temperature. 
Thionyl chloride (2.5 cm3, 34.4 mmol) in chloroform (20 cm3) was added dropwise to the butane-1,4-
diol solution over the course of 40 minutes. The reaction was heated to 60 °C for one hour. The 
reaction mixture was then cooled to 0 °C using an ice bath. Triethylamine was added dropwise until 
the fumes were no longer formed upon addition. The reaction mixture was added to a separating 
funnel and diluted with diethylether (80 cm3). The organic layer was washed with distilled water (20 
cm3), saturated aqueous NaHCO3 solution (2 x 20 cm3) and finally brine (20 cm3). Solvent was 
evaporated under vacuum to leave a pale yellow liquid.  
Yield 2.2 g, 16.2 mmol,  47 % 
1H NMR (400 MHz, CDCl3) δ 4.49-4.43 (m, 2H), 3.98-3.93 (m, 2H), 1.91-1.80 (m, 4H) 
13C {1H} NMR (101 MHz, CDCl3) δ 64.05, 28.36 
m/z 137 (M+H+, 100 %), 102 (16), 73 (30), 55 (34)  
Synthesis of cucurbituril mixtures 
A mixture of cucurbiturils with ring sizes 5, 6, 7 and 8 referred to as CB5, CB6 CB7 and CB8, was 
successfully synthesised by the method of Day et al.2 The acid catalyst chosen was 5 M HCl, as this 
maximised the production of CB6 and CB7 according to the study of reaction conditions by Day et al.2 
To separate the cucurbiturils a series of fractional crystallisations are required. As the exact ring size 
requirement to host the model compounds and create inclusion complexes of the model compounds 
in macrocyclic rings is not known, it was decided to use crude mixtures as a thorough and complete 
fractional crystallisation is time consuming and the selectivity for a particular ring size should aid 
crystallisation. Whilst a full fractional crystallisation was not undertaken, the first step of the fraction 
crystallisation outlined by Senler3 was performed. As much of the crude material as possible was 
dissolved in water. That which did not dissolved, fraction 1, was filtered off. The filtrate was 
evaporated to leave fraction 2. Carbon-13 NMR spectroscopy was used to identify which cucurbiturils 
are present in reaction mixtures as the chemical shift for the methine and methylene carbon atoms 
increases with ring size. Fraction 1 shows a single methylene peak and a single methine peak at 67.3 
and 48.6 ppm respectively. The attempted recrystallisation of fraction 1 with bisVCap from dilute HCl 
resulted in crystals of CB6 with a chloride ion, hydronium ion and water and no bisVCap, confirmed by 
single crystal x-ray crystallography. The crystals are of too low quality to allow full placement of the 
solvent and cation which are very disordered. Positive identification of CB6 confirms that the peaks in 
at 67.3 and 48.6 ppm in the 13C NMR spectrum correspond to CB6. 
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Fraction 2 gave two methine peaks at 49.9 and 47.3 ppm and two major methylene peaks at 68.4 and 
66.3 ppm. As one set of peaks is at higher chemical shift than that for CB6 and one set of peaks is 
lower than that for CB6 and according to the scheme by Senler3 this fraction should contain CB5 and 
CB7, the peaks at 68.4 and 49.9 ppm were assigned to CB7 and the peaks at 66.3 and 47.3 ppm 
assigned to CB5. The carbon-13 NMR spectrum of fraction 2 also has a weak peak at 67.3 ppm, 
suggesting that there is a small amount of CB6 present which is too small for the methine peak to be 
visible.  
 
Glycouril (5.00 g, 35.2 mmol) was dissolved in 30 cm3 of 5 M HCl. Paraformaldehyde (1.06 g, 35.2 mmol 
formaldehyde) was added slowly in 0.05 g portions at room temperature over 5 min. The reaction 
mixture was then heated to 100 °C for 4 hours. The reaction was then cooled and the solvent removed 
under vacuum resulting in a solid off white residue.  
50 cm3 of water was added to the off-white product and sonicated for 10 min. Any undissolved solid, 
fraction 1, was filtered off and dried in a vacuum desiccator. The filtrate was evaporated by heating 
resulting in an off-white solid, fraction 2, which was then thoroughly dried in a vacuum desiccator. 
Fraction 1 
1H NMR (400 MHz, DCl) δ 2.17 (s, 1H), 2.05 (d, J = 16.0 Hz, 1H), 0.93 (d, J = 16.0 Hz, 1H) 
13C {1H} NMR (101 MHz, DCl) δ 153.7, 67.3, 48.6 
Fraction 2 
1H NMR (400 MHz, DCl) δ 2.31 (s, 1H), 2.22 (d, J = 17.0 Hz, 1H), 1.04 (d, J = 17.0 Hz, 1H) 
13C {1H} NMR (101 MHz, DCl) δ 154.0, 68.4, 67.3, 66.3, 49.9, 47.3 
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